| Symbol | BIIB |
|---|---|
| Name | BIOGEN INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 225 BINNEY STREET, CAMBRIDGE, Massachusetts, 02142, United States |
| Telephone | +1 617 679-2000 |
| Fax | — |
| — | |
| Website | https://www.biogen.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000875045 |
| Description | Biogen and Idec merged in 2003, combining forces to market Biogens multiple sclerosis drug Avonex and Idecs cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogens MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firms first Alzheimers disease therapy in June 2021. Additional info from NASDAQ: |
2026-07-12 15:18
LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026
Read more
2026-06-29 10:59
Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen
Read more
2026-06-25 14:00
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
Read more
2026-06-18 14:00
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
Read more
2026-06-17 22:59
Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.
Read more
2026-06-11 21:50
Director HAWKINS WILLIAM A 🟢 acquired 1.5K shares of BIOGEN INC. (BIIB) Transaction Date: Jun 09, 2026 | Filing ID: 000065
Read more
2026-06-11 21:47
Director SHERWIN STEPHEN A 🟢 acquired 1.5K shares of BIOGEN INC. (BIIB) Transaction Date: Jun 09, 2026 | Filing ID: 000064
Read more
2026-06-11 21:46
Director Rowinsky Eric K 🟢 acquired 1.5K shares of BIOGEN INC. (BIIB) Transaction Date: Jun 09, 2026 | Filing ID: 000063
Read more
2026-06-11 21:44
Director Mantas Jesus B 🟢 acquired 1.5K shares of BIOGEN INC. (BIIB) Transaction Date: Jun 09, 2026 | Filing ID: 000062
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT00535314 | Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma | Phase2 | Malignant Melanoma | Withdrawn | — | — | ClinicalTrials.gov |
| NCT00000721 | An Escalating Dose Tolerance Trial of BG8962 (rCD4) in Patients Who Are HIV Ant… | Phase1 | HIV Infections | Completed | — | 1991-03-01 | ClinicalTrials.gov |
| NCT00000659 | A Phase II Trial of rsCD4 and AZT in Patients With AIDS or Advanced AIDS Relate… | Phase2 | HIV Infections | Terminated | — | — | ClinicalTrials.gov |
| NCT00451815 | BIIB014 Phase 2a Monotherapy | Phase2 | Parkinson's Disease | Withdrawn | — | — | ClinicalTrials.gov |
| NCT03593499 | Expanded Access to Omaveloxolone for Melanoma for Patients Previously Enrolled … | — | Melanoma | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT02865109 | Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-ons… | — | Infantile-onset Spinal Muscular Atrophy | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT04972487 | Expanded Access Program for Tofersen in Participants With Superoxide Dismutase … | — | Superoxide Dismutase 1-Amyotropic Lateral Sclerosis | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT03460782 | An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gl… | — | Glioblastoma | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT07483632 | A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fuma… | Phase3 | Relapsing Forms of Multiple Sclerosis | Not_Yet_Recruiting | 2026-11-16 | 2035-06-19 | ClinicalTrials.gov |
| NCT06628687 | A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants… | — | Friedreich Ataxia | Recruiting | 2026-10-26 | 2035-04-30 | ClinicalTrials.gov |
| NCT07444450 | A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Give… | Phase3 | Muscular Atrophy, Spinal | Not_Yet_Recruiting | 2026-09-04 | 2033-07-26 | ClinicalTrials.gov |
| NCT07722546 | A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its S… | Phase2 | Graves' Disease | Not_Yet_Recruiting | 2026-08-15 | 2028-03-31 | ClinicalTrials.gov |
| NCT07662148 | A Study to Learn More About the Safety of a Single Dose of BIIB144 and How it i… | Phase1 | Healthy Volunteer | Recruiting | 2026-07-21 | 2028-06-19 | ClinicalTrials.gov |
| NCT07448974 | Vitamin D and Type 2 Diabetes - Treat-To-Target | Phase3 | Prediabetes | Not_Yet_Recruiting | 2026-05-01 | 2031-03-01 | ClinicalTrials.gov |
| NCT07221669 | A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safet… | Phase3 | Muscular Atrophy, Spinal | Recruiting | 2026-04-28 | 2032-05-29 | ClinicalTrials.gov |
| NCT07444489 | A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Inf… | Phase3 | Antibody-mediated Rejection | Enrolling_By_Invitation | 2026-04-16 | 2031-05-28 | ClinicalTrials.gov |
| NCT07444476 | A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safet… | Phase3 | Spinal Muscular Atrophy | Recruiting | 2026-04-03 | 2032-06-22 | ClinicalTrials.gov |
| NCT07444333 | Cardiac Output and Fatigue in Friedreich's Ataxia | Na | Friedreich's Ataxia | Not_Yet_Recruiting | 2026-04-01 | 2028-04-01 | ClinicalTrials.gov |
| NCT07685015 | The Impact of Myo-Inositol on Glycemic Control and Oxidative Stress in Gestatio… | Na | Gestational Diabetes Mellitus (GDM) | Recruiting | 2026-03-23 | 2027-07-01 | ClinicalTrials.gov |
| NCT07400198 | Gait and Bone Health in SMA | — | Spinal Muscular Atrophy Type 3 | Recruiting | 2026-03-05 | 2027-06-30 | ClinicalTrials.gov |
| NCT07316361 | GYNORYLAQ™-VLINIVAL™: Ψ-Guided Personalized Neoantigen Peptide Vaccine for High… | Early_Phase1 | Endometrial Carcinoma | Enrolling_By_Invitation | 2026-02-02 | 2031-12-02 | ClinicalTrials.gov |
| NCT07328087 | COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS … | Early_Phase1 | Colorectal Cancer Metastatic | Recruiting | 2026-02-02 | 2031-12-02 | ClinicalTrials.gov |
| NCT07285434 | Clinical Study of the Therapeutic Effectiveness of In-silico-Designed, Machine … | Early_Phase1 | NSCLC (Non-small Cell Lung Cancer) | Enrolling_By_Invitation | 2026-02-02 | 2030-02-02 | ClinicalTrials.gov |
| NCT07219043 | A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidn… | Phase2 | Microvascular Inflammation | Recruiting | 2026-01-05 | 2028-02-10 | ClinicalTrials.gov |
| NCT07259980 | A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Parti… | — | Amyotrophic Lateral Sclerosis | Recruiting | 2026-01-02 | 2033-12-30 | ClinicalTrials.gov |
| NCT07294144 | Tofersen in Non-SOD1 ALS | Phase2 | ALS (Amyotrophic Lateral Sclerosis) | Recruiting | 2025-12-29 | 2028-05-01 | ClinicalTrials.gov |
| NCT07398469 | A Long-Term Study of Patient-Reported Changes in Postpartum Depression Symptoms… | — | Postpartum Depression | Recruiting | 2025-12-22 | 2027-03-29 | ClinicalTrials.gov |
| NCT07225517 | A Study to Learn More About the Safety of BIIB145 and How it is Processed in th… | Phase1 | Healthy Volunteer | Recruiting | 2025-12-18 | 2027-02-02 | ClinicalTrials.gov |
| NCT07297199 | A Study to Learn How the Body Processes BIIB141 (Omaveloxolone) When Taken as a… | Phase1 | Healthy Volunteer | Completed | 2025-12-12 | 2026-05-01 | ClinicalTrials.gov |
| NCT07223723 | A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chine… | Phase4 | Amyotrophic Lateral Sclerosis | Recruiting | 2025-12-11 | 2027-12-16 | ClinicalTrials.gov |
| NCT07149415 | A Study to Learn if Taking BIIB141 (Omaveloxolone) Affects How Omeprazole is Pr… | Phase1 | Healthy Volunteer | Completed | 2025-09-02 | 2025-10-16 | ClinicalTrials.gov |
| NCT07133828 | A Study to Learn About the Safety of BIIB142 and How it is Processed in the Bod… | Phase1 | Healthy Volunteer | Recruiting | 2025-08-29 | 2026-08-06 | ClinicalTrials.gov |
| NCT07027072 | Study to Evaluate the Efficacy and Safety of KDS2010 in Patients With Alzheimer… | Phase2 | Mild Cognitive Impairment (MCI) | Recruiting | 2025-08-06 | 2027-12-31 | ClinicalTrials.gov |
| NCT07009171 | Study to Evaluate the Efficacy and Safety of KDS2010 in Overweight or Obese Pat… | Phase2 | Overweight | Recruiting | 2025-07-29 | 2027-06-30 | ClinicalTrials.gov |
| NCT07077616 | Clinical Study for the Safety and Therapeutic Efficacy of the AI-QMMM Designed … | Early_Phase1 | Glioma | Recruiting | 2025-07-01 | 2029-12-01 | ClinicalTrials.gov |
| NCT07047820 | A Study to Learn More About How Zuranolone Affects Postpartum Depression Sympto… | — | Depression, Postpartum | Recruiting | 2025-06-30 | 2026-08-24 | ClinicalTrials.gov |
| NCT07019064 | A Study to Learn How BIIB141 (Omaveloxolone) is Processed in the Body When Take… | Phase1 | Healthy Volunteer | Completed | 2025-06-11 | 2025-08-19 | ClinicalTrials.gov |
| NCT06953583 | A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (… | Phase3 | Friedreich Ataxia | Recruiting | 2025-06-09 | 2029-11-22 | ClinicalTrials.gov |
| NCT06962800 | A Study to Learn More About the Effects and Safety of Felzartamab Infusions in … | Phase3 | Primary Membranous Nephropathy | Recruiting | 2025-05-22 | 2029-03-29 | ClinicalTrials.gov |
| NCT06935357 | A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immu… | Phase3 | Immunoglobulin A Nephropathy (IgAN) | Recruiting | 2025-05-08 | 2029-06-05 | ClinicalTrials.gov |
| NCT06955897 | Characterizing Perceived Physical Fatigability in Nusinersen-treated SMA | — | Spinal Muscular Atrophy | Recruiting | 2025-04-24 | 2027-02-26 | ClinicalTrials.gov |
| NCT06454721 | A Study to Determine the Biodistribution, Safety, and Tolerability of a Microdo… | Phase1 | Healthy Volunteer | Completed | 2025-01-30 | 2026-03-05 | ClinicalTrials.gov |
| NCT06555419 | A Study to Find Out How Nusinersen is Processed in the Body When Given Through … | Phase1 | Muscular Atrophy, Spinal | Recruiting | 2025-01-16 | 2027-06-25 | ClinicalTrials.gov |
| NCT06741657 | A Study to Find Out How Litifilimab is Processed in the Body in Healthy Partici… | Phase1 | Healthy Volunteer | Completed | 2025-01-02 | 2026-03-10 | ClinicalTrials.gov |
| NCT06623890 | A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in … | — | Friedreich Ataxia | Recruiting | 2024-12-12 | 2029-10-01 | ClinicalTrials.gov |
| NCT06685757 | A Study to Learn More About the Effects and Safety of Felzartamab Infusions in … | Phase3 | Antibody-mediated Rejection | Active_Not_Recruiting | 2024-12-03 | 2027-06-01 | ClinicalTrials.gov |
| NCT06612879 | A Study to Find Out How BIIB141 (Omaveloxolone) Moves From the Blood Into the B… | Phase1 | Healthy Volunteer | Completed | 2024-10-18 | 2025-04-08 | ClinicalTrials.gov |
| NCT06640933 | A Study to Find Out How Different Forms of BIIB091 is Processed in The Body Wit… | Phase1 | Healthy Volunteer | Completed | 2024-10-16 | 2025-02-07 | ClinicalTrials.gov |
| NCT06574828 | A Study to Find Out How Multiple Doses of BIIB091 Affect the Electrical Activit… | Phase1 | Healthy Volunteer | Completed | 2024-08-29 | 2025-03-22 | ClinicalTrials.gov |
| NCT06054893 | A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to… | Phase1 | Friedreich Ataxia | Recruiting | 2024-07-01 | 2030-11-22 | ClinicalTrials.gov |
| NCT05767736 | A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants … | — | Multiple Sclerosis | Active_Not_Recruiting | 2024-06-08 | 2032-12-01 | ClinicalTrials.gov |
| NCT06437938 | The Effects of Dietary Supplements on Glycemic Control, Body Composition and He… | Na | PreDiabetes | Recruiting | 2024-04-25 | 2025-08-31 | ClinicalTrials.gov |
| NCT06311786 | A Study to Look at How a Single Oral Dose of Carbon-14-Labelled [14C] BIIB091 M… | Phase1 | Healthy Volunteer | Completed | 2024-04-08 | 2024-05-11 | ClinicalTrials.gov |
| NCT05764122 | A Study to Evaluate the Efficacy and Safety of BIIB131 for Participants With Is… | Phase2 | Ischemic Stroke | Withdrawn | 2024-03-29 | 2025-07-07 | ClinicalTrials.gov |
| NCT06452082 | Risk in Devel Long-COVID in Contracting SARS-CoV-2 Infection After COVID-19 Vac… | — | Vitamin d Deficiency | Completed | 2024-03-20 | 2025-09-10 | ClinicalTrials.gov |
| NCT06264440 | A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions… | Phase1 | Healthy Volunteer | Completed | 2024-02-12 | 2024-06-18 | ClinicalTrials.gov |
| NCT06262477 | A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 … | Phase1 | Healthy Volunteer | Completed | 2024-01-02 | 2024-10-04 | ClinicalTrials.gov |
| NCT05789758 | A Study to Learn How Nusinersen (Spinraza) Affects Participants With Spinal Mus… | — | Muscular Atrophy, Spinal | Recruiting | 2023-12-15 | 2033-10-31 | ClinicalTrials.gov |
| NCT06602921 | The Effects of Nitrate, Caffeine, and Cold Exposure on Cardiovascular Function. | Na | Nitrate | Completed | 2023-12-05 | 2025-04-01 | ClinicalTrials.gov |
| NCT05866419 | Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscu… | Na | Spinal Muscular Atrophy | Recruiting | 2023-11-27 | 2030-07-01 | ClinicalTrials.gov |
| NCT06127095 | A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Mo… | — | Multiple Sclerosis, Relapsing-Remitting | Completed | 2023-11-24 | 2024-11-28 | ClinicalTrials.gov |
| NCT06064929 | A Study to Learn More About the Safety and Effects of Felzartamab in Adults Wit… | Phase1 | Lupus Nephritis | Completed | 2023-11-01 | 2026-07-08 | ClinicalTrials.gov |
| NCT05658497 | Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate) | — | Multiple Sclerosis | Recruiting | 2023-10-27 | 2032-07-06 | ClinicalTrials.gov |
| NCT06044337 | A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB… | Phase3 | Subacute Cutaneous Lupus Erythematosus | Enrolling_By_Invitation | 2023-10-03 | 2029-12-11 | ClinicalTrials.gov |
| NCT05895552 | A Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropath… | Phase2 | Diabetic Peripheral Neuropathic Pain | Terminated | 2023-07-28 | 2024-11-15 | ClinicalTrials.gov |
| NCT05798520 | A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammati… | Phase2 | Relapsing Forms of Multiple Sclerosis | Completed | 2023-07-25 | 2026-02-10 | ClinicalTrials.gov |
| NCT05927649 | A TQTc Study for Omaveloxolone | Phase1 | Health Adult Subjects | Completed | 2023-07-11 | 2023-09-01 | ClinicalTrials.gov |
| NCT05618301 | Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Ge… | Phase1 | Sickle Cell Disease | Completed | 2023-07-07 | 2025-06-24 | ClinicalTrials.gov |
| NCT05928585 | A Study of Safety and Drug Levels of HIB210 in Healthy Volunteers | Phase1 | Immune System Diseases | Completed | 2023-07-06 | 2024-06-10 | ClinicalTrials.gov |
| NCT05909644 | An Open-label DDI Study of Omaveloxolone in Healthy Subjects | Phase1 | Healthy Adult Subjects | Completed | 2023-07-05 | 2023-08-30 | ClinicalTrials.gov |
| NCT05925049 | A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS… | — | Multiple Sclerosis | Active_Not_Recruiting | 2023-06-30 | 2026-10-31 | ClinicalTrials.gov |
| NCT05658484 | A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RM… | Phase4 | Multiple Sclerosis | Completed | 2023-06-09 | 2025-04-12 | ClinicalTrials.gov |
| NCT03070132 | 802NP301 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal N… | Phase3 | Trigeminal Neuralgia | Withdrawn | 2023-04-19 | 2026-08-21 | ClinicalTrials.gov |
| NCT05655507 | Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With … | Phase1 | Major Depressive Disorder | Completed | 2023-04-19 | 2024-10-18 | ClinicalTrials.gov |
| NCT03637387 | 802NP302 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal N… | Phase3 | Trigeminal Neuralgia | Withdrawn | 2023-03-01 | 2026-09-29 | ClinicalTrials.gov |
| NCT05701423 | A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple S… | — | Multiple Sclerosis | Terminated | 2023-02-08 | 2024-07-31 | ClinicalTrials.gov |
| NCT05532163 | A Study to Investigate the Radiological Onset of Action After Treatment Initiat… | Phase4 | Multiple Sclerosis, Relapsing-Remitting | Terminated | 2023-01-23 | 2023-10-09 | ClinicalTrials.gov |
| NCT05618379 | Adult Spinal Muscular Atrophy (SMA) China Registry | — | Muscular Atrophy, Spinal | Active_Not_Recruiting | 2023-01-06 | 2028-06-01 | ClinicalTrials.gov |
| NCT05418010 | Natalizumab for the Treatment of People With Inflammatory Demyelination Suggest… | Phase2 | Multiple Sclerosis | Recruiting | 2022-12-01 | 2027-10-31 | ClinicalTrials.gov |
| NCT03426254 | Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazopa… | Phase1 | Advanced or Recurrent Solid Tumors | Withdrawn | 2022-11-10 | 2024-01-10 | ClinicalTrials.gov |
| NCT05575011 | A Study to Learn About the Safety of BIIB115 Injections and How BIIB115 is Proc… | Phase1 | Healthy Volunteer | Active_Not_Recruiting | 2022-10-10 | 2031-11-14 | ClinicalTrials.gov |
| NCT05177718 | Natalizumab and Chronic Inflammation | Phase4 | Multiple Sclerosis | Terminated | 2022-09-16 | 2023-04-05 | ClinicalTrials.gov |
| NCT05531565 | A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Sy… | Phase2 | Subacute Cutaneous Lupus Erythematosus | Active_Not_Recruiting | 2022-09-13 | 2027-12-14 | ClinicalTrials.gov |
| NCT06089018 | Observational Study of Digital Biomarkers of Myotonia and Gait in Adults and Ch… | — | Myotonic Dystrophy 1 | Unknown | 2022-09-10 | 2024-09-10 | ClinicalTrials.gov |
| NCT05418673 | A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-S… | Phase3 | Parkinson Disease | Terminated | 2022-08-26 | 2023-07-27 | ClinicalTrials.gov |
| NCT05399888 | A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whethe… | Phase2 | Mild Cognitive Impairment Due to Alzheimer's Disease | Active_Not_Recruiting | 2022-08-24 | 2028-06-06 | ClinicalTrials.gov |
| NCT05475691 | Longitudinal Data Collection in Pediatric and Adult Patients With Spinal Muscul… | — | Spinal Muscular Atrophy | Unknown | 2022-08-17 | 2025-01-30 | ClinicalTrials.gov |
| NCT06978985 | Adult SMA Research and Clinical Hub | — | Spinal Muscular Atrophy (SMA) | Recruiting | 2022-07-29 | 2027-04-30 | ClinicalTrials.gov |
| NCT05561621 | Prediction of Non-motor Symptoms in Fully Ambulatory MS Patients Using Vocal Bi… | — | Multiple Sclerosis | Completed | 2022-07-15 | 2022-12-20 | ClinicalTrials.gov |
| NCT05209815 | Safety of Exposure to Natalizumab During Pregnancy | — | Multiple Sclerosis | Completed | 2022-06-20 | 2023-12-22 | ClinicalTrials.gov |
| NCT05352919 | An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BII… | Phase3 | Systemic Lupus Erythematosus (SLE) | Enrolling_By_Invitation | 2022-06-10 | 2030-03-29 | ClinicalTrials.gov |
| NCT05310071 | A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early… | Phase3 | Alzheimer's Disease | Terminated | 2022-06-02 | 2024-08-12 | ClinicalTrials.gov |
| NCT07433010 | German Dementia Registry | — | Dementia Disorder | Recruiting | 2022-05-16 | 2099-12-01 | ClinicalTrials.gov |
| NCT05354414 | Virtual Reality for the Mitigation of Anxiety During Intrathecal Administration… | Na | Spinal Muscular Atrophy (SMA) | Completed | 2022-05-11 | 2024-07-12 | ClinicalTrials.gov |
| NCT05265728 | A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of… | Phase3 | Multiple Sclerosis, Relapsing-Remitting | Terminated | 2022-04-26 | 2024-05-27 | ClinicalTrials.gov |
| NCT05348785 | A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow … | Phase2 | Parkinson Disease | Completed | 2022-04-19 | 2026-03-09 | ClinicalTrials.gov |
| NCT05229562 | A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety… | Phase1 | Healthy Volunteer | Completed | 2022-02-17 | 2022-09-07 | ClinicalTrials.gov |
| NCT05109637 | A Study to Assess the Clinical Validity of Konectom™ in Adults Living With Neur… | Na | Spinal Muscular Atrophy | Completed | 2022-02-10 | 2023-07-25 | ClinicalTrials.gov |
| NCT05446285 | Multiple Sclerosis Outcome Determination Evaluating Real Differences After TimE | — | Relapsing Remitting Multiple Sclerosis | Unknown | 2022-02-07 | 2023-08-01 | ClinicalTrials.gov |
| NCT05160558 | A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar A… | Phase1 | Spinocerebellar Ataxia Type 3 | Terminated | 2022-02-02 | 2023-07-25 | ClinicalTrials.gov |
| NCT05216887 | A Study to Assess the Pharmacokinetic (PK) Comparability of 2 Fixed Subcutaneou… | Phase1 | Healthy Volunteer | Completed | 2022-02-01 | 2022-07-27 | ClinicalTrials.gov |
| NCT05195008 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics, With Target… | Phase1 | Healthy Volunteer | Completed | 2022-01-24 | 2023-07-10 | ClinicalTrials.gov |
| NCT05067790 | A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given… | Phase3 | Spinal Muscular Atrophy | Active_Not_Recruiting | 2022-01-21 | 2027-09-24 | ClinicalTrials.gov |
| NCT05173012 | Study to Evaluate SAGE-324 in Participants With Essential Tremor | Phase2 | Essential Tremor | Completed | 2022-01-05 | 2024-05-16 | ClinicalTrials.gov |
| NCT05106465 | A Study to Explore Association Patterns Between Digital Outcome Assessments Fro… | — | Multiple Sclerosis (MS) | Completed | 2021-12-15 | 2024-04-03 | ClinicalTrials.gov |
| NCT05152485 | A Study to Evaluate the Relative Bioavailability of Two Formulations of BIIB104… | Phase1 | Healthy Volunteers | Completed | 2021-12-15 | 2022-01-31 | ClinicalTrials.gov |
| NCT04948606 | Exploring Diroximel Fumarate Real-world Experience in Canada and Israel | — | Relapsing Forms of MS | Terminated | 2021-12-09 | 2023-04-14 | ClinicalTrials.gov |
| NCT05127564 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Diroximel… | Phase1 | Healthy Volunteers | Completed | 2021-12-03 | 2022-06-29 | ClinicalTrials.gov |
| NCT05148481 | A Study to Evaluate Safety and Pharmacokinetics of BIIB104 in Healthy Japanese … | Phase1 | Healthy Volunteer | Completed | 2021-11-23 | 2022-02-12 | ClinicalTrials.gov |
| NCT05097131 | An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Dise… | — | Alzheimers Disease | Terminated | 2021-11-18 | 2022-05-20 | ClinicalTrials.gov |
| NCT05083923 | A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific… | Phase3 | Relapsing Forms of Multiple Sclerosis | Completed | 2021-11-18 | 2024-09-11 | ClinicalTrials.gov |
| NCT05042921 | Pediatric Spinal Muscular Atrophy (SMA) China Registry | — | Muscular Atrophy, Spinal | Active_Not_Recruiting | 2021-11-18 | 2027-09-02 | ClinicalTrials.gov |
| NCT05304520 | A Study for Tysabri Participant Preference | — | Relapsing-Remitting Multiple Sclerosis (RRMS) | Completed | 2021-10-12 | 2024-04-30 | ClinicalTrials.gov |
| NCT03481842 | Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the… | Phase1 | Endometriosis | Withdrawn | 2021-10-10 | 2021-10-10 | ClinicalTrials.gov |
| NCT05021484 | Felzartamab in Late Antibody-Mediated Rejection | Phase2 | Antibody-mediated Rejection | Completed | 2021-10-06 | 2024-03-07 | ClinicalTrials.gov |
| NCT05688436 | A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Par… | — | Multiple Sclerosis | Active_Not_Recruiting | 2021-09-24 | 2031-01-17 | ClinicalTrials.gov |
| NCT05058950 | An Observational Study Using Multimodal Sensors to Measure Cognitive Health in … | — | Mild Cognitive Impairment | Terminated | 2021-09-20 | 2023-09-19 | ClinicalTrials.gov |
| NCT05065970 | Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Fe… | Phase2 | Immunoglobulin A (IgA) Nephropathy | Completed | 2021-08-31 | 2024-05-06 | ClinicalTrials.gov |
| NCT05119790 | A Study of Mass Balance, Pharmacokinetics, Metabolite Profile, and Metabolite I… | Phase1 | Healthy Volunteers | Completed | 2021-08-27 | 2021-11-05 | ClinicalTrials.gov |
| NCT04924153 | A Natural History Study of Participants With Potassium Sodium-Activated Channel… | — | KCNT1-Related Epilepsy | Completed | 2021-08-17 | 2023-08-29 | ClinicalTrials.gov |
| NCT05005338 | A Study to Determine the Absolute Bioavailability of BIIB122/DNL151 in Healthy … | Phase1 | Healthy Volunteers | Completed | 2021-07-28 | 2021-09-23 | ClinicalTrials.gov |
| NCT04961567 | A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Wheth… | Phase3 | Lupus Erythematosus, Systemic | Active_Not_Recruiting | 2021-07-16 | 2027-03-16 | ClinicalTrials.gov |
| NCT04870203 | Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis | Phase3 | Rheumatoid Arthritis | Active_Not_Recruiting | 2021-07-15 | 2027-03-01 | ClinicalTrials.gov |
| NCT05197699 | Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2)-Related Multi… | — | Multiple Sclerosis (MS) | Terminated | 2021-07-01 | 2023-09-30 | ClinicalTrials.gov |
| NCT04079088 | Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer… | Phase2 | Relapsing Multiple Sclerosis | Withdrawn | 2021-06-30 | 2024-09-18 | ClinicalTrials.gov |
| NCT04924140 | A Study to Assess Absolute Bioavailability of Aducanumab in Healthy Volunteers | Phase1 | Healthy Volunteers | Completed | 2021-06-30 | 2021-10-01 | ClinicalTrials.gov |
| NCT04895241 | A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Wheth… | Phase3 | Lupus Erythematosus, Systemic | Active_Not_Recruiting | 2021-05-25 | 2027-03-16 | ClinicalTrials.gov |
| NCT04856982 | A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults Wit… | Phase3 | Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation | Active_Not_Recruiting | 2021-05-17 | 2028-04-30 | ClinicalTrials.gov |
| NCT04819555 | Frequency of SOD1 and C9orf72 Gene Mutations in French ALS | — | Amyotrophic Lateral Sclerosis | Completed | 2021-04-30 | 2023-05-15 | ClinicalTrials.gov |
| NCT04655222 | Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcu… | — | Multiple Sclerosis | Completed | 2021-04-30 | 2021-10-15 | ClinicalTrials.gov |
| NCT04729907 | A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB… | Phase3 | Muscular Atrophy, Spinal | Active_Not_Recruiting | 2021-04-19 | 2026-07-31 | ClinicalTrials.gov |
| NCT04756687 | Real World Analysis on Lymphocyte Reconstitution After Lymphopenia in Participa… | — | Multiple Sclerosis | Completed | 2021-03-10 | 2021-06-15 | ClinicalTrials.gov |
| NCT04746976 | Study of Diroximel Fumarate in the Real-World Setting | — | Relapsing Forms of MS | Terminated | 2021-03-01 | 2023-04-14 | ClinicalTrials.gov |
| NCT04490096 | Multimodal Imaging Outcome Measures for ALS (Image ALS) | Phase1 | ALS | Terminated | 2021-02-25 | 2022-03-17 | ClinicalTrials.gov |
| NCT04702997 | A Trial of Bardoxolone Methyl in Patients With CKD at Risk of Rapid Progression… | Phase2 | Chronic Kidney Diseases | Completed | 2021-02-09 | 2021-11-23 | ClinicalTrials.gov |
| NCT04702087 | Omega 3, Leucine, Probiotic Lactobacillus Paracasei PS23 on Muscle Mass in Sarc… | Na | Sarcopenia | Unknown | 2021-01-22 | 2022-12-01 | ClinicalTrials.gov |
| NCT04733040 | Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R+ Membranous Nephropathy (aMN… | Phase2 | Glomerulonephritis | Completed | 2021-01-20 | 2023-12-14 | ClinicalTrials.gov |
| NCT04488133 | A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections t… | Phase4 | Muscular Atrophy, Spinal | Completed | 2021-01-04 | 2025-10-09 | ClinicalTrials.gov |
| NCT04750785 | A Study to Assess Choroideremia (CHM) Health Outcomes | — | Choroideremia | Completed | 2020-12-15 | 2021-09-27 | ClinicalTrials.gov |
| NCT05058729 | MS PATHS COVID-19 Questionnaire Data Linkage Sub-Study | — | Multiple Sclerosis (MS) | Completed | 2020-12-07 | 2021-10-08 | ClinicalTrials.gov |
| NCT04289909 | Identification of Retinal Perivascular Inflammation in Patients With Multiple S… | Na | Relapsing Remitting Multiple Sclerosis | Completed | 2020-12-01 | 2024-07-17 | ClinicalTrials.gov |
| NCT04419233 | Non-Interventional, Postmarketing Surveillance Study of Nusinersen Sodium Injec… | — | Muscular Atrophy, Spinal | Completed | 2020-11-18 | 2023-11-21 | ClinicalTrials.gov |
| NCT05260151 | Tau Protein and SV2a Imaging in Patients With Tau Protein-related Diseases | — | Alzheimer Disease | Unknown | 2020-11-18 | 2022-12-31 | ClinicalTrials.gov |
| NCT04476030 | A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plu… | Phase3 | Depressive Disorder, Major | Completed | 2020-11-09 | 2021-12-22 | ClinicalTrials.gov |
| NCT04593121 | Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics o… | Phase1 | Healthy Volunteers | Completed | 2020-10-30 | 2024-03-05 | ClinicalTrials.gov |
| NCT04599023 | Assessing the Feasibility of the MSPT Device in Routine Clinical Practice in th… | — | Multiple Sclerosis | Terminated | 2020-10-16 | 2022-08-31 | ClinicalTrials.gov |
| NCT04571424 | A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic… | Phase1 | Healthy Volunteers | Completed | 2020-10-14 | 2021-04-08 | ClinicalTrials.gov |
| NCT04756700 | Validation of DigiCog and Konectom Tools to Support Digitalized Clinical Assess… | Na | Multiple Sclerosis | Completed | 2020-10-12 | 2022-07-26 | ClinicalTrials.gov |
| NCT04106050 | Pharmacodynamic Study of BIIB095 and BIIB074 in Healthy Participants and Partic… | Phase1 | Healthy Volunteers | Withdrawn | 2020-09-30 | 2022-01-21 | ClinicalTrials.gov |
| NCT04564612 | Study of BIIB091 Formulations in Healthy Participants | Phase1 | Healthy Volunteers | Completed | 2020-09-28 | 2022-09-07 | ClinicalTrials.gov |
| NCT04494256 | A Study to Assess the Safety, Tolerability, and Effect on Disease Progression o… | Phase1 | Amyotrophic Lateral Sclerosis | Terminated | 2020-09-28 | 2024-08-13 | ClinicalTrials.gov |
| NCT04580381 | Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Co… | — | Multiple Sclerosis, Relapsing-Remitting | Completed | 2020-09-01 | 2021-10-30 | ClinicalTrials.gov |
| NCT04795206 | Natural Disease Progression in Participants With Choroideremia | — | Choroideremia | Completed | 2020-08-26 | 2021-08-10 | ClinicalTrials.gov |
| NCT04442503 | A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Se… | Phase3 | Depression, Postpartum | Completed | 2020-06-08 | 2022-04-12 | ClinicalTrials.gov |
| NCT04288128 | Integrated Functional Evaluation of the Cerebellum | — | Spinocerebellar Ataxia Type 2 | Completed | 2020-05-28 | 2022-06-01 | ClinicalTrials.gov |
| NCT04442490 | A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Particip… | Phase3 | Depressive Disorder, Major | Completed | 2020-05-12 | 2021-04-21 | ClinicalTrials.gov |
| NCT04288856 | Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disea… | Phase1 | Amyotrophic Lateral Sclerosis | Terminated | 2020-04-28 | 2022-05-03 | ClinicalTrials.gov |
| NCT05017142 | Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD) | — | Optic Neuritis | Recruiting | 2020-04-14 | 2071-01-01 | ClinicalTrials.gov |
| NCT04089566 | Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy | Phase3 | Muscular Atrophy, Spinal | Completed | 2020-03-26 | 2024-05-30 | ClinicalTrials.gov |
| NCT04241068 | A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With … | Phase3 | Alzheimer's Disease | Terminated | 2020-03-02 | 2024-07-22 | ClinicalTrials.gov |
| NCT04103333 | Angelman Syndrome (AS) Biomarker Study | Early_Phase1 | Angelman Syndrome | Completed | 2019-12-18 | 2022-01-02 | ClinicalTrials.gov |
| NCT04068532 | A Study to Explore Pharmacodynamic Effects of BIIB104 on Brain Circuitry in Hea… | Phase1 | Healthy Volunteers | Completed | 2019-11-15 | 2020-11-11 | ClinicalTrials.gov |
| NCT03958877 | A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginter… | Phase3 | Multiple Sclerosis, Relapsing-Remitting | Active_Not_Recruiting | 2019-10-18 | 2027-05-20 | ClinicalTrials.gov |
| NCT04145440 | Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephro… | Phase1 | Glomerulonephritis, Membranous | Completed | 2019-10-15 | 2022-08-02 | ClinicalTrials.gov |
| NCT04079101 | Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB104 in He… | Phase1 | Healthy Volunteers | Completed | 2019-10-02 | 2019-12-27 | ClinicalTrials.gov |
| NCT04221191 | Dimethyl Fumarate (DMF, Tecfidera®) Persistence in RR-MS Patients Included in t… | — | Multiple Sclerosis, Relapsing-Remitting | Completed | 2019-08-19 | 2022-09-14 | ClinicalTrials.gov |
| NCT04007367 | A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants Wi… | Phase3 | Major Depressive Disorder | Terminated | 2019-08-06 | 2020-01-06 | ClinicalTrials.gov |
| NCT04056689 | Study to Evaluate DNL151 in Subjects With Parkinson's Disease | Phase1 | Parkinson's Disease | Completed | 2019-07-23 | 2020-12-02 | ClinicalTrials.gov |
| NCT03902002 | A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment an… | Phase1 | Hepatic Impairment | Completed | 2019-07-19 | 2020-01-27 | ClinicalTrials.gov |
| NCT04048577 | A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Do… | Phase4 | Multiple Sclerosis | Unknown | 2019-07-03 | 2021-12-01 | ClinicalTrials.gov |
| NCT04317794 | Observational, Postmarketing Surveillance Study of Spinraza Injection (Nusiners… | — | Muscular Atrophy, Spinal | Active_Not_Recruiting | 2019-07-02 | 2027-02-05 | ClinicalTrials.gov |
| NCT04002492 | Effects of a Weight Based Training Program on MS Patients | Na | Multiple Sclerosis | Unknown | 2019-07-01 | 2019-12-01 | ClinicalTrials.gov |
| NCT04089514 | A Real-world Study of Imraldi® Use | — | Arthritis, Rheumatoid (RA) | Completed | 2019-06-30 | 2021-11-30 | ClinicalTrials.gov |
| NCT03926637 | Feasibility of the Multiple Sclerosis Performance Test in Participants With Mul… | — | Multiple Sclerosis | Terminated | 2019-06-17 | 2022-12-05 | ClinicalTrials.gov |
| NCT04008186 | A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone | Phase1 | Healthy Adult Subjects | Completed | 2019-06-14 | 2019-08-28 | ClinicalTrials.gov |
| NCT04268147 | Instrumented Data Exchange for Ataxia Study | — | Spinocerebellar Ataxia Type 1 | Completed | 2019-06-01 | 2024-06-30 | ClinicalTrials.gov |
| NCT03945279 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodyn… | Phase1 | Amyotrophic Lateral Sclerosis | Completed | 2019-05-30 | 2021-06-21 | ClinicalTrials.gov |
| NCT03918447 | A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON | Phase3 | Autosomal Dominant Polycystic Kidney | Terminated | 2019-05-29 | 2023-08-08 | ClinicalTrials.gov |
| NCT03943056 | A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of BIIB091, … | Phase1 | Healthy Volunteer | Completed | 2019-05-13 | 2020-01-10 | ClinicalTrials.gov |
| NCT04145284 | Quantitative Magnetic Resonance Imaging (MRI) Sub-Study of MS PATHS | — | Multiple Sclerosis | Completed | 2019-04-30 | 2020-04-30 | ClinicalTrials.gov |
| NCT03681015 | Wearable Assessments in the Clinic and Home in PD | — | Parkinson Disease | Completed | 2019-04-24 | 2022-03-30 | ClinicalTrials.gov |
| NCT03931590 | A Human AME Study for Omaveloxolone | Phase1 | Healthy Male Subjects | Completed | 2019-04-11 | 2019-05-31 | ClinicalTrials.gov |
| NCT03887455 | A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early … | Phase3 | Early Alzheimer's Disease | Active_Not_Recruiting | 2019-03-27 | 2029-06-30 | ClinicalTrials.gov |
| NCT03870763 | Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and … | Phase3 | Multiple Sclerosis, Relapsing-Remitting | Terminated | 2019-03-19 | 2022-07-21 | ClinicalTrials.gov |
| NCT03716570 | A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic… | Phase1 | Parkinson's Disease | Terminated | 2019-03-12 | 2021-04-23 | ClinicalTrials.gov |
| NCT03749447 | An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE) | Phase3 | Chronic Kidney Diseases | Terminated | 2019-03-08 | 2023-08-23 | ClinicalTrials.gov |
| NCT03864614 | A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disord… | Phase3 | Major Depressive Disorder | Completed | 2019-02-27 | 2023-06-22 | ClinicalTrials.gov |
| NCT03771664 | A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared… | Phase3 | Major Depressive Disorder | Terminated | 2019-02-04 | 2020-01-17 | ClinicalTrials.gov |
| NCT05236777 | TOPIK Study: A Study to Report Progressive Multifocal Leukoencephalopathy and O… | — | Multiple Sclerosis | Completed | 2019-01-01 | 2025-04-30 | ClinicalTrials.gov |
| NCT03639987 | A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alz… | Phase2 | Cognitive Dysfunction | Terminated | 2018-12-20 | 2019-07-30 | ClinicalTrials.gov |
| NCT03764488 | A Study to Evaluate Safety, Tolerability, and Distribution of a Microdose of Ra… | Phase1 | Healthy Volunteers | Completed | 2018-12-20 | 2021-07-10 | ClinicalTrials.gov |
| NCT03689972 | A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (B… | Phase3 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2018-11-27 | 2023-07-24 | ClinicalTrials.gov |
| NCT03672175 | A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Particip… | Phase3 | Major Depressive Disorder | Completed | 2018-11-19 | 2020-03-17 | ClinicalTrials.gov |
| NCT03745820 | A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cog… | Phase2 | Cognitive Impairment Associated With Schizophrenia | Completed | 2018-11-15 | 2022-04-07 | ClinicalTrials.gov |
| NCT03664453 | A Pharmacokinetic Study of Omaveloxolone in Healthy Volunteers | Phase1 | Healthy | Completed | 2018-10-29 | 2018-11-20 | ClinicalTrials.gov |
| NCT04591678 | Adults With SMA Treated With Nusinersen | — | Spinal Muscular Atrophy | Completed | 2018-10-01 | 2021-06-25 | ClinicalTrials.gov |
| NCT03573505 | An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmona… | Phase2 | Idiopathic Pulmonary Fibrosis | Terminated | 2018-09-24 | 2019-11-14 | ClinicalTrials.gov |
| NCT03626012 | A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in … | Phase1 | Amyotrophic Lateral Sclerosis | Completed | 2018-09-10 | 2021-11-17 | ClinicalTrials.gov |
| NCT03692910 | A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a … | Phase2 | Bipolar Disorder I | Completed | 2018-08-23 | 2019-05-21 | ClinicalTrials.gov |
| NCT02454907 | The Use of Technology to Improve MS Clinical Trials and Patient Care | Na | Multiple Sclerosis | Completed | 2018-07-31 | 2026-05-25 | ClinicalTrials.gov |
| NCT03662919 | One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi:… | — | Arthritis, Rheumatoid | Completed | 2018-07-02 | 2022-06-30 | ClinicalTrials.gov |
| NCT03579030 | Safety and PK/PD of RTA 1701 in Healthy Adults | Phase1 | Healthy | Completed | 2018-06-20 | 2019-06-28 | ClinicalTrials.gov |
| NCT03584165 | Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroid… | Phase3 | Choroideremia | Completed | 2018-06-04 | 2026-06-22 | ClinicalTrials.gov |
| NCT03339336 | Efficacy and Safety Study of BIIB074 in Participants With Small Fiber Neuropathy | Phase2 | Small Fiber Neuropathy | Terminated | 2018-05-31 | 2021-04-12 | ClinicalTrials.gov |
| NCT03352557 | Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease | Phase2 | Alzheimer's Disease | Terminated | 2018-05-03 | 2021-08-30 | ClinicalTrials.gov |
| NCT03454126 | Evaluating the Safety, Tolerability, and Pharmacokinetics of BIIB095 in Healthy… | Phase1 | Healthy Volunteer | Completed | 2018-03-29 | 2019-04-30 | ClinicalTrials.gov |
| NCT03283371 | Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilep… | Phase2 | Epilepsy, Focal Seizures, Partial Seizures | Completed | 2018-03-20 | 2020-11-18 | ClinicalTrials.gov |
| NCT03498625 | Crohn's Disease Endoscopic REmission Definition in an Objective Way | Na | CD | Completed | 2018-03-13 | 2021-12-31 | ClinicalTrials.gov |
| NCT03487900 | Is the Endoscopic Remission Evaluation, Using the CREDO 1 Index / Score in CD P… | Na | CD | Unknown | 2018-03-13 | 2023-12-31 | ClinicalTrials.gov |
| NCT03554343 | Sun May Arise on SMA : Newborn Screening of Spinal Muscular Atrophy in Belgium | — | Spinal Muscular Atrophy | Completed | 2018-03-05 | 2021-02-28 | ClinicalTrials.gov |
| NCT03088956 | Cognitive, Behavioral, and Functional Change in Behavioral Variant Frontotempor… | — | Frontotemporal Dementia | Completed | 2018-01-19 | 2019-09-23 | ClinicalTrials.gov |
| NCT03318523 | Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB… | Phase2 | Parkinson's Disease | Terminated | 2018-01-10 | 2021-04-29 | ClinicalTrials.gov |
| NCT03366337 | A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients Wi… | Phase2 | IgA Nephropathy | Completed | 2017-12-26 | 2019-01-29 | ClinicalTrials.gov |
| NCT02996084 | MS PATHS Normative Sub-Study | — | Healthy Volunteer | Completed | 2017-12-12 | 2022-12-31 | ClinicalTrials.gov |
| NCT03496012 | Efficacy and Safety of BIIB111 for the Treatment of Choroideremia | Phase3 | Choroideremia | Completed | 2017-12-11 | 2020-12-01 | ClinicalTrials.gov |
| NCT03507686 | A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of… | Phase2 | Choroideremia | Completed | 2017-11-29 | 2022-06-29 | ClinicalTrials.gov |
| NCT03347370 | A Post-Authorization Safety Study of Interferon Beta Therapy in Participants Wi… | — | Multiple Sclerosis, Relapsing-Remitting | Completed | 2017-11-27 | 2019-07-31 | ClinicalTrials.gov |
| NCT03222973 | Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Mod… | Phase2 | Multiple Sclerosis | Terminated | 2017-11-15 | 2021-02-12 | ClinicalTrials.gov |
| NCT03324685 | A Drug Interaction Study of BIIB074 and an Oral Contraceptive Regimen | Phase1 | Drug Interactions | Completed | 2017-11-11 | 2018-03-15 | ClinicalTrials.gov |
| NCT03264079 | Effect of Itraconazole on the Pharmacokinetics of Bardoxolone Methyl in Healthy… | Phase1 | Healthy Volunteers | Completed | 2017-10-16 | 2017-11-13 | ClinicalTrials.gov |
| NCT03224793 | Safety, Tolerability, and Pharmacokinetics of Single Doses of BIIB059 in Health… | Phase1 | Healthy Subjects | Completed | 2017-10-04 | 2018-06-12 | ClinicalTrials.gov |
| NCT03424733 | Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side … | Phase4 | Multiple Sclerosis | Unknown | 2017-09-25 | 2020-05-31 | ClinicalTrials.gov |
| NCT03284931 | A Study to Assess the Pharmacodynamic Effects of SAGE-217 in Healthy Adults Usi… | Phase1 | Healthy | Completed | 2017-09-14 | 2017-12-18 | ClinicalTrials.gov |
| NCT04926129 | Natural History of the Progression of X-Linked Retinitis Pigmentosa | — | X-Linked Retinitis Pigmentosa | Completed | 2017-09-13 | 2022-12-16 | ClinicalTrials.gov |
| NCT03385525 | Study to Evaluate the Effect of UGT Inhibition by Valproic Acid on the Pharmaco… | Phase1 | Drug Interaction | Completed | 2017-09-12 | 2017-10-13 | ClinicalTrials.gov |
| NCT03300869 | Natural History of Types 2 and 3 SMA in Taiwan | — | Spinal Muscular Atrophy | Unknown | 2017-09-01 | 2019-12-01 | ClinicalTrials.gov |
| NCT03662750 | TSPO PET as a Measure of Post-stroke Brain Inflammation: a Natural History Coho… | Na | Stroke, Ischemic | Completed | 2017-08-31 | 2019-12-31 | ClinicalTrials.gov |
| NCT03327454 | Benepali® PEN Patient Satisfaction Survey | — | Rheumatoid Arthritis | Completed | 2017-08-10 | 2018-06-21 | ClinicalTrials.gov |
| NCT03100734 | Observational Study to Evaluate the Real-Life Effectiveness of Benepali Followi… | — | Rheumatoid Arthritis | Completed | 2017-06-01 | 2018-11-30 | ClinicalTrials.gov |
| NCT03399981 | Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries | — | Progressive Multifocal Leukoencephalopathy | Completed | 2017-06-01 | 2023-12-31 | ClinicalTrials.gov |
| NCT03068468 | Study of BIIB092 in Participants With Progressive Supranuclear Palsy | Phase2 | Supranuclear Palsy, Progressive | Terminated | 2017-06-01 | 2020-02-07 | ClinicalTrials.gov |
| NCT03068130 | Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Pat… | Phase3 | Pulmonary Hypertension | Terminated | 2017-04-18 | 2020-09-30 | ClinicalTrials.gov |
| NCT02881567 | Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Nata… | Phase3 | Relapsing-Remitting Multiple Sclerosis (RRMS) | Terminated | 2017-04-18 | 2018-09-12 | ClinicalTrials.gov |
| NCT02978781 | A Study to Evaluate SAGE-217 in Participants With Essential Tremor | Phase2 | Essential Tremor | Completed | 2017-03-24 | 2017-12-05 | ClinicalTrials.gov |
| NCT03093324 | A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple… | Phase3 | Relapsing Remitting Multiple Sclerosis | Completed | 2017-03-15 | 2019-06-27 | ClinicalTrials.gov |
| NCT03091569 | Effects of Vitamin K on Redness Associated With Injection Site Reactions in Par… | Phase4 | Relapsing-Remitting Multiple Sclerosis | Completed | 2017-03-10 | 2018-01-27 | ClinicalTrials.gov |
| NCT03116113 | A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Usin… | Phase1 | X-Linked Retinitis Pigmentosa | Completed | 2017-03-08 | 2020-11-18 | ClinicalTrials.gov |
| NCT03070119 | Long-Term Evaluation of BIIB067 (Tofersen) | Phase3 | ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation | Completed | 2017-03-08 | 2024-08-12 | ClinicalTrials.gov |
| NCT03019185 | A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients … | Phase2 | Alport Syndrome | Completed | 2017-03-02 | 2020-10-30 | ClinicalTrials.gov |
| NCT03056729 | Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants W… | Phase1 | Alzheimer's Disease | Completed | 2017-02-17 | 2020-03-03 | ClinicalTrials.gov |
| NCT04123353 | Scan-Rescan Sub-Study of MS PATHS | — | Multiple Sclerosis | Completed | 2017-02-11 | 2017-05-09 | ClinicalTrials.gov |
| NCT02957617 | Extension Study to Evaluate the Long-Term Safety, Tolerability, and Maintenance… | Phase2 | Neuropathic Pain From Lumbosacral Radiculopathy | Terminated | 2017-02-10 | 2019-02-07 | ClinicalTrials.gov |
| NCT03218111 | Glymphatic Kinetics In Healthy Adult Volunteers | Na | Healthy | Completed | 2017-02-06 | 2018-02-08 | ClinicalTrials.gov |
| NCT03177083 | Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning… | Phase4 | Relapsing Remitting Multiple Sclerosis | Completed | 2017-01-30 | 2020-10-26 | ClinicalTrials.gov |
| NCT02978326 | A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression | Phase3 | Postpartum Depression | Completed | 2017-01-04 | 2018-12-11 | ClinicalTrials.gov |
| NCT02666963 | A Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multipl… | Phase1 | Healthy | Completed | 2017-01-01 | 2017-07-23 | ClinicalTrials.gov |
| NCT02969304 | Study of Utilization Patterns of Dimethyl Fumarate in Germany | — | Multiple Sclerosis | Completed | 2016-12-30 | 2017-03-02 | ClinicalTrials.gov |
| NCT03047369 | The Myelin Disorders Biorepository Project | — | Leukodystrophy | Recruiting | 2016-12-08 | 2030-12-08 | ClinicalTrials.gov |
| NCT03000530 | A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depr… | Phase2 | Major Depression | Completed | 2016-12-07 | 2017-11-08 | ClinicalTrials.gov |
| NCT02951221 | New Formulation and Food Effect Study of BIIB074 | Phase1 | Trigeminal Neuralgia (TN) | Completed | 2016-12-01 | 2017-02-01 | ClinicalTrials.gov |
| NCT02981082 | Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hyp… | Phase1 | Systemic Sclerosis | Terminated | 2016-12-01 | 2020-02-10 | ClinicalTrials.gov |
| NCT02959658 | Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis | Phase2 | Primary Progressive Multiple Sclerosis | Completed | 2016-12-01 | 2020-12-09 | ClinicalTrials.gov |
| NCT03000569 | A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease | Phase2 | Parkinson Disease | Completed | 2016-11-30 | 2017-09-11 | ClinicalTrials.gov |
| NCT02839460 | A Prospective Study Of Biomarkers Of Skeletal Muscle Atrophy | — | Sarcopenia | Completed | 2016-11-01 | 2019-03-01 | ClinicalTrials.gov |
| NCT02935608 | Study to Evaluate the Efficacy and Safety of BIIB074 in Neuropathic Pain From L… | Phase2 | Lumbosacral Radiculopathy | Completed | 2016-10-31 | 2018-08-06 | ClinicalTrials.gov |
| NCT02847598 | Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) … | Phase2 | Systemic Lupus Erythematosus | Completed | 2016-10-20 | 2019-11-18 | ClinicalTrials.gov |
| NCT02956486 | A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in… | Phase3 | Alzheimer's Disease | Terminated | 2016-10-20 | 2020-01-15 | ClinicalTrials.gov |
| NCT02657356 | Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmon… | Phase3 | Connective Tissue Disease-Associated Pulmonary Arterial Hypertension | Terminated | 2016-10-04 | 2020-05-07 | ClinicalTrials.gov |
| NCT02917187 | A Phase 2a Study of BIIB074 in the Treatment of Erythromelalgia | Phase2 | Primary Inherited Erythromelalgia | Completed | 2016-09-09 | 2017-01-05 | ClinicalTrials.gov |
| NCT02855411 | A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cog… | Phase2 | Cognitive Impairment Associated With Schizophrenia (CIAS) | Terminated | 2016-08-29 | 2016-09-26 | ClinicalTrials.gov |
| NCT02829541 | A Phase 1, Single-Ascending-Dose, Safety, Tolerability, Pharmacokinetic(PK), an… | Phase1 | Systemic Lupos Erythematosus, SLE | Completed | 2016-08-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02133924 | Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk … | Phase2 | Acute Graft Versus Host Disease | Completed | 2016-08-01 | 2021-11-21 | ClinicalTrials.gov |
| NCT02831517 | PK and Safety Study of BIIB074 in Healthy Japanese and Caucasian Participants | Phase1 | Healthy | Completed | 2016-08-01 | 2017-02-01 | ClinicalTrials.gov |
| NCT02730455 | Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke | Phase2 | Acute Ischemic Stroke | Completed | 2016-07-18 | 2017-11-20 | ClinicalTrials.gov |
| NCT02833142 | Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinuma… | Phase1 | Multiple Sclerosis | Completed | 2016-07-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT02795897 | Genomic Translation for Amyotrophic Lateral Sclerosis Care | — | ALS | Completed | 2016-06-08 | 2022-06-29 | ClinicalTrials.gov |
| NCT02749396 | EPID Multiple Sclerosis Pregnancy Study | — | Multiple Sclerosis | Completed | 2016-05-02 | 2018-08-14 | ClinicalTrials.gov |
| NCT02776072 | Observational Study to Characterize Real-world Clinical Outcomes With Relapsing… | — | Multiple Sclerosis | Completed | 2016-05-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02782975 | Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in … | Phase1 | Alzheimer's Disease | Completed | 2016-05-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT02428218 | Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Sub… | Phase3 | Relapsing-Remitting Multiple Sclerosis | Withdrawn | 2016-05-01 | 2027-01-01 | ClinicalTrials.gov |
| NCT02796222 | Factor Product Utilization and Health Outcomes in Patients With Hemophilia | — | Hemophilia A, Congenital | Completed | 2016-04-01 | 2021-04-26 | ClinicalTrials.gov |
| NCT02751905 | Absorption, Metabolism, and Excretion Study of BIIB074 | Phase1 | Neuropathic Pain | Completed | 2016-04-01 | 2016-05-01 | ClinicalTrials.gov |
| NCT02675413 | Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS | Phase4 | Multiple Sclerosis | Withdrawn | 2016-04-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02691702 | Multiple Dose Study Of BIIB118 (PF-05251749) In Healthy Volunteers | Phase1 | Healthy Adult Subjects | Completed | 2016-03-28 | 2017-01-12 | ClinicalTrials.gov |
| NCT02739542 | Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS) | Phase4 | Multiple Sclerosis (MS) | Completed | 2016-03-19 | 2021-03-31 | ClinicalTrials.gov |
| NCT02657915 | Long-Term Assessment of Remyelinating Therapy | Phase2 | Acute Optic Neuritis | Completed | 2016-03-10 | 2017-01-23 | ClinicalTrials.gov |
| NCT02664324 | MSPT Device Usability Study | — | Multiple Sclerosis | Completed | 2016-03-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02658916 | Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy … | Phase1 | Supranuclear Palsy, Progressive | Terminated | 2016-02-22 | 2020-03-31 | ClinicalTrials.gov |
| NCT02555215 | Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multi… | Phase3 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2016-02-22 | 2018-09-24 | ClinicalTrials.gov |
| NCT02587065 | Plegridy Satisfaction Study in Participants | Phase4 | Relapsing-Remitting Multiple Sclerosis (RRMS) | Completed | 2016-02-03 | 2017-12-21 | ClinicalTrials.gov |
| NCT02644083 | Tecfidera and MRI for Brain Energy in MS | — | Multiple Sclerosis | Terminated | 2016-02-01 | 2018-07-01 | ClinicalTrials.gov |
| NCT02568111 | Brimonidine Tartrate for the Treatment of Injection Related Erythema | Phase4 | Relapsing-Remitting Multiple Sclerosis (RRMS) | Withdrawn | 2016-02-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02778438 | A Validation Study of the Novel Application of Telehealth in Clinical Drug Deve… | — | Mild Cognitive Impairment | Completed | 2016-02-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02698267 | Effect of Itraconazole on the Pharmacokinetics of BIIB074 | Phase1 | Neuropathic Pain | Completed | 2016-02-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02641041 | Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB… | Phase1 | Central Nervous System (CNS) Demyelinating Disease | Completed | 2016-02-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT02623699 | An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study … | Phase3 | Amyotrophic Lateral Sclerosis | Completed | 2016-01-20 | 2021-07-16 | ClinicalTrials.gov |
| NCT02611674 | Methodology Study of Novel Outcome Measures to Assess Progression of ALS | — | Amyotrophic Lateral Sclerosis | Completed | 2016-01-06 | 2019-08-01 | ClinicalTrials.gov |
| NCT02677077 | Clinical Disease Activity With Long Term Natalizumab Treatment | — | Relapsing-Remitting Multiple Sclerosis | Completed | 2015-12-31 | 2016-08-18 | ClinicalTrials.gov |
| NCT02634307 | A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS)… | Phase3 | Multiple Sclerosis | Completed | 2015-12-10 | 2021-11-11 | ClinicalTrials.gov |
| NCT02531009 | Systemic Sclerosis Clinical and Biomarker Study | — | Healthy | Withdrawn | 2015-12-01 | 2017-03-01 | ClinicalTrials.gov |
| NCT02471560 | Tecfidera and the Gut Microbiota | Phase4 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2015-11-06 | 2017-06-12 | ClinicalTrials.gov |
| NCT02594124 | A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Part… | Phase3 | Spinal Muscular Atrophy | Completed | 2015-11-04 | 2023-08-21 | ClinicalTrials.gov |
| NCT02460094 | Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092… | Phase1 | Progressive Supranuclear Palsy | Completed | 2015-10-02 | 2016-10-19 | ClinicalTrials.gov |
| NCT02543346 | Comparability and Standardization of Controlled Allergen Challenge Facilities | Phase4 | Allergic Rhinitis | Completed | 2015-10-01 | 2016-05-01 | ClinicalTrials.gov |
| NCT02410200 | Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric… | Phase2 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2015-09-30 | 2016-09-23 | ClinicalTrials.gov |
| NCT02555085 | Single Ascending Doses of BIIB063 in Healthy Volunteers | Phase1 | Healthy | Terminated | 2015-09-30 | 2016-06-01 | ClinicalTrials.gov |
| NCT02484547 | 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease | Phase3 | Alzheimer's Disease | Terminated | 2015-09-15 | 2019-08-05 | ClinicalTrials.gov |
| NCT02462759 | A Study to Assess the Safety and Tolerability of Nusinersen (ISIS 396443) in Pa… | Phase2 | Spinal Muscular Atrophy | Terminated | 2015-08-19 | 2018-09-24 | ClinicalTrials.gov |
| NCT02477800 | 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease | Phase3 | Alzheimer's Disease | Terminated | 2015-08-13 | 2019-08-08 | ClinicalTrials.gov |
| NCT02525874 | Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Re… | Phase3 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2015-08-11 | 2018-04-23 | ClinicalTrials.gov |
| NCT01532154 | Fampridine Pregnancy Exposure Registry | — | Multiple Sclerosis | Terminated | 2015-08-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT02683863 | Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers | Phase4 | Multiple Sclerosis | Completed | 2015-08-01 | 2017-01-31 | ClinicalTrials.gov |
| NCT02521545 | Single-Dose Study of a New Formulation of BIIB061 | Phase1 | Multiple Sclerosis | Completed | 2015-07-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT02519413 | Tecfidera Lymphocyte Chart Review | — | Multiple Sclerosis | Completed | 2015-07-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT02472938 | Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity o… | Phase4 | Relapsing Remitting Multiple Sclerosis | Withdrawn | 2015-07-01 | 2020-07-01 | ClinicalTrials.gov |
| NCT02459886 | Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkin… | Phase1 | Parkinson's Disease | Completed | 2015-07-01 | 2017-11-20 | ClinicalTrials.gov |
| NCT03359551 | Natural History of the Progression of Choroideremia Study | — | Choroideremia | Completed | 2015-06-30 | 2020-10-01 | ClinicalTrials.gov |
| NCT02434718 | Single and Multiple Ascending Dose Study of Aducanumab (BIIB037) in Japanese Pa… | Phase1 | Alzheimer's Disease | Completed | 2015-06-24 | 2016-12-09 | ClinicalTrials.gov |
| NCT02090348 | Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Scl… | Phase4 | Relapsing-Remitting Multiple Sclerosis | Withdrawn | 2015-06-01 | 2017-10-01 | ClinicalTrials.gov |
| NCT02466529 | Natural History of Spinal Muscular Atrophy Type 1 in Taiwan | — | Natural History of Type 1 Spinal Muscular Atrophy (SMA) | Completed | 2015-06-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02443740 | Safety, Tolerability and Pharmacokinetics of BIIB118 (PF-05251749) | Phase1 | Healthy | Completed | 2015-05-31 | 2015-10-31 | ClinicalTrials.gov |
| NCT02386553 | A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With… | Phase2 | Spinal Muscular Atrophy | Completed | 2015-05-18 | 2024-12-17 | ClinicalTrials.gov |
| NCT02461069 | Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Re… | Phase4 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2015-05-06 | 2018-05-07 | ClinicalTrials.gov |
| NCT02255422 | RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTOR | Phase2 | MItochondrial Myopathies | Completed | 2015-05-05 | 2017-11-30 | ClinicalTrials.gov |
| NCT02323269 | Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Report… | — | Multiple Sclerosis, Relapsing-Remitting | Terminated | 2015-05-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT02430532 | BG00012 and Delay of Disability Progression in Secondary Progressive Multiple S… | Phase3 | Multiple Sclerosis, Secondary Progressive | Terminated | 2015-05-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT02736279 | Impact of Tecfidera on Gut Microbiota | — | Multiple Sclerosis | Unknown | 2015-05-01 | 2020-12-01 | ClinicalTrials.gov |
| NCT02551497 | Study to Evaluate the Interaction Between a Drug and CNV1014802 in Healthy Subj… | Phase1 | Healthy | Completed | 2015-04-30 | 2016-08-26 | ClinicalTrials.gov |
| NCT02428231 | Tecfidera Slow-Titration Study | Phase3 | Multiple Sclerosis | Terminated | 2015-04-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT02422407 | A Longitudinal, Observational Biomarker Study in Participants With Primary Sjog… | — | Healthy | Completed | 2015-03-26 | 2017-08-22 | ClinicalTrials.gov |
| NCT02386566 | Observational Study to Assess the Correlation of EDSS With Quality of Life in M… | — | Multiple Sclerosis | Completed | 2015-03-20 | 2018-01-28 | ClinicalTrials.gov |
| NCT02410278 | Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsin… | Phase4 | Multiple Sclerosis | Completed | 2015-03-12 | 2017-04-27 | ClinicalTrials.gov |
| NCT03093545 | Effect of Rabies Immunoglobulin on Immunogenicity of Post-exposure Rabies Vacci… | Na | Rabies | Completed | 2015-03-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT02097849 | Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participant… | Phase2 | Relapsing Forms of Multiple Sclerosis | Completed | 2015-02-28 | 2016-05-02 | ClinicalTrials.gov |
| NCT02343159 | Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Impro… | Phase4 | Multiple Sclerosis | Terminated | 2015-02-28 | 2016-04-15 | ClinicalTrials.gov |
| NCT02341482 | A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of PF-04… | Phase1 | Healthy | Completed | 2015-02-05 | 2015-03-31 | ClinicalTrials.gov |
| NCT02359344 | PK & Tolerability of CNV1014802 in Young and Elderly Healthy Volunteers | Phase1 | Trigeminal Neuralgia | Completed | 2015-02-03 | 2015-04-20 | ClinicalTrials.gov |
| NCT02686268 | Understanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS | — | C9ORF72 Amyotrophic Lateral Sclerosis (ALS) | Completed | 2015-02-01 | 2018-10-02 | ClinicalTrials.gov |
| NCT03092544 | Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fum… | Phase4 | Multiple Sclerosis | Unknown | 2015-02-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT02255435 | A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in Peo… | Phase2 | Friedreich Ataxia | Completed | 2015-01-31 | 2025-12-19 | ClinicalTrials.gov |
| NCT02332798 | Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia | Phase1 | Schizophrenia | Completed | 2015-01-06 | 2015-04-15 | ClinicalTrials.gov |
| NCT02369224 | Multicenter Validation of The Evergreen Myometric Strength Test for Lower Extre… | — | Multiple Sclerosis | Completed | 2015-01-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT02176031 | Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD | Phase2 | Graft Versus Host Disease | Completed | 2015-01-01 | 2019-02-01 | ClinicalTrials.gov |
| NCT02294851 | A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of … | Phase1 | Tauopathies | Completed | 2014-12-31 | 2016-04-30 | ClinicalTrials.gov |
| NCT02142192 | Natalizumab Subcutaneous Immunogenicity and Safety Study | Phase2 | Relapsing Multiple Sclerosis | Terminated | 2014-12-01 | 2015-06-04 | ClinicalTrials.gov |
| NCT02342704 | Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Scleros… | Phase4 | Relapsing-Remitting Multiple Sclerosis | Terminated | 2014-11-30 | 2016-05-18 | ClinicalTrials.gov |
| NCT02322021 | Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in P… | Phase2 | Alzheimer Disease | Terminated | 2014-11-26 | 2019-12-20 | ClinicalTrials.gov |
| NCT02292537 | A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Partic… | Phase3 | Spinal Muscular Atrophy | Completed | 2014-11-24 | 2017-02-20 | ClinicalTrials.gov |
| NCT02230969 | Plegridy Observational Program | — | Relapsing Forms of Multiple Sclerosis | Completed | 2014-11-12 | 2022-01-20 | ClinicalTrials.gov |
| NCT02283918 | Observational Study to Establish Patient-Matched Population Norms for the Multi… | — | Healthy | Completed | 2014-11-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT02259231 | RTA 408 Capsules in Patients With Melanoma - REVEAL | Phase1 | Melanoma | Completed | 2014-10-31 | 2018-07-23 | ClinicalTrials.gov |
| NCT02234869 | Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Ther… | Phase4 | Relapsing Multiple Sclerosis | Withdrawn | 2014-10-01 | 2018-03-01 | ClinicalTrials.gov |
| NCT02269930 | Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1… | Phase1 | Multiple Sclerosis | Completed | 2014-10-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT02440126 | Longitudinal Analysis And Sample Collection To Evaluate PML Risk Host Markers f… | — | Multiple Sclerosis | Completed | 2014-10-01 | 2020-07-01 | ClinicalTrials.gov |
| NCT02241785 | Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Scler… | Phase4 | Relapsing Multiple Sclerosis | Terminated | 2014-09-30 | 2016-05-02 | ClinicalTrials.gov |
| NCT02228395 | Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses… | Phase1 | Healthy | Completed | 2014-09-22 | 2014-11-13 | ClinicalTrials.gov |
| NCT02219932 | Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With … | Phase3 | Multiple Sclerosis | Completed | 2014-09-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT02283853 | Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Rel… | Phase3 | Relapsing-Remitting Multiple Sclerosis | Completed | 2014-08-28 | 2025-07-08 | ClinicalTrials.gov |
| NCT02193074 | A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infant… | Phase3 | Spinal Muscular Atrophy | Terminated | 2014-08-19 | 2016-11-21 | ClinicalTrials.gov |
| NCT02228707 | Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB061 in He… | Phase1 | Healthy | Completed | 2014-08-01 | 2016-05-01 | ClinicalTrials.gov |
| NCT02217982 | Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation | Phase4 | Relapsing Remitting Multiple Sclerosis | Terminated | 2014-07-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT02159573 | Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG0… | — | Relapsing-Remitting Multiple Sclerosis | Completed | 2014-07-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT02201849 | A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults | Phase1 | Multiple Sclerosis | Completed | 2014-07-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT02142959 | RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE | Phase2 | Breast Cancer | Completed | 2014-06-30 | 2015-04-30 | ClinicalTrials.gov |
| NCT02125604 | Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With R… | Phase4 | Relapsing-Remitting Multiple Sclerosis | Completed | 2014-06-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT02171208 | A Healthy Volunteer Study to Establish the Bioequivalence of BG00012 Supplied b… | Phase1 | Healthy | Completed | 2014-06-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT02036970 | Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LA… | Phase2 | Pulmonary Arterial Hypertension | Completed | 2014-05-31 | 2018-05-16 | ClinicalTrials.gov |
| NCT02128113 | RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Lo… | Phase2 | Corneal Endothelial Cell Loss | Completed | 2014-05-31 | 2015-04-30 | ClinicalTrials.gov |
| NCT02090413 | Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Par… | Phase4 | Relapsing-Remitting Multiple Sclerosis | Completed | 2014-05-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02143167 | Resistance Training and Amino Pyridine in Multiple Sclerosis | Phase4 | Multiple Sclerosis | Completed | 2014-05-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT02125695 | Pilot Tape Harvesting Study | — | Atopic Dermatitis | Completed | 2014-05-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02106897 | Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses… | Phase1 | Systemic Lupus Erythematosus | Completed | 2014-04-30 | 2016-05-24 | ClinicalTrials.gov |
| NCT02579681 | Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Pati… | Phase3 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2014-04-30 | 2016-12-21 | ClinicalTrials.gov |
| NCT02137109 | Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri | — | Multiple Sclerosis | Completed | 2014-03-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02099370 | Adherence to Treatment With Tecfidera™ in Multiple Sclerosis Patients | — | Multiple Sclerosis | Completed | 2014-03-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT02236624 | Aerobic Exercise and Flu-like Symptoms Following Interferon Beta 1a Injections … | Na | Multiple Sclerosis | Completed | 2014-03-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02065375 | RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain… | Phase2 | Inflammation and Pain Following Ocular Surgery | Completed | 2014-02-28 | 2014-09-30 | ClinicalTrials.gov |
| NCT02052791 | An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Part… | Phase1 | Spinal Muscular Atrophy | Completed | 2014-01-31 | 2017-01-31 | ClinicalTrials.gov |
| NCT01955707 | Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke | Phase2 | Acute Ischemic Stroke | Completed | 2014-01-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT02029729 | RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER | Phase1 | Metastatic or Incurable Non-small Cell Lung Cancer | Completed | 2013-12-31 | 2015-10-01 | ClinicalTrials.gov |
| NCT02029716 | RTA 408 Lotion in Healthy Volunteers | Phase1 | Healthy | Completed | 2013-12-31 | 2014-04-01 | ClinicalTrials.gov |
| NCT02071121 | Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics o… | Phase1 | Healthy | Completed | 2013-12-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT01978652 | Pharmacokinetic Study of Peginterferon Beta-1a in Japanese and Caucasian Adult … | Phase1 | Healthy | Completed | 2013-12-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT02047097 | Dimethyl Fumarate (DMF) Observational Study | — | Multiple Sclerosis | Completed | 2013-11-19 | 2022-10-31 | ClinicalTrials.gov |
| NCT04832399 | Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants | — | Relapsing Remitting Multiple Sclerosis | Completed | 2013-11-12 | 2023-10-02 | ClinicalTrials.gov |
| NCT01930890 | BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis | Phase2 | Lupus Nephritis | Terminated | 2013-11-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT01939002 | Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transit… | Phase3 | Relapsing Multiple Sclerosis | Completed | 2013-11-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02308657 | Multicenter Observational Study of Myotonic Dystrophy Type 1 | — | Myotonic Dystrophy Type 1 | Completed | 2013-11-01 | 2017-10-01 | ClinicalTrials.gov |
| NCT01930708 | A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multip… | Phase4 | Relapsing-Remitting Multiple Sclerosis | Completed | 2013-10-31 | 2020-01-09 | ClinicalTrials.gov |
| NCT01911767 | Biogen Multiple Sclerosis Pregnancy Exposure Registry | — | Multiple Sclerosis | Completed | 2013-10-30 | 2022-02-10 | ClinicalTrials.gov |
| NCT01943513 | A Study of the Effect of BIIB023 on Muscle Atrophy in Healthy Male Volunteers | Phase1 | Healthy | Completed | 2013-10-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01929746 | Daclizumab Japanese PK Study | Phase1 | Healthy | Completed | 2013-10-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01816100 | The Effect of Exercise on Strength and Mobility and Corresponding CNS Plasticit… | Na | Multiple Sclerosis | Completed | 2013-09-16 | 2015-09-01 | ClinicalTrials.gov |
| NCT01945359 | Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate C… | — | Relapsing Remitting Multiple Sclerosis | Completed | 2013-09-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT01915901 | PeptoBismol® Use to Reduce Gastrointestinal Events in Healthy Volunteers Receiv… | Phase1 | Healthy | Completed | 2013-08-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01924832 | BG00012 Regional Absorption Study | Phase1 | Healthy | Completed | 2013-08-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01917019 | A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in J… | Phase3 | Multiple Sclerosis, Remittent Progressive | Completed | 2013-08-01 | 2017-03-01 | ClinicalTrials.gov |
| NCT01903291 | Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS | — | Relapsing Forms of Multiple Sclerosis | Completed | 2013-08-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT01864148 | Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BII… | Phase2 | Multiple Sclerosis | Completed | 2013-08-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT01884935 | PK and PD Study of Natalizumab in Pediatric Subjects With RRMS | Phase1 | Relapsing-Remitting Multiple Sclerosis | Completed | 2013-07-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT02076841 | Tolerability and Quality of Life Study in Participants Who Switched to Avonex P… | — | Relapsing-Remitting Multiple Sclerosis | Completed | 2013-07-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT01731054 | Functional MRI in Lupus Nephritis | — | Healthy | Completed | 2013-06-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01873404 | BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With… | Phase2 | Painful Lumbar Radiculopathy | Completed | 2013-06-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01839656 | A Study to Assess the Efficacy, Safety and Pharmacokinetics of Nusinersen (ISIS… | Phase2 | Spinal Muscular Atrophy | Completed | 2013-05-08 | 2017-08-21 | ClinicalTrials.gov |
| NCT01873417 | Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients Wi… | Phase4 | Relapsing Forms of Multiple Sclerosis | Completed | 2013-05-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01842126 | Phase 1 Subcutaneous Single and Multiple Ascending Dose Study of BG00010 (Neubl… | Phase1 | Painful Lumbar Radiculopathy | Completed | 2013-04-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01838668 | An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects W… | Phase3 | Relapsing-Remitting Multiple Sclerosis | Completed | 2013-03-28 | 2018-09-04 | ClinicalTrials.gov |
| NCT01797965 | Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Comp… | Phase3 | Relapsing-Remitting Multiple Sclerosis | Terminated | 2013-02-15 | 2018-09-24 | ClinicalTrials.gov |
| NCT01780246 | An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Part… | Phase1 | Spinal Muscular Atrophy | Completed | 2013-01-31 | 2014-02-28 | ClinicalTrials.gov |
| NCT01764594 | Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus | Phase1 | Immune System Diseases | Completed | 2013-01-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01767311 | A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects… | Phase2 | Alzheimer's Disease | Completed | 2012-12-20 | 2024-12-10 | ClinicalTrials.gov |
| NCT01272128 | Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - … | — | Multiple Sclerosis | Completed | 2012-12-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT01749098 | A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Imp… | Phase1 | Schizophrenia | Completed | 2012-12-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01721161 | BIIB033 In Acute Optic Neuritis (AON) | Phase2 | Acute Optic Neuritis | Completed | 2012-12-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01706107 | Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remittin… | — | Relapsing-Remitting Multiple Sclerosis | Terminated | 2012-11-07 | 2015-10-02 | ClinicalTrials.gov |
| NCT01767493 | Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS … | Phase4 | Multiple Sclerosis | Completed | 2012-11-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01703988 | An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Dos… | Phase1 | Spinal Muscular Atrophy | Completed | 2012-10-31 | 2015-01-31 | ClinicalTrials.gov |
| NCT01677572 | Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ I… | Phase1 | Alzheimer's Disease | Terminated | 2012-10-05 | 2019-07-31 | ClinicalTrials.gov |
| NCT01655186 | A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Effects of … | Phase2 | Renal Insufficiency, Chronic | Withdrawn | 2012-09-30 | 2012-10-31 | ClinicalTrials.gov |
| NCT01689428 | Ism1 Versus EmbryoGen Media for Embryo Culture in Previous Pregnancy Loss Cases | — | Infertility | Unknown | 2012-09-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01689454 | ISM1 Versus EmbrioGen Media for Embryo Culture With Previous Failure Implantati… | — | Infertility | Unknown | 2012-09-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01689116 | Multiple-Dose Study of Effect of Bardoxolone Methyl on QT/QTC Interval Voluntee… | Phase1 | Healthy Volunteers | Completed | 2012-08-31 | 2012-11-30 | ClinicalTrials.gov |
| NCT01652937 | BIIB057 in Subjects With Rheumatoid Arthritis and Inadequate Response to Diseas… | Phase2 | Rheumatoid Arthritis | Withdrawn | 2012-08-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01597297 | Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Abili… | Phase2 | Multiple Sclerosis | Completed | 2012-08-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01576887 | A Double-Blind, Randomized, Placebo-Controlled Safety Study Evaluating the Effe… | Phase2 | End-Stage Renal Disease | Withdrawn | 2012-07-31 | 2012-10-31 | ClinicalTrials.gov |
| NCT01371305 | STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) | Phase2 | Idiopathic Pulmonary Fibrosis (IPF) | Completed | 2012-07-16 | 2017-03-31 | ClinicalTrials.gov |
| NCT01749943 | Validation of Hand Held Dynamometer for Assessment of Lower Limb Muscle Strengt… | — | Multiple Sclerosis | Completed | 2012-07-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01646840 | Study Of The PF-04958242 Blood Concentrations Of A Capsule Formulation Of PF-04… | Phase1 | Healthy | Completed | 2012-07-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01632449 | Study in Healthy Volunteers to Establish the Bioequivalence of Two Different Ma… | Phase1 | Healthy Volunteers | Completed | 2012-07-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01626248 | Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab P… | — | Multiple Sclerosis | Completed | 2012-07-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01552681 | Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögr… | Phase2 | Primary Sjögren's Syndrome | Terminated | 2012-07-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT01499355 | BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis | Phase2 | Lupus Nephritis | Terminated | 2012-07-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01598363 | An Open-Label Study of the Effect of Bardoxolone Methyl on the Single Dose Phar… | Phase1 | Healthy Volunteers | Completed | 2012-06-30 | 2012-07-31 | ClinicalTrials.gov |
| NCT01622088 | Phase 3 Extension Study of Dexpramipexole in ALS | Phase3 | Amyotrophic Lateral Sclerosis | Terminated | 2012-06-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01610310 | Peginterferon Beta-1a (BIIB017) Autoinjector Pharmacokinetic Study in Healthy V… | Phase1 | Healthy | Completed | 2012-06-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01656148 | FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on… | Phase4 | Multiple Sclerosis | Completed | 2012-06-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT02142205 | Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants … | Phase4 | Relapsing-Remitting Multiple Sclerosis | Completed | 2012-05-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01641120 | Assessing Tolerability of Avonex Intramuscular Injections | Na | Multiple Sclerosis | Completed | 2012-05-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01551446 | Pilot Assessment of the Effects of Bardoxolone Methyl on Renal Perfusion, Syste… | Phase1 | Renal Insufficiency, Chronic | Withdrawn | 2012-04-30 | 2012-11-30 | ClinicalTrials.gov |
| NCT01563562 | Single-Dose, Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects… | Phase1 | Hepatic Impairment | Completed | 2012-04-30 | 2012-11-30 | ClinicalTrials.gov |
| NCT01549769 | Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients Wit… | Phase1 | Renal Insufficiency, Chronic | Terminated | 2012-04-30 | 2013-10-31 | ClinicalTrials.gov |
| NCT01480063 | An Observational Study to Collect Information on Safety and to Document the Dru… | — | Multiple Sclerosis | Completed | 2012-04-16 | 2019-02-08 | ClinicalTrials.gov |
| NCT01568112 | Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastroint… | Phase3 | Healthy | Completed | 2012-04-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01540630 | A Phase IIa Withdrawal Study of CNV1014802 in Patients With Trigeminal Neuralgia | Phase2 | Trigeminal Neuralgia | Completed | 2012-03-31 | 2014-06-30 | ClinicalTrials.gov |
| NCT01489748 | Canadian Avonex PEN Productivity Study | — | Multiple Sclerosis | Completed | 2012-03-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01591551 | NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple S… | Phase4 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2012-03-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01485003 | Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis … | — | Relapsing-Remitting Multiple Sclerosis | Completed | 2012-02-07 | 2018-11-26 | ClinicalTrials.gov |
| NCT01518660 | Multiple Sclerosis and Progressive Resistance Training | Na | Multiple Sclerosis (Relapsing Remitting) | Completed | 2012-02-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01480076 | Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine… | Phase4 | Multiple Sclerosis | Completed | 2012-02-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01500798 | A Pharmacodynamic Study of Measured Glomerular Filtration Rate in Patients With… | Phase1 | Chronic Kidney Disease | Terminated | 2012-01-31 | 2013-10-01 | ClinicalTrials.gov |
| NCT01453426 | Phase 1 Study to Evaluate the PK, Safety, and Tolerability of BG00012 in Chines… | Phase1 | Healthy | Completed | 2012-01-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01500408 | Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two… | Phase1 | Multiple Sclerosis | Completed | 2012-01-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01518920 | A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss | Phase1 | Hearing Loss, Sensorineural | Completed | 2011-12-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01503866 | A Phase I Study to Investigate the Absorption, Metabolism and Excretion in Heal… | Phase1 | Healthy | Completed | 2011-12-01 | 2011-12-31 | ClinicalTrials.gov |
| NCT01943526 | Ireland Natalizumab (TYSABRI) Observational Program | — | Relapsing-Remitting Multiple Sclerosis | Completed | 2011-11-30 | 2017-12-31 | ClinicalTrials.gov |
| NCT01494701 | An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen … | Phase1 | Spinal Muscular Atrophy | Completed | 2011-11-30 | 2013-01-31 | ClinicalTrials.gov |
| NCT01477801 | Effects of Cholecalciferol Supplementation in Patients With Chronic Heart Failu… | Phase2 | Heart Failure | Unknown | 2011-11-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01518894 | A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242… | Phase1 | Schizophrenia | Completed | 2011-11-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT01462318 | An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yiel… | Phase3 | Relapsing-Remitting Multiple Sclerosis | Completed | 2011-11-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT01461161 | A Single-Dose, Open-Label, Randomized, Food Effect and Blinded, Randomized, Dos… | Phase1 | Healthy Volunteers | Completed | 2011-10-31 | 2011-12-31 | ClinicalTrials.gov |
| NCT01450046 | Vitamin E δ-Tocotrienol Multiple Dose in Healthy Subjects | Phase1 | Pancreatic Cancer | Completed | 2011-10-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT01416181 | A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progress… | Phase3 | Secondary Progressive Multiple Sclerosis | Terminated | 2011-09-13 | 2016-04-13 | ClinicalTrials.gov |
| NCT01446952 | Vitamin E δ-Tocotrienol (VEDT) Single Dose in Healthy Subjects | Phase1 | Pancreatic Cancer | Completed | 2011-09-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT01405872 | Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex… | — | Multiple Sclerosis | Completed | 2011-09-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01407406 | Phase 1 Study to Evaluate the PK, Safety, Tolerability of BIIB023 in Chinese, J… | Phase1 | Healthy Volunteers | Completed | 2011-09-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01416207 | A Multiple-Dose, Open-Label, Phase 1, Pharmacokinetic, Pharmacodynamic, and Saf… | Phase1 | Healthy | Completed | 2011-08-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01424163 | Dexpramipexole Japanese PK Study | Phase1 | Amyotrophic Lateral Sclerosis | Completed | 2011-08-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01420458 | Study in Healthy Volunteers to Establish the BioEquivalence of Two Formulations… | Phase1 | Healthy Volunteers | Completed | 2011-08-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT01405820 | Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens… | Phase2 | Relapsing-Remitting Multiple Sclerosis | Completed | 2011-08-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01405833 | Study of the Safety, Tolerability, Pharmacokinetics and Safety of BG00010 (Neub… | Phase1 | Sciatica | Completed | 2011-07-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01351675 | Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type … | Phase3 | Renal Insufficiency, Chronic | Terminated | 2011-06-30 | 2012-12-31 | ClinicalTrials.gov |
| NCT01365338 | A Study To Assess Effects Of PF-04958242 On Bold Functional Magnetic Resonance … | Phase1 | Healthy Volunteer | Completed | 2011-06-24 | 2012-12-14 | ClinicalTrials.gov |
| NCT01366040 | Avonex PEN Satisfaction and Patients Experience Clinical Trial | — | Multiple Sclerosis | Completed | 2011-06-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01397539 | Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's Disease | Phase1 | Alzheimer's Disease | Completed | 2011-06-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01511510 | Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeated Dos… | Phase1 | Schizophrenia | Completed | 2011-06-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT01561027 | Crossover Study of CNV1014802 in Subjects With Neuropathic Pain From Lumbosacra… | Phase2 | Lumbosacral Radiculopathy | Completed | 2011-04-30 | 2012-08-31 | ClinicalTrials.gov |
| NCT01332019 | Long-Term Safety and Efficacy Study of Peginterferon Beta-1a | Phase3 | Relapsing Multiple Sclerosis | Completed | 2011-04-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT01330498 | Longitudinal Pharmacokinetic, Pharmacodynamic, Immunological, and Biochemical | — | Multiple Sclerosis | Completed | 2011-04-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01313364 | A Safety Study in Healthy Volunteers of the Single-Use Autoinjector Containing … | Phase1 | Healthy | Terminated | 2011-03-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT01556685 | MATRIX: Measuring Neutralizing Antibodies in the Patients Treated With Interfer… | Phase4 | Multiple Sclerosis | Completed | 2011-03-01 | — | ClinicalTrials.gov |
| NCT01335633 | Psychometric Validation of Cognitive Endpoints | — | Multiple Sclerosis | Completed | 2011-03-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01281111 | Alternate Dosing Regimens of BG00012 in Healthy Volunteers | Phase1 | Healthy | Completed | 2011-02-01 | 2011-03-18 | ClinicalTrials.gov |
| NCT01250678 | Neurocognitive Changes in Patients With Remitting Relapsing Multiple Sclerosis … | — | Multiple Sclerosis | Unknown | 2011-01-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01235221 | Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Famp… | Phase3 | Multiple Sclerosis | Completed | 2010-12-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01238679 | Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PF-04958242 … | Phase1 | Healthy Volunteers | Terminated | 2010-11-24 | 2011-05-03 | ClinicalTrials.gov |
| NCT01440101 | Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Re… | Phase2 | Multiple Sclerosis | Completed | 2010-11-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01327729 | Y- Shaped Pegylated Interferon (YPEG-IFNα-2a) Plus Ribavirin in Egyptian Patien… | Phase2 | Self Efficacy | Unknown | 2010-11-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01244139 | Safety Study of BIIB033 in Subjects With Multiple Sclerosis | Phase1 | Relapsing-Remitting Multiple Sclerosis | Completed | 2010-10-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01416155 | Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Part… | Phase2 | Relapsing-Remitting Multiple Sclerosis | Completed | 2010-10-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01215084 | A Pharmacokinetics (PK) and Safety Study of Oral Fampridine-PR 10 mg in Chinese… | Phase1 | Healthy | Completed | 2010-10-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT01211639 | Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal … | — | Progressive Multifocal Leukoencephalopathy | Terminated | 2010-10-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT02004444 | JC Virus Reactivation in Multiple Sclerosis | — | Progressive Multifocal Leukoencephalopathy | Completed | 2010-10-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT01211665 | Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS) | Phase4 | Immune Reconstitution Inflammatory Syndrome | Terminated | 2010-09-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01185717 | JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS) | — | Multiple Sclerosis | Completed | 2010-09-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01181089 | Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects o… | Phase1 | Secondary Progressive Multiple Sclerosis | Withdrawn | 2010-09-01 | — | ClinicalTrials.gov |
| NCT01337427 | Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of… | Phase3 | Relapsing Remitting Multiple Sclerosis | Withdrawn | 2010-08-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01159483 | First-in-Human Study of PF-04958242 in Healthy Volunteers | Phase1 | Healthy Volunteer | Completed | 2010-07-15 | 2010-10-16 | ClinicalTrials.gov |
| NCT01156298 | Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neu… | — | Multiple Sclerosis | Terminated | 2010-06-01 | 2017-03-01 | ClinicalTrials.gov |
| NCT01065090 | A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Part… | — | Exercise | Completed | 2010-06-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01156311 | BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis | Phase2 | Relapsing-Remitting Multiple Sclerosis | Completed | 2010-06-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT01211678 | Biomarkers of Anti-TNF-α Therapy Efficacy in Rheumatoid Arthritis to Define Unr… | — | Arthritis, Rheumatoid | Completed | 2010-06-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01119677 | A Study of Avonex to Determine the Effects of Dose Titration on the Incidence o… | Phase1 | Healthy Volunteers | Completed | 2010-05-05 | 2010-10-23 | ClinicalTrials.gov |
| NCT01119781 | A Single-Dose, Pharmacokinetic/Pharmacodynamic (PK/PD), & Safety Study of BIIB0… | Phase1 | Healthy | Completed | 2010-05-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01064401 | Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interfero… | Phase3 | Relapsing-Remitting Multiple Sclerosis | Completed | 2010-05-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01181115 | Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Scle… | Phase3 | Multiple Sclerosis | Completed | 2010-04-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01071512 | Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis | Na | Multiple Sclerosis | Completed | 2010-04-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT01051349 | Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) … | Phase2 | Relapsing-Remitting Multiple Sclerosis | Completed | 2010-03-31 | 2016-08-25 | ClinicalTrials.gov |
| NCT01070823 | JC-Virus (JCV) Antibody Program | — | Multiple Sclerosis | Completed | 2010-03-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01077466 | Natalizumab Treatment of Progressive Multiple Sclerosis | Phase2 | Primary Progressive Multiple Sclerosis | Completed | 2010-03-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01071083 | Treatment Interruption of Natalizumab | Phase2 | Relapsing Remitting Multiple Sclerosis | Completed | 2010-03-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT01070836 | JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Tr… | — | Relapsing Multiple Sclerosis | Completed | 2010-03-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT01058005 | Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis | Phase3 | Relapsing Remitting Multiple Sclerosis | Terminated | 2010-03-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01070719 | Pharmacokinetic, Immunological and Biochemical Sample Collection and Analysis o… | — | Multiple Sclerosis | Completed | 2010-02-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT01053936 | Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl o… | Phase2 | Renal Insufficiency, Chronic | Completed | 2010-01-31 | 2011-02-28 | ClinicalTrials.gov |
| NCT01132703 | Safety Study of RP-1127 (Glyburide for Injection) in Healthy Volunteers | Phase1 | Traumatic Brain Injury | Completed | 2010-01-07 | 2010-05-07 | ClinicalTrials.gov |
| NCT01056848 | International, Multicenter Study of a Twenty-eight Week, Open-label, Titrated O… | — | Hyponatremia With Normal Extracellular Fluid Volume | Completed | 2010-01-01 | — | ClinicalTrials.gov |
| NCT01052506 | BIIB033 Single Ascending Dose Study in Healthy Volunteer Subjects | Phase1 | Healthy | Completed | 2010-01-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01035515 | BIIB014 Cardiovascular Monitoring Study | Phase1 | Healthy | Completed | 2009-12-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT01017666 | BIIB014 Effects on the Pharmacokinetics (PK) of Rosiglitazone, Warfarin, and Mi… | Phase1 | Healthy | Completed | 2009-11-01 | 2010-06-02 | ClinicalTrials.gov |
| NCT01017198 | Effect of Food and Antacid on BIIB021 With Advanced Solid Tumors | Phase1 | Advanced Solid Tumors | Completed | 2009-11-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT01004081 | Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aroma… | Phase2 | Breast Cancer | Completed | 2009-11-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT00970580 | A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects W… | Phase1 | Non-Small Cell Lung Cancer | Completed | 2009-10-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT01069913 | Pharmacokinetics Profile Study of BG00012 Standard Formulation and BG00012 Acti… | Phase1 | Healthy | Completed | 2009-10-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00961766 | Evaluate the Safety, Tolerability and Pharmacokinetics of BG00010 (Neublastin) … | Phase1 | Sciatica | Completed | 2009-08-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT00956436 | Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC) | Phase1 | Hepatocellular Carcinoma | Completed | 2009-08-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT00871780 | A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natal… | Phase4 | Relapsing Remitting Multiple Sclerosis (RRMS) | Completed | 2009-08-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT00964288 | Effect of GSK1014802 on Electrical Hyperalgesia and Threshold Tracking in Healt… | Phase1 | Pain, Neuropathic | Terminated | 2009-07-31 | 2009-11-30 | ClinicalTrials.gov |
| NCT00955396 | Study to Investigate the Effect of GSK1014802 on Ambulatory Blood Pressure | Phase1 | Healthy Volunteer | Completed | 2009-07-31 | 2009-12-31 | ClinicalTrials.gov |
| NCT00876876 | International, Multicenter, Open-Label and Randomized Withdrawal Study of Oral … | Phase3 | Hypervolemic Hyponatremia | Withdrawn | 2009-07-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00876798 | A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate t… | Phase3 | Euvolemic Hyponatremia | Completed | 2009-06-01 | — | ClinicalTrials.gov |
| NCT00906399 | Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsi… | Phase3 | Relapsing Multiple Sclerosis | Completed | 2009-06-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT00811889 | Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With T… | Phase2 | Chronic Kidney Disease | Completed | 2009-04-30 | 2010-12-31 | ClinicalTrials.gov |
| NCT00858156 | BG9928 in Subjects With Hepatic Impairment | Phase1 | Hepatic Impairment | Completed | 2009-04-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00884481 | Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participan… | — | Relapsing-Remitting Multiple Sclerosis | Completed | 2009-03-23 | 2011-06-30 | ClinicalTrials.gov |
| NCT00818038 | A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing … | — | Relapsing-Remitting Multiple Sclerosis | Completed | 2009-03-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT00837785 | A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Admini… | Phase1 | Relapsing Remitting Multiple Sclerosis | Completed | 2009-02-28 | 2009-10-31 | ClinicalTrials.gov |
| NCT00835770 | BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (… | Phase3 | Relapsing-Remitting Multiple Sclerosis | Completed | 2009-02-03 | 2019-11-08 | ClinicalTrials.gov |
| NCT00870740 | Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) … | Phase2 | Relapsing-Remitting Multiple Sclerosis | Completed | 2009-02-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT00498368 | Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy | Phase4 | IgA Nephropathy | Completed | 2009-02-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT00745316 | Oral Tonapofylline (BG9928) in Patients With Heart Failure and Renal Insufficie… | Phase2 | Renal Insufficiency | Terminated | 2009-02-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00746941 | Study to Explore the Effect of Mefloquine in Participants With Progressive Mult… | Phase1 | Progressive Multifocal Leukoencephalopathy | Terminated | 2009-01-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00828204 | Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in M… | Phase3 | Multiple Sclerosis | Completed | 2009-01-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00752778 | Magnetic Resonance Imaging (MRI) Follow-up of Macrophagic Infiltration in MS Pa… | Phase4 | Multiple Sclerosis | Terminated | 2008-12-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT00810836 | Efficacy and Safety Study of BG00012 With Methotrexate in Patients With Active … | Phase2 | Rheumatoid Arthritis | Completed | 2008-12-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00801125 | Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy | Phase4 | Crohn's Disease | Withdrawn | 2008-12-01 | — | ClinicalTrials.gov |
| NCT00744679 | A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State | Phase4 | Multiple Sclerosis | Completed | 2008-11-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00771043 | A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Pati… | Phase4 | Relapsing-remitting Multiple Sclerosis | Withdrawn | 2008-11-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00771329 | BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis | Phase1 | Rheumatoid Arthritis | Completed | 2008-10-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT00784836 | Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Bet… | Phase3 | Multiple Sclerosis | Terminated | 2008-10-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00675428 | Study of Natalizumab in Relapsed/Refractory Multiple Myeloma | Phase1 | Multiple Myeloma | Terminated | 2008-09-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00651443 | Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicul… | Phase1 | Lymphoma, Non-Hodgkin's | Terminated | 2008-08-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00709865 | Study to Assess the Safety and Tolerability of IV Tonapofylline in Subjects Wit… | Phase3 | Renal Insufficiency | Completed | 2008-07-31 | 2009-12-31 | ClinicalTrials.gov |
| NCT04292574 | UK SMA Patient Registry | — | Spinal Muscular Atrophy | Recruiting | 2008-07-13 | 2025-05-31 | ClinicalTrials.gov |
| NCT00726648 | CDP323 Biomarker Study | Phase1 | Relapsing Multiple Sclerosis | Completed | 2008-07-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00707512 | CD INFORM: Investigating Natalizumab Through Further Observational Research and… | — | Crohn's Disease | Terminated | 2008-06-30 | 2015-05-28 | ClinicalTrials.gov |
| NCT00725933 | Administration of BIIB028 to Subjects With Solid Tumors | Phase1 | Advanced Solid Tumors | Completed | 2008-06-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT00674947 | A Phase I Study of BIIB015 in Relapsed/Refractory Solid Tumors | Phase1 | Solid Tumors | Completed | 2008-06-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT00908154 | Safety, Tolerability and Pharmacokinetics of Repeat Doses of GSK1014802. | Phase1 | Bipolar Depression | Completed | 2008-05-31 | 2008-12-31 | ClinicalTrials.gov |
| NCT00675883 | COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS | — | Multiple Sclerosis, Relapsing-Remitting | Completed | 2008-05-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT00616434 | A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis | Phase2 | Active Ulcerative Colitis | Completed | 2008-05-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00675701 | A Study to Define the ECG Effects of Lixivaptan Compared to Placebo and Moxiflo… | Phase1 | Healthy | Completed | 2008-05-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00664027 | Phase IIa Trial to Determine the Effects of Bardoxolone Methyl on Renal Functio… | Phase2 | Diabetic Nephropathy | Completed | 2008-04-30 | 2009-05-31 | ClinicalTrials.gov |
| NCT00660959 | Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the… | Phase3 | Hyponatremia With Normal Extracellular Fluid Volume | Completed | 2008-04-01 | — | ClinicalTrials.gov |
| NCT02125578 | A Multiple Dose Safety Study of PEG-IFN in Healthy Volunteers | Phase1 | Healthy | Completed | 2008-03-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00618267 | ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay. | — | Multiple Sclerosis | Completed | 2008-03-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00618319 | An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in… | Phase2 | GIST | Completed | 2008-02-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00390221 | Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat R… | Phase2 | Relapsing-Remitting Multiple Sclerosis | Completed | 2008-02-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT00801060 | Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituxim… | Phase2 | Chronic Lymphocytic Leukemia | Terminated | 2008-02-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00618735 | Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid T… | Phase1 | Advanced Solid Tumors | Completed | 2008-02-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00536120 | The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets… | Phase4 | Multiple Sclerosis | Completed | 2008-01-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT01848028 | PsoBest - The German Psoriasis Registry | — | Psoriasis | Recruiting | 2008-01-01 | 2032-12-01 | ClinicalTrials.gov |
| NCT00555724 | Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refracto… | Phase1 | Solid Tumors | Completed | 2008-01-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00412412 | CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study | Phase1 | Breast Cancer | Completed | 2007-12-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT00384150 | Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma… | Phase3 | Lymphoma, Non-Hodgkin's | Terminated | 2007-11-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00664573 | 104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthriti… | Phase2 | Rheumatoid Arthritis | Terminated | 2007-11-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00937677 | Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Fo… | — | Multiple Sclerosis | Completed | 2007-11-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00538343 | RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Bra… | Phase2 | Brain Metastases | Terminated | 2007-10-31 | 2009-01-01 | ClinicalTrials.gov |
| NCT00559702 | Safety Study of Natalizumab to Treat Multiple Sclerosis (MS) | Phase1 | Relapsing-Remitting Multiple Sclerosis | Completed | 2007-10-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT00529113 | Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Ca… | Phase1 | Pancreatic Neoplasms | Terminated | 2007-09-30 | 2009-11-01 | ClinicalTrials.gov |
| NCT00531193 | Using PET Scans to Study Brain Receptor Occupancy of BIIB014 in Healthy Male Vo… | Phase1 | Healthy | Completed | 2007-09-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00516841 | A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinu… | Phase2 | Ovarian Cancer | Terminated | 2007-08-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00523328 | BG9924 in Combination With Methotrexate Extension of Study 104RA203 (NCT 004588… | Phase2 | Rheumatoid Arthritis | Terminated | 2007-08-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00442780 | Dose-Finding Safety Study of BIIB014 in Early-Stage Parkinson's Disease | Phase2 | Parkinson's Disease | Completed | 2007-08-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00464074 | Evaluation of Natalizumab for thE Relief of MS Associated FatiGue | — | Multiple Sclerosis | Completed | 2007-08-01 | 2010-07-31 | ClinicalTrials.gov |
| NCT00635193 | Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Dox… | Phase1 | Ovarian Cancer, Primary Peritoneal Cancer | Completed | 2007-07-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00664716 | Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Pa… | Phase2 | Rheumatoid Arthritis | Completed | 2007-07-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00493298 | Tysabri Observational Program | — | Relapsing-Remitting Multiple Sclerosis | Completed | 2007-06-29 | 2023-11-01 | ClinicalTrials.gov |
| NCT00451451 | Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Re… | Phase3 | Relapsing-Remitting Multiple Sclerosis | Completed | 2007-06-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT00574041 | How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs… | Phase4 | Relapsing Remitting Multiple Sclerosis | Terminated | 2007-06-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00424749 | Rituxan in Churg Strauss Syndrome With Renal Involvement | Phase2 | Churg-Strauss Syndrome | Terminated | 2007-06-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00488566 | GSK Drug Single Dose Escalation And Their Effect On Resting Motor Threshold In … | Phase1 | Bipolar Disorder | Completed | 2007-05-31 | 2008-05-31 | ClinicalTrials.gov |
| NCT00484536 | Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the… | Phase2 | Multiple Sclerosis | Terminated | 2007-05-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00550849 | Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 in Pa… | Phase1 | Liver Disease | Terminated | 2007-04-30 | 2007-11-30 | ClinicalTrials.gov |
| NCT00438607 | Dose-Finding Safety Study of BIIB014 in Combination With Levodopa in Moderate t… | Phase2 | Parkinson's Disease | Completed | 2007-04-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00458861 | BG9924 in Combination With Methotrexate for Participants With Active Rheumatoid… | Phase2 | Rheumatoid Arthritis | Terminated | 2007-03-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00525343 | Avonex 15 Year Long Term Follow-up Study | — | Multiple Sclerosis | Completed | 2007-03-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00476515 | Rituximab Therapy for Patients on Kidney Transplant Waiting List With Positive … | Phase1 | Kidney Insufficiency | Withdrawn | 2007-03-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00420212 | Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis | Phase3 | Relapsing-Remitting Multiple Sclerosis | Completed | 2007-01-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT00477113 | TYSABRI Global Observational Program in Safety | — | Multiple Sclerosis | Completed | 2007-01-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT00443443 | A Study of the Safety of Rituxan in Patients With Rheumatoid Arthritis After an… | — | Rheumatoid Arthritis | Completed | 2007-01-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT00472992 | Pregnancy Exposure Registry for Tysabri® | — | Crohn's Disease | Completed | 2007-01-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT00578695 | THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class … | Phase3 | Hyponatremia | Completed | 2007-01-01 | — | ClinicalTrials.gov |
| NCT00443651 | A Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Dru… | Phase3 | Rheumatoid Arthritis | Completed | 2007-01-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT00424788 | A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the… | Early_Phase1 | Relapsing Forms of Multiple Sclerosis | Completed | 2007-01-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00415909 | TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients | Phase2 | Chronic Myelogenous Leukemia | Terminated | 2006-12-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT00369395 | A Study of Volociximab in Metastatic Melanoma | Phase2 | Stage IV Melanoma | Terminated | 2006-12-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00391066 | Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR … | Phase2 | Chronic Lymphocytic Leukemia | Terminated | 2006-11-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00527410 | A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Me… | Phase1 | Leptomeningeal Carcinomatosis | Terminated | 2006-10-31 | — | ClinicalTrials.gov |
| NCT00516893 | Natalizumab High Titer Immunogenicity and Safety | Phase2 | Multiple Sclerosis | Completed | 2006-10-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00363636 | A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-H… | Phase3 | Lymphoma, Non-Hodgkin's | Terminated | 2006-09-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00483847 | TYGRIS - ROW: TYSABRI Global Observational Program in Safety - Rest of World | — | Multiple Sclerosis | Completed | 2006-09-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT00379587 | Rituximab for Prevention of Chronic GVHD | Phase1 | Hematological Malignancies | Completed | 2006-09-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT00493467 | Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas | Phase2 | Lymphoma | Completed | 2006-06-01 | 2022-08-11 | ClinicalTrials.gov |
| NCT00298272 | Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotre… | Phase2 | Rheumatoid Arthritis | Terminated | 2006-05-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00529438 | RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies | Phase1 | Advanced Solid Tumors | Completed | 2006-04-30 | 2008-12-01 | ClinicalTrials.gov |
| NCT00493454 | Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas | Phase2 | Lymphoma | Terminated | 2006-04-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT00492570 | GER-009-06-AVX Early Therapy in Multiple Sclerosis | — | Relapsing-Remitting Multiple Sclerosis | Completed | 2006-04-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00306592 | Natalizumab Re-Initiation of Dosing | Phase3 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2006-03-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00297232 | Natalizumab (Tysabri) Re-Initiation of Dosing | Phase3 | Relapsing-Remitting Multiple Sclerosis | Terminated | 2006-03-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT00299962 | Gene Therapy for Pleural Malignancies | Phase1 | Pleural Mesothelioma | Completed | 2006-03-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00106184 | Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (D… | Phase2 | Myositis | Completed | 2006-03-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00344786 | Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL | Phase1 | B-Cell Chronic Lymphocytic Leukemia | Terminated | 2006-02-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00345189 | Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors | Phase1 | Tumors | Completed | 2006-02-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00492765 | Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of R… | Phase4 | Multiple Sclerosis | Completed | 2006-02-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00584935 | Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid | Phase1 | Ocular Cicatricial Pemphigoid | Completed | 2006-01-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00288990 | A Serologic Study to Correlate Beta-IFN NAb Titers to Beta-IFN Induced Biomarke… | — | Multiple Sclerosis | Completed | 2006-01-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00376129 | Open-Label,Singel Center Study of Alefacept in Patients With Atopic Dermatitis | Phase2 | Atopic Dermatitis | Completed | 2006-01-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00526812 | A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas | Phase1 | Glioma | Completed | 2005-11-30 | — | ClinicalTrials.gov |
| NCT00292422 | Dose-Escalating Study of BG9924 in Combination With Methotrexate in Active Rheu… | Phase2 | Rheumatoid Arthritis | Completed | 2005-11-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00242268 | A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remi… | Phase3 | Relapsing Remitting Multiple Sclerosis | Unknown | 2005-10-01 | — | ClinicalTrials.gov |
| NCT01592474 | Evaluation of Brain Atrophy in CIS Patients on Avonex | — | Multiple Sclerosis | Completed | 2005-10-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT00642655 | Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal Tr… | Phase1 | Kidney Transplant | Completed | 2005-09-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00915577 | Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-F… | Phase3 | Multiple Sclerosis | Completed | 2005-08-01 | 2006-04-01 | ClinicalTrials.gov |
| NCT00697996 | Rituximab for Pediatric Renal Transplant Rejection | Phase2 | Kidney Transplantation | Completed | 2005-06-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00463710 | Effect of Interferon Beta-1a (Avonex®) on Changes of Non-conventional MRI Measu… | — | Multiple Sclerosis | Completed | 2005-06-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00301002 | Study to Evaluate the Efficacy of Alefacept to Treat Palmar Plantar Pustulosis | Phase2 | Psoriasis | Completed | 2005-06-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00319930 | Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positiv… | Phase1 | Chronic Lymphocytic Leukemia | Terminated | 2005-05-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00107861 | Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorecta… | Phase1 | Colorectal Carcinoma | Completed | 2005-05-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00119730 | Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma | Phase2 | Mantle Cell Lymphoma | Completed | 2005-02-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT00102024 | Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorec… | Phase1 | Colorectal Cancer | Terminated | 2005-01-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT00105170 | Safety and Tolerability of hCBE-11 in Subjects With Advanced Solid Tumors | Phase1 | Tumors | Terminated | 2005-01-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00422617 | Evaluate the Efficacy and Safety of One Course of Amevive in Taiwan Patients | Na | Chronic Plaque Psoriasis | Completed | 2005-01-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00588822 | Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal … | Phase2 | Precancerous Condition | Terminated | 2005-01-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT00168701 | Efficacy and Safety of BG00012 in MS | Phase2 | Multiple Sclerosis | Completed | 2004-10-01 | 2006-03-31 | ClinicalTrials.gov |
| NCT00831649 | A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerabilit… | Phase2 | Rheumatoid Arthritis | Terminated | 2004-09-01 | — | ClinicalTrials.gov |
| NCT00223301 | Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept… | Phase2 | Multiple Sclerosis | Completed | 2004-07-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00168753 | Community Based Trial for AMEVIVE® | Phase4 | Moderate to Severe Chronic Plaque Psoriasis | Completed | 2004-07-01 | 2005-03-01 | ClinicalTrials.gov |
| NCT00290511 | Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for Hi… | Phase2 | Lymphoma | Completed | 2004-06-29 | 2021-02-12 | ClinicalTrials.gov |
| NCT02097745 | A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients … | Phase3 | Rheumatoid Arthritis | Completed | 2004-06-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT00280241 | Protocol for the Treatment of Patients With Previously Untreated Chronic Lympho… | Phase2 | Chronic Lymphocytic Leukemia | Completed | 2004-06-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT00493077 | Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Ant… | Phase4 | Multiple Sclerosis | Completed | 2004-05-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00186589 | 90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplan… | Phase1 | Lymphoma, Non-Hodgkin | Completed | 2004-05-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00083759 | Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Meth… | Phase2 | Rheumatoid Arthritis | Terminated | 2004-05-01 | — | ClinicalTrials.gov |
| NCT00223457 | Factors That Influence Compliance With Disease-Modifying Therapy in Multiple Sc… | — | Multiple Sclerosis | Completed | 2004-04-01 | 2005-09-01 | ClinicalTrials.gov |
| NCT00135733 | A Safety and Efficacy Study of Alefacept in the Treatment of Moderate to Severe… | Phase2 | Lichen Planus | Terminated | 2004-04-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT00078611 | A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Acti… | Phase3 | Crohn's Disease | Completed | 2004-03-01 | 2005-03-01 | ClinicalTrials.gov |
| NCT00103558 | Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocyt… | Phase1 | Chronic Lymphocytic Leukemia | Completed | 2004-03-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00099489 | Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinati… | Phase2 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Completed | 2004-02-01 | 2006-02-01 | ClinicalTrials.gov |
| NCT00794807 | Safety and Tolerability of Repeat Courses of IM Alefacept | Phase4 | Chronic Plaque Psoriasis | Completed | 2004-02-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00387023 | Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma | Na | Non-Hodgkin's Lymphoma | Completed | 2004-02-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT00168714 | Pregnancy Exposure Registry for Avonex (Interferon Beta-1a) | — | Prenatal Exposure Delayed Effects | Completed | 2004-02-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT00232193 | Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MS | — | Relapsing-remitting Multiple Sclerosis | Completed | 2003-12-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00246324 | Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to… | Phase4 | Multiple Sclerosis | Completed | 2003-12-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00276172 | Open-Label Natalizumab Safety Extension Study | Phase3 | Multiple Sclerosis | Completed | 2003-12-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT00117156 | Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymp… | Phase2 | Lymphoma, Non-Hodgkin | Completed | 2003-12-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT00177554 | Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma | Phase2 | Non-Hodgkin Lymphoma | Completed | 2003-11-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00774202 | Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, … | Phase2 | Immune Thrombocytopenic Purpura | Completed | 2003-11-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00673556 | A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients fo… | Phase3 | Chronic Plaque Psoriasis | Completed | 2003-10-01 | 2005-05-01 | ClinicalTrials.gov |
| NCT00493116 | Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neut… | Phase4 | Relapsing-Remitting Multiple Sclerosis | Completed | 2003-10-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00143806 | Transitioning From Cyclosporine to Alefacept in Psoriasis | Phase2 | Psoriasis | Completed | 2003-10-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00090038 | Effect of Rituximab on Immunological Recall Response to Specific Antigens in th… | Phase4 | Non-Hodgkin's Lymphoma | Completed | 2003-10-01 | 2007-11-01 | ClinicalTrials.gov |
| NCT00193505 | Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refrac… | Phase2 | Non-Hodgkins Lymphoma | Completed | 2003-10-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00150982 | Alefacept Mechanism of Action in Psoriasis | Phase2 | Psoriasis | Completed | 2003-09-01 | 2005-02-01 | ClinicalTrials.gov |
| NCT00659412 | A Placebo-controlled Study With an Extension Examining the Safety and Efficacy … | Phase2 | Psoriatic Arthritis | Completed | 2003-09-01 | 2005-03-01 | ClinicalTrials.gov |
| NCT01538472 | Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma | Phase1 | Lymphoma | Completed | 2003-09-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT00913250 | A Bioequivalence Study of Serum Free Avonex and Serum Containing Avonex in Heal… | Phase1 | Multiple Sclerosis | Completed | 2003-08-01 | 2003-10-01 | ClinicalTrials.gov |
| NCT00090051 | FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in R… | Phase3 | Chronic Lymphocytic Leukemia | Completed | 2003-07-31 | 2012-05-31 | ClinicalTrials.gov |
| NCT00674063 | A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept i… | Phase3 | Chronic Plaque Psoriasis | Completed | 2003-07-01 | 2004-04-01 | ClinicalTrials.gov |
| NCT00168727 | Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-H… | Phase4 | Lymphoma, Non-Hodgkin | Completed | 2003-06-01 | 2005-10-31 | ClinicalTrials.gov |
| NCT00112034 | AVONEX® Combination Trial - "ACT" | Phase4 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2003-06-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00097760 | Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relaps… | Phase2 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2003-06-01 | 2004-03-01 | ClinicalTrials.gov |
| NCT00468546 | A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combinat… | Phase3 | Rheumatoid Arthritis | Completed | 2003-05-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01713738 | Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic… | Phase1 | Idiopathic Thrombocytopenic Purpura (ITP) | Completed | 2003-05-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00057343 | Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma | Phase3 | Non-Hodgkin's Lymphoma | Terminated | 2003-03-01 | — | ClinicalTrials.gov |
| NCT00492466 | Investigating if Interferon-Beta Can be Used in Patients With MS After They Hav… | Phase4 | Relapsing-Remitting Multiple Sclerosis | Completed | 2003-03-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00912860 | Immunogenicity and Safety Study of Serum-Free Avonex | Phase2 | Multiple Sclerosis | Completed | 2003-01-01 | 2005-01-01 | ClinicalTrials.gov |
| NCT00168766 | Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatmen… | Phase4 | Relapsing-remitting Multiple Sclerosis | Completed | 2003-01-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00233662 | Safety and Tolerability of Repeat Courses of IM Alefacept | Phase3 | Chronic Plaque Psoriasis | Completed | 2002-12-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00048555 | Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of… | Phase1 | Non-Hodgkin's Lymphoma | Completed | 2002-11-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00913666 | Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunom… | Phase4 | Multiple Sclerosis | Completed | 2002-11-01 | 2004-11-01 | ClinicalTrials.gov |
| NCT00048737 | Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymp… | Phase1 | Lymphoma | Completed | 2002-10-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT00046488 | Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemi… | Phase1 | Chronic Lymphocytic Leukemia | Completed | 2002-09-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00599274 | Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Re… | — | Multiple Sclerosis | Completed | 2002-08-01 | 2003-05-01 | ClinicalTrials.gov |
| NCT00280956 | Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease | Phase4 | Crohn's Disease | Completed | 2002-07-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT00031083 | Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the … | Phase1 | Glioblastoma Multiforme | Completed | 2002-04-02 | 2003-10-10 | ClinicalTrials.gov |
| NCT00193440 | Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Lo… | Phase2 | Non-Hodgkins Lymphoma | Completed | 2002-04-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00055536 | Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatmen… | Phase2 | Crohn's Disease | Completed | 2002-04-01 | 2003-07-01 | ClinicalTrials.gov |
| NCT00055367 | Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Activ… | Phase2 | Crohn's Disease | Completed | 2002-04-01 | 2004-05-01 | ClinicalTrials.gov |
| NCT00038623 | Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relap… | Phase2 | Lymphoma, Mantle-Cell | Completed | 2002-04-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT00032786 | Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease | Phase3 | Crohn's Disease | Completed | 2002-03-01 | 2004-03-01 | ClinicalTrials.gov |
| NCT00030966 | Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment … | Phase3 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2002-01-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00575068 | Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma | Phase1 | Non-Hodgkin's Lymphoma | Completed | 2002-01-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00031642 | Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Au… | Phase1 | Lymphoma | Completed | 2002-01-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00692172 | Open-label Study to Evaluate Safety of Multiple Courses of IM Alefacept During … | Phase3 | Psoriasis | Completed | 2001-12-01 | 2004-11-01 | ClinicalTrials.gov |
| NCT00032799 | Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease | Phase3 | Crohn's Disease | Completed | 2001-12-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00027300 | Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis | Phase3 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2001-11-01 | 2005-01-01 | ClinicalTrials.gov |
| NCT00037102 | Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexat… | Phase4 | Multiple Sclerosis | Completed | 2001-07-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT00179478 | Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis | Phase4 | Multiple Sclerosis | Completed | 2001-02-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT01863069 | Avonex®: Safety, Blood Levels and Effects | Phase1 | Multiple Sclerosis (MS) | Completed | 2001-01-01 | 2001-10-01 | ClinicalTrials.gov |
| NCT00534261 | Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interf… | Phase4 | Relapsing Remitting Multiple Sclerosis | Completed | 1999-11-01 | 2004-02-01 | ClinicalTrials.gov |
| NCT00005592 | Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lympho… | Phase2 | Lymphoma | Completed | 1999-11-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00915460 | Open-Label Safety Extension Study of Avonex | Phase4 | Multiple Sclerosis | Completed | 1999-09-01 | 2003-07-01 | ClinicalTrials.gov |
| NCT00168740 | Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Kno… | Phase3 | Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma | Completed | 1995-04-01 | — | ClinicalTrials.gov |
Total clinical trials: 703
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Nusinersen Sodium Injection | Other | Preclinical | Muscular Atrophy, Spinal | ACTIVE_NOT_RECRUITING | NCT04317794 |
| Placebo | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT05531565 |
| Litifilimab | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT05531565 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | RECRUITING | NCT07662148 |
| BIIB144 | Other | Phase PHASE1 | Healthy Volunteer | RECRUITING | NCT07662148 |
| Placebo | Other | Phase PHASE2 | Graves' Disease | NOT_YET_RECRUITING | NCT07722546 |
| Felzartamab | Other | Phase PHASE2 | Graves' Disease | NOT_YET_RECRUITING | NCT07722546 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE1 | Lupus Nephritis | COMPLETED | NCT06064929 |
| Placebo | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT05531565 |
| Litifilimab | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT05531565 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Diranersen | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06454721 |
| [89Zr]Zr-DFO-Diranersen | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06454721 |
| Omaveloxolone | Other | Preclinical | Friedreich Ataxia | RECRUITING | NCT06628687 |
| BIIB115-Matching Placebo | Other | Phase PHASE1 | Healthy Volunteer | ACTIVE_NOT_RECRUITING | NCT05575011 |
| BIIB115 | Other | Phase PHASE1 | Healthy Volunteer | ACTIVE_NOT_RECRUITING | NCT05575011 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Placebo | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT05531565 |
| Litifilimab | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT05531565 |
| Salanersen | Other | Phase PHASE3 | Muscular Atrophy, Spinal | RECRUITING | NCT07221669 |
| Nutrition therapy | Drug | Approved | Gestational Diabetes Mellitus (GDM) | RECRUITING | NCT07685015 |
| Insulin therapy | Drug | Approved | Gestational Diabetes Mellitus (GDM) | RECRUITING | NCT07685015 |
| Folic acid 200 µg | Other | Approved | Gestational Diabetes Mellitus (GDM) | RECRUITING | NCT07685015 |
| Myo-inositol 2 g + Folic acid 200 µg | Other | Approved | Gestational Diabetes Mellitus (GDM) | RECRUITING | NCT07685015 |
| BIIB112 | Other | Phase PHASE3 | Choroideremia | COMPLETED | NCT03584165 |
| BIIB111 | Other | Phase PHASE3 | Choroideremia | COMPLETED | NCT03584165 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Diranersen-matching placebo | Other | Phase PHASE2 | Mild Cognitive Impairment Due to Alzheimer's Disease | ACTIVE_NOT_RECRUITING | NCT05399888 |
| Diranersen | Other | Phase PHASE2 | Mild Cognitive Impairment Due to Alzheimer's Disease | ACTIVE_NOT_RECRUITING | NCT05399888 |
| Felzartamab | Other | Phase PHASE3 | Antibody-mediated Rejection | ENROLLING_BY_INVITATION | NCT07444489 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Placebo | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT05531565 |
| Litifilimab | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT05531565 |
| Tofersen | Other | Phase PHASE2 | ALS (Amyotrophic Lateral Sclerosis) | RECRUITING | NCT07294144 |
| Placebo | Other | Phase PHASE2 | Overweight | RECRUITING | NCT07009171 |
| KDS2010 | Other | Phase PHASE2 | Overweight | RECRUITING | NCT07009171 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | NOT_YET_RECRUITING | NCT07662148 |
| BIIB144 | Other | Phase PHASE1 | Healthy Volunteer | NOT_YET_RECRUITING | NCT07662148 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Placebo | Other | Phase PHASE2 | Mild Cognitive Impairment (MCI) | RECRUITING | NCT07027072 |
| KDS2010 | Other | Phase PHASE2 | Mild Cognitive Impairment (MCI) | RECRUITING | NCT07027072 |
| Placebo | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT05531565 |
| Litifilimab | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT05531565 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Placebo | Other | Phase PHASE2 | Overweight | RECRUITING | NCT07009171 |
| KDS2010 | Other | Phase PHASE2 | Overweight | RECRUITING | NCT07009171 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Placebo | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT05531565 |
| Litifilimab | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT05531565 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Placebo | Other | Phase PHASE3 | Friedreich Ataxia | RECRUITING | NCT06953583 |
| Omaveloxolone | Other | Phase PHASE3 | Friedreich Ataxia | RECRUITING | NCT06953583 |
| Sham Procedure | Procedure | Phase PHASE3 | Muscular Atrophy, Spinal | NOT_YET_RECRUITING | NCT07444450 |
| Salanersen | Other | Phase PHASE3 | Muscular Atrophy, Spinal | NOT_YET_RECRUITING | NCT07444450 |
| Salanersen | Other | Phase PHASE3 | Muscular Atrophy, Spinal | RECRUITING | NCT07221669 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Tofersen | Other | Phase PHASE2 | ALS (Amyotrophic Lateral Sclerosis) | RECRUITING | NCT07294144 |
| Salanersen | Other | Phase PHASE3 | Muscular Atrophy, Spinal | RECRUITING | NCT07221669 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Sham Procedure | Procedure | Phase PHASE3 | Muscular Atrophy, Spinal | NOT_YET_RECRUITING | NCT07444450 |
| Salanersen | Other | Phase PHASE3 | Muscular Atrophy, Spinal | NOT_YET_RECRUITING | NCT07444450 |
| Placebo | Other | Phase PHASE3 | Antibody-mediated Rejection | ACTIVE_NOT_RECRUITING | NCT06685757 |
| Felzartamab | Other | Phase PHASE3 | Antibody-mediated Rejection | ACTIVE_NOT_RECRUITING | NCT06685757 |
| BIIB080-matching placebo | Other | Phase PHASE2 | Mild Cognitive Impairment Due to Alzheimer's Disease | ACTIVE_NOT_RECRUITING | NCT05399888 |
| BIIB080 | Other | Phase PHASE2 | Mild Cognitive Impairment Due to Alzheimer's Disease | ACTIVE_NOT_RECRUITING | NCT05399888 |
| BIIB122-Matching Placebo | Other | Phase PHASE2 | Parkinson Disease | COMPLETED | NCT05348785 |
| BIIB122 | Other | Phase PHASE2 | Parkinson Disease | COMPLETED | NCT05348785 |
| Siponimod | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Ponesimod | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Peginterferon beta-1a | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Ozanimod | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Ofatumumab | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Ocrelizumab | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Natalizumab | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Interferon beta | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Glatiramer acetate | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Fingolimod | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Alemtuzumab | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Diroximel Fumarate | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Placebo | Other | Phase PHASE3 | Friedreich Ataxia | RECRUITING | NCT06953583 |
| Omaveloxolone | Other | Phase PHASE3 | Friedreich Ataxia | RECRUITING | NCT06953583 |
| Communication with the clinic | Other | Approved | Multiple Sclerosis | COMPLETED | NCT02454907 |
| Siponimod | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Ponesimod | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Peginterferon beta-1a | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Ozanimod | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Ofatumumab | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Ocrelizumab | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Natalizumab | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Interferon beta | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Glatiramer acetate | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Fingolimod | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Alemtuzumab | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Diroximel Fumarate | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Placebo | Other | Phase PHASE3 | Friedreich Ataxia | RECRUITING | NCT06953583 |
| Omaveloxolone | Other | Phase PHASE3 | Friedreich Ataxia | RECRUITING | NCT06953583 |
| BIIB122-Matching Placebo | Other | Phase PHASE2 | Parkinson Disease | COMPLETED | NCT05348785 |
| BIIB122 | Other | Phase PHASE2 | Parkinson Disease | COMPLETED | NCT05348785 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| AI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| PFS | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| OBI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| Litifilimab | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| AI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| PFS | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| OBI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| Litifilimab | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| AI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| PFS | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| OBI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| Litifilimab | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| AI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| PFS | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| OBI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| Litifilimab | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| AI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| PFS | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| OBI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| Litifilimab | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| AI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| PFS | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| OBI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| Litifilimab | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| AI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| PFS | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| OBI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| Litifilimab | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| AI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| PFS | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| OBI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| Litifilimab | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| AI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| PFS | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| OBI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| Litifilimab | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| AI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| PFS | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| OBI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| Litifilimab | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| AI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| PFS | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| OBI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| Litifilimab | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Nusinersen | Other | Phase PHASE3 | Spinal Muscular Atrophy | ACTIVE_NOT_RECRUITING | NCT05067790 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Nusinersen | Other | Phase PHASE3 | Spinal Muscular Atrophy | ACTIVE_NOT_RECRUITING | NCT05067790 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Nusinersen | Other | Phase PHASE3 | Spinal Muscular Atrophy | ACTIVE_NOT_RECRUITING | NCT05067790 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Nusinersen | Other | Phase PHASE3 | Spinal Muscular Atrophy | ACTIVE_NOT_RECRUITING | NCT05067790 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Nusinersen | Other | Phase PHASE3 | Spinal Muscular Atrophy | ACTIVE_NOT_RECRUITING | NCT05067790 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Interferon β-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Interferon β-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Interferon β-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Interferon β-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Interferon β-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Interferon β-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Interferon β-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Interferon β-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Interferon β-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Interferon β-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Interferon β-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Interferon β-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Interferon β-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Interferon β-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Interferon β-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Interferon β-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Interferon beta-1a | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT00534261 |
| Interferon beta-1a | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT00534261 |
| rituximab | Other | Phase PHASE3 | Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma | COMPLETED | NCT00168740 |
| Simvastatin | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | UNKNOWN | NCT00242268 |
| Simvastatin | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | UNKNOWN | NCT00242268 |
| Rituxan (rituximab) | Other | Phase PHASE3 | Non-Hodgkin's Lymphoma | TERMINATED | NCT00057343 |
| Zevalin (ibritumomab tiuxetan) | Other | Phase PHASE3 | Non-Hodgkin's Lymphoma | TERMINATED | NCT00057343 |
| Rituxan (rituximab) | Other | Phase PHASE3 | Non-Hodgkin's Lymphoma | TERMINATED | NCT00057343 |
| Zevalin (ibritumomab tiuxetan) | Other | Phase PHASE3 | Non-Hodgkin's Lymphoma | TERMINATED | NCT00057343 |
| Rituxan (rituximab) | Other | Phase PHASE3 | Non-Hodgkin's Lymphoma | TERMINATED | NCT00057343 |
| Zevalin (ibritumomab tiuxetan) | Other | Phase PHASE3 | Non-Hodgkin's Lymphoma | TERMINATED | NCT00057343 |
| Alefacept | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT00301002 |
| Alefacept | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT00301002 |
| Alefacept | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT00301002 |
| Alefacept (Amevive) | Other | Approved | Chronic Plaque Psoriasis | COMPLETED | NCT00422617 |
| Factors that influence compliance | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT00223457 |
| Factors that influence compliance | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT00223457 |
| Factors that influence compliance | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT00223457 |
| Alefacept | Other | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT00376129 |
| Alefacept | Other | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT00376129 |
| low immunogenic interferon-beta-1a | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00493077 |
| low immunogenic interferon-beta-1a | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00493077 |
| methylprednisolone | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00492466 |
| Interferon-beta-1a | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00492466 |
| methylprednisolone | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00492466 |
| Interferon-beta-1a | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00492466 |
| BG9924 | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00292422 |
| BG9924 | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00292422 |
| BG9924 | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00292422 |
| Transitioning patients from cyclosporine to alefacept | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT00143806 |
| Transitioning patients from cyclosporine to alefacept | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT00143806 |
| Placebo | Other | Phase PHASE2 | Parkinson's Disease | COMPLETED | NCT00442780 |
| BIIB014 | Other | Phase PHASE2 | Parkinson's Disease | COMPLETED | NCT00442780 |
| Placebo | Other | Phase PHASE2 | Parkinson's Disease | COMPLETED | NCT00442780 |
| BIIB014 | Other | Phase PHASE2 | Parkinson's Disease | COMPLETED | NCT00442780 |
| Placebo | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00030966 |
| Natalizumab | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00030966 |
| Placebo | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00030966 |
| Natalizumab | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00030966 |
| Interferon Beta-1a | Other | Phase PHASE2 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | COMPLETED | NCT00099489 |
| Interferon Beta-1a | Other | Phase PHASE2 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | COMPLETED | NCT00099489 |
| 90Y-IDEC-159 | Other | Phase PHASE1 | Colorectal Cancer | TERMINATED | NCT00102024 |
| 111In-IDEC-159 | Other | Phase PHASE1 | Colorectal Cancer | TERMINATED | NCT00102024 |
| Unconjugated IDEC-159 | Other | Phase PHASE1 | Colorectal Cancer | TERMINATED | NCT00102024 |
| 90Y-IDEC-159 | Other | Phase PHASE1 | Colorectal Cancer | TERMINATED | NCT00102024 |
| 111In-IDEC-159 | Other | Phase PHASE1 | Colorectal Cancer | TERMINATED | NCT00102024 |
| Unconjugated IDEC-159 | Other | Phase PHASE1 | Colorectal Cancer | TERMINATED | NCT00102024 |
| Omaveloxolone | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT07297199 |
| Observational | Other | Preclinical | Spinal Muscular Atrophy | RECRUITING | NCT06955897 |
| Omaveloxolone | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT07297199 |
| Observational | Other | Preclinical | Spinal Muscular Atrophy | RECRUITING | NCT06955897 |
| Omaveloxolone | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT07297199 |
| Observational | Other | Preclinical | Spinal Muscular Atrophy | RECRUITING | NCT06955897 |
| Omaveloxolone | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT07297199 |
| Observational | Other | Preclinical | Spinal Muscular Atrophy | RECRUITING | NCT06955897 |
| Omaveloxolone | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT07297199 |
| Observational | Other | Preclinical | Spinal Muscular Atrophy | RECRUITING | NCT06955897 |
| Omaveloxolone | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT07297199 |
| Observational | Other | Preclinical | Spinal Muscular Atrophy | RECRUITING | NCT06955897 |
| IV methylprednisolone | Other | Phase PHASE4 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00112034 |
| Methotrexate | Other | Phase PHASE4 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00112034 |
| Chemotherapy and Radioimmunotherapy | Drug | Phase PHASE2 | Non-Hodgkin Lymphoma | COMPLETED | NCT00177554 |
| Chemotherapy and Radioimmunotherapy | Drug | Phase PHASE2 | Non-Hodgkin Lymphoma | COMPLETED | NCT00177554 |
| [11C]SCH442416 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00531193 |
| BIIB014 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00531193 |
| [11C]SCH442416 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00531193 |
| BIIB014 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00531193 |
| Mechanism of action of alefacept | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT00150982 |
| Mechanism of action of alefacept | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT00150982 |
| Interferon beta-1a | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT00574041 |
| Interferon beta-1a | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT00574041 |
| Alefacept | Other | Phase PHASE4 | Chronic Plaque Psoriasis | COMPLETED | NCT00794807 |
| Alefacept | Other | Phase PHASE4 | Chronic Plaque Psoriasis | COMPLETED | NCT00794807 |
| Alefacept | Other | Phase PHASE4 | Chronic Plaque Psoriasis | COMPLETED | NCT00794807 |
| Rituximab for transplant rejection | Other | Phase PHASE2 | Kidney Transplantation | COMPLETED | NCT00697996 |
| Rituximab for transplant rejection | Other | Phase PHASE2 | Kidney Transplantation | COMPLETED | NCT00697996 |
| Placebo | Other | Phase PHASE2 | Lichen Planus | TERMINATED | NCT00135733 |
| Amevive (Alefacept) | Other | Phase PHASE2 | Lichen Planus | TERMINATED | NCT00135733 |
| Placebo | Other | Phase PHASE2 | Lichen Planus | TERMINATED | NCT00135733 |
| Amevive (Alefacept) | Other | Phase PHASE2 | Lichen Planus | TERMINATED | NCT00135733 |
| Placebo | Other | Phase PHASE2 | Lichen Planus | TERMINATED | NCT00135733 |
| Amevive (Alefacept) | Other | Phase PHASE2 | Lichen Planus | TERMINATED | NCT00135733 |
| Interferon beta-1a (Avonex) | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00913666 |
| Interferon beta-1a (Avonex) | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00913666 |
| Interferon beta-1a (Avonex) | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00913666 |
| Interferon beta-1a (Avonex) | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00913666 |
| Serum Free Avonex | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT00913250 |
| Serum containing Avonex | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT00913250 |
| Serum Free Avonex | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT00913250 |
| Serum containing Avonex | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT00913250 |
| CNF2024 (BIIB021) | Other | Phase PHASE1 | B-Cell Chronic Lymphocytic Leukemia | TERMINATED | NCT00344786 |
| Single-use autoinjector | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT00915577 |
| Interferon beta-1a | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT00915577 |
| Single-use autoinjector | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT00915577 |
| Interferon beta-1a | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT00915577 |
| Interferon beta-1a (Avonex) | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00915460 |
| Interferon beta-1a (Avonex) | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00915460 |
| Interferon beta-1a | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT00912860 |
| Interferon beta-1a | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT00912860 |
| Placebo | Other | Phase PHASE2 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00097760 |
| Natalizumab | Other | Phase PHASE2 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00097760 |
| Placebo | Other | Phase PHASE2 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00097760 |
| Natalizumab | Other | Phase PHASE2 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00097760 |
| Placebo | Other | Phase PHASE2 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00097760 |
| Natalizumab | Other | Phase PHASE2 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00097760 |
| Natalizumab | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT00276172 |
| Placebo | Other | Phase PHASE2 | Parkinson's Disease | COMPLETED | NCT00438607 |
| BIIB014 | Other | Phase PHASE2 | Parkinson's Disease | COMPLETED | NCT00438607 |
| CNF2024 | Other | Phase PHASE1 | Tumors | COMPLETED | NCT00345189 |
| CNF2024 | Other | Phase PHASE1 | Tumors | COMPLETED | NCT00345189 |
| Ad.hIFN-β (BG00001, IDEC-201) | Other | Phase PHASE1 | Colorectal Carcinoma | COMPLETED | NCT00107861 |
| Ad.hIFN-β (BG00001, IDEC-201) | Other | Phase PHASE1 | Colorectal Carcinoma | COMPLETED | NCT00107861 |
| natalizumab treatment | Drug | Phase EARLY_PHASE1 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT00424788 |
| Plasma exchange | Other | Phase EARLY_PHASE1 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT00424788 |
| natalizumab treatment | Drug | Phase EARLY_PHASE1 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT00424788 |
| Plasma exchange | Other | Phase EARLY_PHASE1 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT00424788 |
| natalizumab treatment | Drug | Phase EARLY_PHASE1 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT00424788 |
| Plasma exchange | Other | Phase EARLY_PHASE1 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT00424788 |
| rituximab | Other | Phase PHASE4 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00090038 |
| rituximab | Other | Phase PHASE4 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00090038 |
| BG9928 | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT00858156 |
| Interferon beta-1a | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT00599274 |
| Interferon beta-1a | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT00599274 |
| Interferon beta-1a | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT00599274 |
| BG00012 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01069913 |
| BG00012 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01069913 |
| BG00012 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01069913 |
| CNF1010 (17-AAG) | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | TERMINATED | NCT00319930 |
| CNF1010 (17-AAG) | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | TERMINATED | NCT00319930 |
| BIIB014 100mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01035515 |
| BIIB014 50mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01035515 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01035515 |
| BIIB014 100mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01035515 |
| BIIB014 50mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01035515 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01035515 |
| Placebo | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00492765 |
| Simvastatin | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00492765 |
| Interferon-beta-1a | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00492765 |
| Placebo | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00492765 |
| Simvastatin | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00492765 |
| Interferon-beta-1a | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00492765 |
| Lixivaptan | Other | Phase PHASE3 | Hypervolemic Hyponatremia | WITHDRAWN | NCT00876876 |
| Lixivaptan | Other | Phase PHASE3 | Hypervolemic Hyponatremia | WITHDRAWN | NCT00876876 |
| Galiximab | Other | Phase PHASE1 | Lymphoma, Non-Hodgkin's | TERMINATED | NCT00651443 |
| Zidovudine | Other | Phase PHASE2 | HIV Infections | TERMINATED | NCT00000659 |
| CD4 Antigens | Other | Phase PHASE2 | HIV Infections | TERMINATED | NCT00000659 |
| Zidovudine | Other | Phase PHASE2 | HIV Infections | TERMINATED | NCT00000659 |
| CD4 Antigens | Other | Phase PHASE2 | HIV Infections | TERMINATED | NCT00000659 |
| Zidovudine | Other | Phase PHASE2 | HIV Infections | TERMINATED | NCT00000659 |
| CD4 Antigens | Other | Phase PHASE2 | HIV Infections | TERMINATED | NCT00000659 |
| pegylated interferon alpha 2a YPEG-IFN α-2a 180mcg | Other | Phase PHASE2 | Self Efficacy | UNKNOWN | NCT01327729 |
| pegylated interferon alpha 2a YPEG-IFN α-2a 180mcg | Other | Phase PHASE2 | Self Efficacy | UNKNOWN | NCT01327729 |
| Avonex | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01416207 |
| Avonex | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01416207 |
| Natalizumab | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05925049 |
| Omaveloxolone | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT07297199 |
| Observational | Other | Preclinical | Spinal Muscular Atrophy | RECRUITING | NCT06955897 |
| moxifloxacin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00675701 |
| lixivaptan | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00675701 |
| placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00675701 |
| moxifloxacin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00675701 |
| lixivaptan | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00675701 |
| placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00675701 |
| moxifloxacin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00675701 |
| lixivaptan | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00675701 |
| placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00675701 |
| Placebo | Other | Phase PHASE3 | Euvolemic Hyponatremia | COMPLETED | NCT00876798 |
| Lixivaptan | Other | Phase PHASE3 | Euvolemic Hyponatremia | COMPLETED | NCT00876798 |
| Placebo | Other | Phase PHASE3 | Euvolemic Hyponatremia | COMPLETED | NCT00876798 |
| Lixivaptan | Other | Phase PHASE3 | Euvolemic Hyponatremia | COMPLETED | NCT00876798 |
| placebo | Other | Phase PHASE3 | Hyponatremia With Normal Extracellular Fluid Volume | COMPLETED | NCT00660959 |
| lixivaptan | Other | Phase PHASE3 | Hyponatremia With Normal Extracellular Fluid Volume | COMPLETED | NCT00660959 |
| placebo | Other | Phase PHASE3 | Hyponatremia With Normal Extracellular Fluid Volume | COMPLETED | NCT00660959 |
| lixivaptan | Other | Phase PHASE3 | Hyponatremia With Normal Extracellular Fluid Volume | COMPLETED | NCT00660959 |
| Placebo | Other | Phase PHASE3 | Hyponatremia | COMPLETED | NCT00578695 |
| lixivaptan | Other | Phase PHASE3 | Hyponatremia | COMPLETED | NCT00578695 |
| 25G x 1" Needle Autoinjector | Other | Phase PHASE1 | Healthy | TERMINATED | NCT01313364 |
| 25G x 1" Needle Autoinjector | Other | Phase PHASE1 | Healthy | TERMINATED | NCT01313364 |
| Tysabri | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT00937677 |
| Tysabri | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT00937677 |
| Rituximab | Other | Phase PHASE2 | Lymphoma, Mantle-Cell | COMPLETED | NCT00038623 |
| Yttrium-ibritumomab (Zevalin) | Other | Phase PHASE2 | Lymphoma, Mantle-Cell | COMPLETED | NCT00038623 |
| Rituximab | Other | Phase PHASE2 | Lymphoma, Mantle-Cell | COMPLETED | NCT00038623 |
| Yttrium-ibritumomab (Zevalin) | Other | Phase PHASE2 | Lymphoma, Mantle-Cell | COMPLETED | NCT00038623 |
| Experimental | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01420458 |
| Experimental | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01420458 |
| Experimental | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01420458 |
| PLACEBO | Other | Phase PHASE2 | Heart Failure | UNKNOWN | NCT01477801 |
| CHOLECALCIFEROL | Other | Phase PHASE2 | Heart Failure | UNKNOWN | NCT01477801 |
| PLACEBO | Other | Phase PHASE2 | Heart Failure | UNKNOWN | NCT01477801 |
| CHOLECALCIFEROL | Other | Phase PHASE2 | Heart Failure | UNKNOWN | NCT01477801 |
| Volociximab | Other | Phase PHASE2 | Ovarian Cancer | TERMINATED | NCT00516841 |
| Volociximab | Other | Phase PHASE2 | Ovarian Cancer | TERMINATED | NCT00516841 |
| Natalizumab | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05925049 |
| Omaveloxolone | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT07297199 |
| Observational | Other | Preclinical | Spinal Muscular Atrophy | RECRUITING | NCT06955897 |
| Natalizumab | Other | Phase PHASE2 | Primary Progressive Multiple Sclerosis | COMPLETED | NCT01077466 |
| Natalizumab | Other | Phase PHASE2 | Primary Progressive Multiple Sclerosis | COMPLETED | NCT01077466 |
| 90Y Ibritumomab tiuxetan | Other | Phase PHASE1 | Lymphoma, Non-Hodgkin | COMPLETED | NCT00186589 |
| 90Y Ibritumomab tiuxetan | Other | Phase PHASE1 | Lymphoma, Non-Hodgkin | COMPLETED | NCT00186589 |
| IDEC-114 | Other | Phase PHASE1 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00575068 |
| IDEC-114 | Other | Phase PHASE1 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00575068 |
| CNF2024 + trastuzumab | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00412412 |
| CNF2024 | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00412412 |
| methylprednisolone | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00493116 |
| Interferon-beta-1a | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00493116 |
| methylprednisolone | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00493116 |
| Interferon-beta-1a | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00493116 |
| Interferon-beta-1a (Avonex) plus methylprednisolone | Other | Phase PHASE4 | Relapsing-remitting Multiple Sclerosis | COMPLETED | NCT00168766 |
| Interferon-beta-1a (Avonex) plus methylprednisolone | Other | Phase PHASE4 | Relapsing-remitting Multiple Sclerosis | COMPLETED | NCT00168766 |
| IDEC-114 | Other | Phase PHASE1 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00048555 |
| IDEC-114 | Other | Phase PHASE1 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00048555 |
| Natalizumab (Tysabri) | Other | Phase PHASE4 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT01591551 |
| Natalizumab (Tysabri) | Other | Phase PHASE4 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT01591551 |
| BIIB019 subcutaneous injection | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01929746 |
| BIIB019 subcutaneous injection | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01929746 |
| BG9418 (interferon beta-1a) | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT00828204 |
| Avonex prefilled syringe via manual IM injection | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT00828204 |
| single-use autoinjector with a prefilled liquid Avonex syringe | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT00828204 |
| BG9418 (interferon beta-1a) | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT00828204 |
| Avonex prefilled syringe via manual IM injection | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT00828204 |
| single-use autoinjector with a prefilled liquid Avonex syringe | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT00828204 |
| BIIB017 (peginterferon beta-1a) Autoinjector | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01610310 |
| BIIB017 (peginterferon beta-1a) Pre-filled syringe (PFS) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01610310 |
| Placebo | Other | Phase PHASE2 | Active Ulcerative Colitis | COMPLETED | NCT00616434 |
| BG9418 (Interferon beta-1a) | Other | Phase PHASE2 | Active Ulcerative Colitis | COMPLETED | NCT00616434 |
| standard of care | Other | Phase PHASE1 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00559702 |
| natalizumab | Other | Phase PHASE1 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00559702 |
| Placebo | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | COMPLETED | NCT00906399 |
| BIIB017 (peginterferon beta-1a) | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | COMPLETED | NCT00906399 |
| BG00002 (natalizumab) | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT00675428 |
| BG00002 (natalizumab) | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT00675428 |
| PF-04958242 oral solution | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01646840 |
| PF-04958242 capsule | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01646840 |
| Natalizumab | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05925049 |
| Natalizumab | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05925049 |
| pet-scan FDG-F18 | Other | Phase PHASE4 | Multiple Sclerosis | TERMINATED | NCT00752778 |
| pet-scan FDG-F18 | Other | Phase PHASE4 | Multiple Sclerosis | TERMINATED | NCT00752778 |
| pet-scan FDG-F18 | Other | Phase PHASE4 | Multiple Sclerosis | TERMINATED | NCT00752778 |
| Interferon beta-1a (new process, manufactured without FBS) | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT01500408 |
| Interferon beta-1a (current approved manufacturing process invloving FBS) | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT01500408 |
| hCBE-11 | Other | Phase PHASE1 | Tumors | TERMINATED | NCT00105170 |
| hCBE-11 | Other | Phase PHASE1 | Tumors | TERMINATED | NCT00105170 |
| hCBE-11 | Other | Phase PHASE1 | Tumors | TERMINATED | NCT00105170 |
| (IM) AVONEX® | Other | Phase PHASE1 | Multiple Sclerosis (MS) | COMPLETED | NCT01863069 |
| Interferon beta 1a | Other | Phase PHASE1 | Multiple Sclerosis (MS) | COMPLETED | NCT01863069 |
| (IM) AVONEX® | Other | Phase PHASE1 | Multiple Sclerosis (MS) | COMPLETED | NCT01863069 |
| Interferon beta 1a | Other | Phase PHASE1 | Multiple Sclerosis (MS) | COMPLETED | NCT01863069 |
| Reference product | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01632449 |
| Test product | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01632449 |
| Reference product | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01632449 |
| Test product | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01632449 |
| ^111 In Ibritumomab Tiuxetan | Other | Phase PHASE2 | Lymphoma | TERMINATED | NCT00493454 |
| Rituximab | Other | Phase PHASE2 | Lymphoma | TERMINATED | NCT00493454 |
| Zevalin | Other | Phase PHASE2 | Lymphoma | TERMINATED | NCT00493454 |
| ^111 In Ibritumomab Tiuxetan | Other | Phase PHASE2 | Lymphoma | TERMINATED | NCT00493454 |
| Rituximab | Other | Phase PHASE2 | Lymphoma | TERMINATED | NCT00493454 |
| Zevalin | Other | Phase PHASE2 | Lymphoma | TERMINATED | NCT00493454 |
| Allogeneic Stem Cell Transplantation | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00048737 |
| Cyclophosphamide | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00048737 |
| Fludarabine | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00048737 |
| Rituximab | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00048737 |
| Zevalin Radioimmunotherapy | Drug | Phase PHASE1 | Lymphoma | COMPLETED | NCT00048737 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | WITHDRAWN | NCT01652937 |
| BIIB057 | Other | Phase PHASE2 | Rheumatoid Arthritis | WITHDRAWN | NCT01652937 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | WITHDRAWN | NCT01652937 |
| BIIB057 | Other | Phase PHASE2 | Rheumatoid Arthritis | WITHDRAWN | NCT01652937 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | WITHDRAWN | NCT01652937 |
| BIIB057 | Other | Phase PHASE2 | Rheumatoid Arthritis | WITHDRAWN | NCT01652937 |
| Blood Sample | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT01556685 |
| clinical and neurological evaluation | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT01556685 |
| Blood Sample | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT01556685 |
| clinical and neurological evaluation | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT01556685 |
| BG00012 Dose 2 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01453426 |
| BG00012 Dose 1 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01453426 |
| BG00012 Dose 2 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01453426 |
| BG00012 Dose 1 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01453426 |
| BIIB023 - high dose IV Dose | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01407406 |
| BIIB023 - low dose IV Dose | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01407406 |
| BIIB023 - high dose IV Dose | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01407406 |
| BIIB023 - low dose IV Dose | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01407406 |
| Avonex | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT01181115 |
| Avonex | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT01181115 |
| Baminercept | Other | Phase PHASE1 | Secondary Progressive Multiple Sclerosis | WITHDRAWN | NCT01181089 |
| Placebo | Other | Phase PHASE1 | Secondary Progressive Multiple Sclerosis | WITHDRAWN | NCT01181089 |
| Baminercept | Other | Phase PHASE1 | Secondary Progressive Multiple Sclerosis | WITHDRAWN | NCT01181089 |
| Placebo | Other | Phase PHASE1 | Secondary Progressive Multiple Sclerosis | WITHDRAWN | NCT01181089 |
| BIIB0121 and Antacid | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT01017198 |
| BIIB021 and Food | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT01017198 |
| BIIB0121 and Antacid | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT01017198 |
| BIIB021 and Food | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT01017198 |
| BIIB022 With Paclitaxel and Carboplatin | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | COMPLETED | NCT00970580 |
| BIIB022 With Paclitaxel and Carboplatin | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | COMPLETED | NCT00970580 |
| Sorafenib | Other | Phase PHASE1 | Hepatocellular Carcinoma | COMPLETED | NCT00956436 |
| BIIB022 | Other | Phase PHASE1 | Hepatocellular Carcinoma | COMPLETED | NCT00956436 |
| placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00810836 |
| BG00012 | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00810836 |
| placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00810836 |
| BG00012 | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00810836 |
| Placebo (sterile normal saline) | Other | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT00771329 |
| BIIB023 | Other | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT00771329 |
| Placebo (sterile normal saline) | Other | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT00771329 |
| BIIB023 | Other | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT00771329 |
| BIIB015 | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT00674947 |
| IDEC-152 | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT00046488 |
| glatiramer acetate | Other | Phase PHASE2 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT01071083 |
| IV placebo | Other | Phase PHASE2 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT01071083 |
| methylprednisolone | Other | Phase PHASE2 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT01071083 |
| interferon beta 1-a | Other | Phase PHASE2 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT01071083 |
| natalizumab | Other | Phase PHASE2 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT01071083 |
| glatiramer acetate | Other | Phase PHASE2 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT01071083 |
| IV placebo | Other | Phase PHASE2 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT01071083 |
| methylprednisolone | Other | Phase PHASE2 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT01071083 |
| interferon beta 1-a | Other | Phase PHASE2 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT01071083 |
| natalizumab | Other | Phase PHASE2 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT01071083 |
| Zevalin | Other | Approved | Non-Hodgkin's Lymphoma | COMPLETED | NCT00387023 |
| Rituximab | Other | Approved | Non-Hodgkin's Lymphoma | COMPLETED | NCT00387023 |
| Zevalin | Other | Approved | Non-Hodgkin's Lymphoma | COMPLETED | NCT00387023 |
| Rituximab | Other | Approved | Non-Hodgkin's Lymphoma | COMPLETED | NCT00387023 |
| dimethyl fumarate (DMF) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01915901 |
| matching placebo (bismuth subsalicylate) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01915901 |
| bismuth subsalicylate (Pepto-Bismol®) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01915901 |
| Zevalin | Other | Phase PHASE2 | Mantle Cell Lymphoma | COMPLETED | NCT00119730 |
| Rituximab | Other | Phase PHASE2 | Mantle Cell Lymphoma | COMPLETED | NCT00119730 |
| Mitoxantrone | Other | Phase PHASE2 | Mantle Cell Lymphoma | COMPLETED | NCT00119730 |
| Fludarabine | Other | Phase PHASE2 | Mantle Cell Lymphoma | COMPLETED | NCT00119730 |
| Zevalin | Other | Phase PHASE2 | Mantle Cell Lymphoma | COMPLETED | NCT00119730 |
| Rituximab | Other | Phase PHASE2 | Mantle Cell Lymphoma | COMPLETED | NCT00119730 |
| Mitoxantrone | Other | Phase PHASE2 | Mantle Cell Lymphoma | COMPLETED | NCT00119730 |
| Fludarabine | Other | Phase PHASE2 | Mantle Cell Lymphoma | COMPLETED | NCT00119730 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02125578 |
| BIIB017 (PEGylated Interferon Beta-1a) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02125578 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02125578 |
| BIIB017 (PEGylated Interferon Beta-1a) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02125578 |
| BG9418 (interferon beta 1-a) | Other | Phase PHASE3 | Multiple Sclerosis | TERMINATED | NCT00784836 |
| BG00002-E (natalizumab high titer) | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT00516893 |
| BG00002-E (natalizumab high titer) | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT00516893 |
| BG00002 | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02142205 |
| BIIB017(peginterferon beta-1a) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01119781 |
| BIIB017(peginterferon beta-1a) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01119781 |
| BG9418 (interferon beta-1a) | Other | Preclinical | Prenatal Exposure Delayed Effects | COMPLETED | NCT00168714 |
| BG9418 (interferon beta-1a) | Other | Preclinical | Prenatal Exposure Delayed Effects | COMPLETED | NCT00168714 |
| BG9418 (interferon beta-1a) | Other | Preclinical | Prenatal Exposure Delayed Effects | COMPLETED | NCT00168714 |
| BIIB017 (peginterferon beta-1a) Autoinjector | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01610310 |
| BIIB017 (peginterferon beta-1a) Pre-filled syringe (PFS) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01610310 |
| BG0002 (natalizumab) | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00818038 |
| TALL-104 cells | Other | Phase PHASE2 | Chronic Myelogenous Leukemia | TERMINATED | NCT00415909 |
| Imatinib Mesylate (IM) | Other | Phase PHASE2 | Chronic Myelogenous Leukemia | TERMINATED | NCT00415909 |
| TALL-104 cells | Other | Phase PHASE2 | Chronic Myelogenous Leukemia | TERMINATED | NCT00415909 |
| Imatinib Mesylate (IM) | Other | Phase PHASE2 | Chronic Myelogenous Leukemia | TERMINATED | NCT00415909 |
| mefloquine | Other | Phase PHASE1 | Progressive Multifocal Leukoencephalopathy | TERMINATED | NCT00746941 |
| mefloquine | Other | Phase PHASE1 | Progressive Multifocal Leukoencephalopathy | TERMINATED | NCT00746941 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01943513 |
| BIIB023 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01943513 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01943513 |
| BIIB023 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01943513 |
| glatiramer acetate | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT01058005 |
| interferon beta-1a | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT01058005 |
| BG00002 (natalizumab) | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT01058005 |
| glatiramer acetate | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT01058005 |
| interferon beta-1a | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT01058005 |
| BG00002 (natalizumab) | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT01058005 |
| glatiramer acetate | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT01058005 |
| interferon beta-1a | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT01058005 |
| BG00002 (natalizumab) | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT01058005 |
| Prednisolone | Other | Phase PHASE4 | Immune Reconstitution Inflammatory Syndrome | TERMINATED | NCT01211665 |
| Methylprednisolone | Other | Phase PHASE4 | Immune Reconstitution Inflammatory Syndrome | TERMINATED | NCT01211665 |
| Prednisolone | Other | Phase PHASE4 | Immune Reconstitution Inflammatory Syndrome | TERMINATED | NCT01211665 |
| Methylprednisolone | Other | Phase PHASE4 | Immune Reconstitution Inflammatory Syndrome | TERMINATED | NCT01211665 |
| Prednisolone | Other | Phase PHASE4 | Immune Reconstitution Inflammatory Syndrome | TERMINATED | NCT01211665 |
| Methylprednisolone | Other | Phase PHASE4 | Immune Reconstitution Inflammatory Syndrome | TERMINATED | NCT01211665 |
| AVONEX PEN | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT01405872 |
| Placebo | Other | Phase PHASE1 | Sciatica | COMPLETED | NCT01405833 |
| BG00010 (Neublastin) | Other | Phase PHASE1 | Sciatica | COMPLETED | NCT01405833 |
| Placebo | Other | Phase PHASE1 | Sciatica | COMPLETED | NCT01405833 |
| BG00010 (Neublastin) | Other | Phase PHASE1 | Sciatica | COMPLETED | NCT01405833 |
| Placebo | Other | Phase PHASE1 | Sciatica | COMPLETED | NCT01405833 |
| BG00010 (Neublastin) | Other | Phase PHASE1 | Sciatica | COMPLETED | NCT01405833 |
| standard of care | Other | Phase PHASE1 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00559702 |
| natalizumab | Other | Phase PHASE1 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00559702 |
| standard of care | Other | Phase PHASE1 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00559702 |
| natalizumab | Other | Phase PHASE1 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00559702 |
| G-CSF | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01538472 |
| Stem Cell Infusion | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01538472 |
| Melphalan | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01538472 |
| Ara-C | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01538472 |
| VP -16 | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01538472 |
| BCNU | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01538472 |
| Rituxan | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01538472 |
| In Zevalin | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01538472 |
| Y Zevalin | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01538472 |
| G-CSF | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01538472 |
| Stem Cell Infusion | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01538472 |
| Melphalan | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01538472 |
| Ara-C | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01538472 |
| VP -16 | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01538472 |
| BCNU | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01538472 |
| Rituxan | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01538472 |
| In Zevalin | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01538472 |
| Y Zevalin | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01538472 |
| BIIB017 | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | WITHDRAWN | NCT01337427 |
| BIIB017 | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | WITHDRAWN | NCT01337427 |
| Placebo | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT01440101 |
| Natalizumab (BG00002) | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT01440101 |
| Placebo | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT01440101 |
| Natalizumab (BG00002) | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT01440101 |
| Placebo | Other | Phase PHASE1 | Sciatica | COMPLETED | NCT00961766 |
| BG00010 (Neublastin) | Other | Phase PHASE1 | Sciatica | COMPLETED | NCT00961766 |
| Placebo | Other | Phase PHASE1 | Sciatica | COMPLETED | NCT00961766 |
| BG00010 (Neublastin) | Other | Phase PHASE1 | Sciatica | COMPLETED | NCT00961766 |
| Placebo | Other | Phase PHASE1 | Sciatica | COMPLETED | NCT00961766 |
| BG00010 (Neublastin) | Other | Phase PHASE1 | Sciatica | COMPLETED | NCT00961766 |
| Peginterferon Beta-1a | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01978652 |
| Peginterferon Beta-1a | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01978652 |
| Natalizumab | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00744679 |
| Natalizumab | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00744679 |
| dimethyl fumarate | Other | Preclinical | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT01903291 |
| dimethyl fumarate | Other | Preclinical | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT01903291 |
| natalizumab | Other | Preclinical | Relapsing Multiple Sclerosis | COMPLETED | NCT01070836 |
| Placebo | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT01597297 |
| BIIB041 (PR Fampridine) | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT01597297 |
| Placebo | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT01597297 |
| BIIB041 (PR Fampridine) | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT01597297 |
| peginterferon beta-1a | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | COMPLETED | NCT01332019 |
| oral corticosteroids | Other | Phase PHASE2 | Lupus Nephritis | TERMINATED | NCT01930890 |
| mycophenolate mofetil | Other | Phase PHASE2 | Lupus Nephritis | TERMINATED | NCT01930890 |
| BIIB023 | Other | Phase PHASE2 | Lupus Nephritis | TERMINATED | NCT01930890 |
| interferon beta-1a | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02076841 |
| interferon beta-1a | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02076841 |
| interferon beta-1a | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02076841 |
| BIIB041 (fampridine) | Other | Phase PHASE3 | Multiple Sclerosis, Remittent Progressive | COMPLETED | NCT01917019 |
| Placebo | Other | Phase PHASE3 | Multiple Sclerosis, Remittent Progressive | COMPLETED | NCT01917019 |
| BIIB041 (fampridine) | Other | Phase PHASE3 | Multiple Sclerosis, Remittent Progressive | COMPLETED | NCT01917019 |
| Placebo | Other | Phase PHASE3 | Multiple Sclerosis, Remittent Progressive | COMPLETED | NCT01917019 |
| BIIB041 (fampridine) | Other | Phase PHASE3 | Multiple Sclerosis, Remittent Progressive | COMPLETED | NCT01917019 |
| Placebo | Other | Phase PHASE3 | Multiple Sclerosis, Remittent Progressive | COMPLETED | NCT01917019 |
| Adherence counseling | Other | Phase PHASE4 | Multiple Sclerosis | TERMINATED | NCT02343159 |
| Medication Event Monitoring System (MEMS) | Drug | Phase PHASE4 | Multiple Sclerosis | TERMINATED | NCT02343159 |
| dimethyl fumarate | Other | Phase PHASE4 | Multiple Sclerosis | TERMINATED | NCT02343159 |
| Adherence counseling | Other | Phase PHASE4 | Multiple Sclerosis | TERMINATED | NCT02343159 |
| Medication Event Monitoring System (MEMS) | Drug | Phase PHASE4 | Multiple Sclerosis | TERMINATED | NCT02343159 |
| dimethyl fumarate | Other | Phase PHASE4 | Multiple Sclerosis | TERMINATED | NCT02343159 |
| Placebo | Other | Phase PHASE2 | Primary Inherited Erythromelalgia | COMPLETED | NCT02917187 |
| BIIB074 | Other | Phase PHASE2 | Primary Inherited Erythromelalgia | COMPLETED | NCT02917187 |
| Placebo | Other | Phase PHASE2 | Primary Inherited Erythromelalgia | COMPLETED | NCT02917187 |
| BIIB074 | Other | Phase PHASE2 | Primary Inherited Erythromelalgia | COMPLETED | NCT02917187 |
| Placebo | Other | Phase PHASE1 | Progressive Supranuclear Palsy | COMPLETED | NCT02460094 |
| BIIB092 | Other | Phase PHASE1 | Progressive Supranuclear Palsy | COMPLETED | NCT02460094 |
| Placebo | Other | Phase PHASE1 | Progressive Supranuclear Palsy | COMPLETED | NCT02460094 |
| BIIB092 | Other | Phase PHASE1 | Progressive Supranuclear Palsy | COMPLETED | NCT02460094 |
| Placebo | Other | Phase PHASE2 | Acute Ischemic Stroke | COMPLETED | NCT02730455 |
| natalizumab | Other | Phase PHASE2 | Acute Ischemic Stroke | COMPLETED | NCT02730455 |
| Placebo | Other | Phase PHASE2 | Acute Ischemic Stroke | COMPLETED | NCT02730455 |
| natalizumab | Other | Phase PHASE2 | Acute Ischemic Stroke | COMPLETED | NCT02730455 |
| Fampridine | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT01480063 |
| Placebo | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01749098 |
| Ketamine | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01749098 |
| PF-04958242 | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01749098 |
| Placebo | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01749098 |
| Ketamine | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01749098 |
| PF-04958242 | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01749098 |
| PF-04958242 oral solution | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01646840 |
| PF-04958242 capsule | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01646840 |
| Placebo | Other | Phase PHASE1 | Hearing Loss, Sensorineural | COMPLETED | NCT01518920 |
| PF-04958242 | Other | Phase PHASE1 | Hearing Loss, Sensorineural | COMPLETED | NCT01518920 |
| placebo | Other | Phase PHASE2 | Cognitive Impairment Associated With Schizophrenia (CIAS) | TERMINATED | NCT02855411 |
| PF-04958242 | Other | Phase PHASE2 | Cognitive Impairment Associated With Schizophrenia (CIAS) | TERMINATED | NCT02855411 |
| placebo | Other | Phase PHASE2 | Cognitive Impairment Associated With Schizophrenia (CIAS) | TERMINATED | NCT02855411 |
| PF-04958242 | Other | Phase PHASE2 | Cognitive Impairment Associated With Schizophrenia (CIAS) | TERMINATED | NCT02855411 |
| Placebo | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT02410278 |
| montelukast | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT02410278 |
| dimethyl fumarate | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT02410278 |
| Placebo | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT02410278 |
| montelukast | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT02410278 |
| dimethyl fumarate | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT02410278 |
| Natalizumab | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05925049 |
| BIIB017 (Peginterferon beta-1a) | Other | Phase PHASE4 | Relapsing Multiple Sclerosis | WITHDRAWN | NCT02234869 |
| Interferon Beta | Other | Phase PHASE4 | Relapsing Multiple Sclerosis | WITHDRAWN | NCT02234869 |
| BIIB017 (Peginterferon beta-1a) | Other | Phase PHASE4 | Relapsing Multiple Sclerosis | WITHDRAWN | NCT02234869 |
| Interferon Beta | Other | Phase PHASE4 | Relapsing Multiple Sclerosis | WITHDRAWN | NCT02234869 |
| BIIB017 (Peginterferon beta-1a) | Other | Phase PHASE4 | Relapsing Multiple Sclerosis | WITHDRAWN | NCT02234869 |
| Interferon Beta | Other | Phase PHASE4 | Relapsing Multiple Sclerosis | WITHDRAWN | NCT02234869 |
| Training | Other | Approved | Multiple Sclerosis (Relapsing Remitting) | COMPLETED | NCT01518660 |
| Training | Other | Approved | Multiple Sclerosis (Relapsing Remitting) | COMPLETED | NCT01518660 |
| dimethyl fumarate - Test form | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02171208 |
| dimethyl fumarate - Reference form | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02171208 |
| dimethyl fumarate - Test form | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02171208 |
| dimethyl fumarate - Reference form | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02171208 |
| dimethyl fumarate - Test form | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02171208 |
| dimethyl fumarate - Reference form | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02171208 |
| Glatiramer Acetate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00451451 |
| Placebo | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00451451 |
| BG00012 | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00451451 |
| Glatiramer Acetate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00451451 |
| Placebo | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00451451 |
| BG00012 | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00451451 |
| Placebo | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00420212 |
| BG00012 | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00420212 |
| Placebo | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00420212 |
| BG00012 | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00420212 |
| Rebif | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT02269930 |
| peginterferon beta-1a | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT02269930 |
| Rebif | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT02269930 |
| peginterferon beta-1a | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT02269930 |
| Rebif | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT02269930 |
| peginterferon beta-1a | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT02269930 |
| 14C-BIIB061 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02071121 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02071121 |
| BIIB061 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02071121 |
| 14C-BIIB061 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02071121 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02071121 |
| BIIB061 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02071121 |
| Placebo SC | Other | Phase PHASE1 | Painful Lumbar Radiculopathy | COMPLETED | NCT01842126 |
| Placebo IV | Other | Phase PHASE1 | Painful Lumbar Radiculopathy | COMPLETED | NCT01842126 |
| BG00010 SC | Other | Phase PHASE1 | Painful Lumbar Radiculopathy | COMPLETED | NCT01842126 |
| BG00010 IV | Other | Phase PHASE1 | Painful Lumbar Radiculopathy | COMPLETED | NCT01842126 |
| Placebo SC | Other | Phase PHASE1 | Painful Lumbar Radiculopathy | COMPLETED | NCT01842126 |
| Placebo IV | Other | Phase PHASE1 | Painful Lumbar Radiculopathy | COMPLETED | NCT01842126 |
| BG00010 SC | Other | Phase PHASE1 | Painful Lumbar Radiculopathy | COMPLETED | NCT01842126 |
| BG00010 IV | Other | Phase PHASE1 | Painful Lumbar Radiculopathy | COMPLETED | NCT01842126 |
| dimethyl fumarate | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01924832 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT01397539 |
| BIIB037 | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT01397539 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT01397539 |
| BIIB037 | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT01397539 |
| SC Placebo | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01405820 |
| IV Placebo | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01405820 |
| natalizumab SC | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01405820 |
| natalizumab IV | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01405820 |
| SC Placebo | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01405820 |
| IV Placebo | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01405820 |
| natalizumab SC | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01405820 |
| natalizumab IV | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01405820 |
| BIIB061 | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT02521545 |
| BIIB061 | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT02521545 |
| dimethyl fumarate | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | WITHDRAWN | NCT02090348 |
| dimethyl fumarate | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | WITHDRAWN | NCT02090348 |
| Placebo | Other | Phase PHASE2 | Painful Lumbar Radiculopathy | COMPLETED | NCT01873404 |
| BG00010 | Other | Phase PHASE2 | Painful Lumbar Radiculopathy | COMPLETED | NCT01873404 |
| Placebo | Other | Phase PHASE2 | Painful Lumbar Radiculopathy | COMPLETED | NCT01873404 |
| BG00010 | Other | Phase PHASE2 | Painful Lumbar Radiculopathy | COMPLETED | NCT01873404 |
| Placebo | Other | Phase PHASE2 | Painful Lumbar Radiculopathy | COMPLETED | NCT01873404 |
| BG00010 | Other | Phase PHASE2 | Painful Lumbar Radiculopathy | COMPLETED | NCT01873404 |
| Folate | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00298272 |
| Methylprednisolone | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00298272 |
| Adalimumab | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00298272 |
| Etanercept | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00298272 |
| Methotrexate | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00298272 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00298272 |
| IDEC-C2B8 (rituximab) | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00298272 |
| Folate | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00298272 |
| Methylprednisolone | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00298272 |
| Adalimumab | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00298272 |
| Etanercept | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00298272 |
| Methotrexate | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00298272 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00298272 |
| IDEC-C2B8 (rituximab) | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00298272 |
| exemestane (Aromasin) | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT01004081 |
| BIIB021 | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT01004081 |
| exemestane (Aromasin) | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT01004081 |
| BIIB021 | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT01004081 |
| FCR | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT00801060 |
| Lumiliximab + FCR | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT00801060 |
| BIIB021 | Other | Phase PHASE2 | GIST | COMPLETED | NCT00618319 |
| BIIB021 | Other | Phase PHASE2 | GIST | COMPLETED | NCT00618319 |
| FCR | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT00391066 |
| FCR + Lumiliximab | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT00391066 |
| FCR | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT00391066 |
| FCR + Lumiliximab | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT00391066 |
| Rituximab in combination with placebo | Other | Phase PHASE3 | Lymphoma, Non-Hodgkin's | TERMINATED | NCT00363636 |
| Galiximab in combination with rituximab | Other | Phase PHASE3 | Lymphoma, Non-Hodgkin's | TERMINATED | NCT00363636 |
| Rituximab in combination with placebo | Other | Phase PHASE3 | Lymphoma, Non-Hodgkin's | TERMINATED | NCT00363636 |
| Galiximab in combination with rituximab | Other | Phase PHASE3 | Lymphoma, Non-Hodgkin's | TERMINATED | NCT00363636 |
| Rituximab in combination with placebo | Other | Phase PHASE3 | Lymphoma, Non-Hodgkin's | TERMINATED | NCT00363636 |
| Galiximab in combination with rituximab | Other | Phase PHASE3 | Lymphoma, Non-Hodgkin's | TERMINATED | NCT00363636 |
| Lumiliximab with FCR | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT00103558 |
| Lumiliximab with FCR | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT00103558 |
| Lumiliximab with FCR | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT00103558 |
| natalizumab | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT02137109 |
| natalizumab | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT02137109 |
| Interferon beta-1a | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT01272128 |
| indium In 111 ibritumomab tiuxetan | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00005592 |
| rituximab | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00005592 |
| 90-Y-ibritumomab tiuxetan | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00005592 |
| indium In 111 ibritumomab tiuxetan | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00005592 |
| rituximab | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00005592 |
| 90-Y-ibritumomab tiuxetan | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00005592 |
| indium In 111 ibritumomab tiuxetan | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00005592 |
| rituximab | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00005592 |
| 90-Y-ibritumomab tiuxetan | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00005592 |
| galiximab in combination with rituximab | Other | Phase PHASE3 | Lymphoma, Non-Hodgkin's | TERMINATED | NCT00384150 |
| Placebo | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | WITHDRAWN | NCT02472938 |
| dimethyl fumarate | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | WITHDRAWN | NCT02472938 |
| Placebo | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | WITHDRAWN | NCT02472938 |
| dimethyl fumarate | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | WITHDRAWN | NCT02472938 |
| Placebo | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | WITHDRAWN | NCT02472938 |
| dimethyl fumarate | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | WITHDRAWN | NCT02472938 |
| natalizumab | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01416155 |
| natalizumab | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01416155 |
| Baminercept alfa 5 | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00664716 |
| Baminercept alfa 4 | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00664716 |
| Baminercept alfa 3 | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00664716 |
| Baminercept alfa 2 | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00664716 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00664716 |
| Baminercept alfa 1 | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00664716 |
| Baminercept alfa (BG9924) | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00664573 |
| BG9924 | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00523328 |
| BG9924 | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00523328 |
| Placebo Comparator | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00458861 |
| BG9924 | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00458861 |
| Placebo Comparator | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00458861 |
| BG9924 | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00458861 |
| Avonex | Other | Approved | Multiple Sclerosis | COMPLETED | NCT01641120 |
| dimethyl fumarate | Other | Preclinical | Multiple Sclerosis, Relapsing-Remitting | TERMINATED | NCT02323269 |
| dimethyl fumarate | Other | Preclinical | Multiple Sclerosis, Relapsing-Remitting | TERMINATED | NCT02323269 |
| dimethyl fumarate | Other | Preclinical | Multiple Sclerosis, Relapsing-Remitting | TERMINATED | NCT02323269 |
| dimethyl fumarate | Other | Preclinical | Multiple Sclerosis, Relapsing-Remitting | TERMINATED | NCT02323269 |
| Vitamin E δ-Tocotrienol | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT01446952 |
| Vitamin E δ-Tocotrienol | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT01446952 |
| Placebo | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | WITHDRAWN | NCT02428218 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | WITHDRAWN | NCT02428218 |
| Placebo | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | WITHDRAWN | NCT02428218 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | WITHDRAWN | NCT02428218 |
| Aerobic exercise | Other | Approved | Multiple Sclerosis | COMPLETED | NCT02236624 |
| Aerobic exercise | Other | Approved | Multiple Sclerosis | COMPLETED | NCT02236624 |
| Aerobic exercise | Other | Approved | Multiple Sclerosis | COMPLETED | NCT02236624 |
| Vehicle Gel | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis (RRMS) | WITHDRAWN | NCT02568111 |
| brimonidine tartrate | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis (RRMS) | WITHDRAWN | NCT02568111 |
| peginterferon beta-1a | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis (RRMS) | WITHDRAWN | NCT02568111 |
| Vehicle Gel | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis (RRMS) | WITHDRAWN | NCT02568111 |
| brimonidine tartrate | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis (RRMS) | WITHDRAWN | NCT02568111 |
| peginterferon beta-1a | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis (RRMS) | WITHDRAWN | NCT02568111 |
| dimethyl fumarate | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02159573 |
| natalizumab | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02159573 |
| dimethyl fumarate | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02159573 |
| natalizumab | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02159573 |
| dimethyl fumarate | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02159573 |
| natalizumab | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02159573 |
| Itraconazole | Other | Phase PHASE1 | Neuropathic Pain | COMPLETED | NCT02698267 |
| BIIB074 | Other | Phase PHASE1 | Neuropathic Pain | COMPLETED | NCT02698267 |
| Itraconazole | Other | Phase PHASE1 | Neuropathic Pain | COMPLETED | NCT02698267 |
| BIIB074 | Other | Phase PHASE1 | Neuropathic Pain | COMPLETED | NCT02698267 |
| ASA placebo | Other | Phase PHASE3 | Healthy | COMPLETED | NCT01568112 |
| ASA | Other | Phase PHASE3 | Healthy | COMPLETED | NCT01568112 |
| BG00012 placebo | Other | Phase PHASE3 | Healthy | COMPLETED | NCT01568112 |
| BG00012 (dimethyl fumarate) | Other | Phase PHASE3 | Healthy | COMPLETED | NCT01568112 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02228707 |
| BIIB061 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02228707 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02228707 |
| BIIB061 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02228707 |
| BIIB074 | Other | Phase PHASE1 | Neuropathic Pain | COMPLETED | NCT02751905 |
| BIIB074 | Other | Phase PHASE1 | Neuropathic Pain | COMPLETED | NCT02751905 |
| natalizumab | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00831649 |
| natalizumab | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00831649 |
| natalizumab | Other | Phase PHASE4 | Crohn's Disease | WITHDRAWN | NCT00801125 |
| natalizumab | Other | Phase PHASE4 | Crohn's Disease | WITHDRAWN | NCT00801125 |
| natalizumab | Other | Phase PHASE4 | Crohn's Disease | COMPLETED | NCT00280956 |
| natalizumab | Other | Phase PHASE4 | Crohn's Disease | COMPLETED | NCT00280956 |
| natalizumab | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT00078611 |
| natalizumab | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT00078611 |
| natalizumab | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT00078611 |
| natalizumab | Other | Phase PHASE2 | Crohn's Disease | COMPLETED | NCT00055536 |
| natalizumab | Other | Phase PHASE2 | Crohn's Disease | COMPLETED | NCT00055536 |
| natalizumab | Other | Phase PHASE2 | Crohn's Disease | COMPLETED | NCT00055367 |
| natalizumab | Other | Phase PHASE2 | Crohn's Disease | COMPLETED | NCT00055367 |
| natalizumab | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT00032799 |
| natalizumab | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT00032786 |
| natalizumab | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT00032786 |
| natalizumab | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT00032786 |
| Natalizumab | Other | Phase PHASE1 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01884935 |
| Natalizumab | Other | Phase PHASE1 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01884935 |
| Placebo | Other | Phase PHASE2 | Acute Optic Neuritis | COMPLETED | NCT01721161 |
| BIIB033 (anti-LINGO-1 mAb) | Other | Phase PHASE2 | Acute Optic Neuritis | COMPLETED | NCT01721161 |
| Placebo | Other | Phase PHASE2 | Acute Optic Neuritis | COMPLETED | NCT01721161 |
| BIIB033 (anti-LINGO-1 mAb) | Other | Phase PHASE2 | Acute Optic Neuritis | COMPLETED | NCT01721161 |
| Placebo | Other | Phase PHASE2 | Acute Optic Neuritis | COMPLETED | NCT01721161 |
| BIIB033 (anti-LINGO-1 mAb) | Other | Phase PHASE2 | Acute Optic Neuritis | COMPLETED | NCT01721161 |
| Placebo | Other | Phase PHASE2 | Acute Ischemic Stroke | COMPLETED | NCT01955707 |
| natalizumab | Other | Phase PHASE2 | Acute Ischemic Stroke | COMPLETED | NCT01955707 |
| Placebo | Other | Phase PHASE2 | Acute Ischemic Stroke | COMPLETED | NCT01955707 |
| natalizumab | Other | Phase PHASE2 | Acute Ischemic Stroke | COMPLETED | NCT01955707 |
| Placebo | Other | Phase PHASE2 | Acute Ischemic Stroke | COMPLETED | NCT01955707 |
| natalizumab | Other | Phase PHASE2 | Acute Ischemic Stroke | COMPLETED | NCT01955707 |
| Vitamin E δ-Tocotrienol | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT01450046 |
| Vitamin E δ-Tocotrienol | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT01450046 |
| Daclizumab High Yield Process Placebo | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01064401 |
| Interferon beta-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01064401 |
| Interferon beta-1a Placebo | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01064401 |
| BIIB019 (Daclizumab High Yield Process) | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01064401 |
| Daclizumab High Yield Process Placebo | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01064401 |
| Interferon beta-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01064401 |
| Interferon beta-1a Placebo | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01064401 |
| BIIB019 (Daclizumab High Yield Process) | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01064401 |
| Placebo | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00390221 |
| BIIB019 (Daclizumab High Yield Process) | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00390221 |
| Placebo | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00390221 |
| BIIB019 (Daclizumab High Yield Process) | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00390221 |
| Natalizumab | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | TERMINATED | NCT00297232 |
| Natalizumab | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | TERMINATED | NCT00297232 |
| placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00083759 |
| natalizumab | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00083759 |
| placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00083759 |
| natalizumab | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00083759 |
| Dimethyl Fumarate | Other | Phase PHASE4 | Multiple Sclerosis | WITHDRAWN | NCT02675413 |
| Dimethyl Fumarate | Other | Phase PHASE4 | Multiple Sclerosis | WITHDRAWN | NCT02675413 |
| dimethyl fumarate | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT02519413 |
| dimethyl fumarate | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT02519413 |
| Placebo | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00870740 |
| BIIB019 (Daclizumab High Yield Process) | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00870740 |
| Placebo | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00870740 |
| BIIB019 (Daclizumab High Yield Process) | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00870740 |
| Skin Biopsy | Other | Preclinical | Atopic Dermatitis | COMPLETED | NCT02125695 |
| Blood Sampling | Other | Preclinical | Atopic Dermatitis | COMPLETED | NCT02125695 |
| Skin Taping | Other | Preclinical | Atopic Dermatitis | COMPLETED | NCT02125695 |
| Skin Biopsy | Other | Preclinical | Atopic Dermatitis | COMPLETED | NCT02125695 |
| Blood Sampling | Other | Preclinical | Atopic Dermatitis | COMPLETED | NCT02125695 |
| Skin Taping | Other | Preclinical | Atopic Dermatitis | COMPLETED | NCT02125695 |
| natalizumab | Other | Preclinical | Relapsing Multiple Sclerosis | COMPLETED | NCT01070836 |
| Placebo | Other | Phase PHASE1 | Central Nervous System (CNS) Demyelinating Disease | COMPLETED | NCT02641041 |
| BIIB033 | Other | Phase PHASE1 | Central Nervous System (CNS) Demyelinating Disease | COMPLETED | NCT02641041 |
| Placebo | Other | Phase PHASE1 | Central Nervous System (CNS) Demyelinating Disease | COMPLETED | NCT02641041 |
| BIIB033 | Other | Phase PHASE1 | Central Nervous System (CNS) Demyelinating Disease | COMPLETED | NCT02641041 |
| Fampridine | Other | Preclinical | Multiple Sclerosis | TERMINATED | NCT01532154 |
| Placebo | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00468546 |
| Methotrexate | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00468546 |
| MabThera/Rituxan | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00468546 |
| Placebo | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00468546 |
| Methotrexate | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00468546 |
| MabThera/Rituxan | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00468546 |
| Placebo | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00468546 |
| Methotrexate | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00468546 |
| MabThera/Rituxan | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00468546 |
| rituximab [MabThera/Rituxan] | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT02097745 |
| methotrexate | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT02097745 |
| Dimethyl fumarate | Other | Preclinical | Multiple Sclerosis | UNKNOWN | NCT02736279 |
| BIIB033 (opicinumab) | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT02833142 |
| BIIB033 (opicinumab) | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT02833142 |
| ASA-Placebo | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02090413 |
| acetylsalicylic acid | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02090413 |
| dimethyl fumarate | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02090413 |
| ASA-Placebo | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02090413 |
| acetylsalicylic acid | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02090413 |
| dimethyl fumarate | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02090413 |
| BIIB021 | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT00618735 |
| BIIB021 | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT00618735 |
| BIIB021 | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT00618735 |
| Placebo | Other | Phase PHASE1 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01244139 |
| BIIB033 | Other | Phase PHASE1 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01244139 |
| Placebo | Other | Phase PHASE1 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01244139 |
| BIIB033 | Other | Phase PHASE1 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01244139 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01052506 |
| BIIB033 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01052506 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01052506 |
| BIIB033 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01052506 |
| BIIB028 | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT00725933 |
| BIIB028 | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT00725933 |
| BIIB022 | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT00555724 |
| BIIB022 | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT00555724 |
| BIIB022 | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT00555724 |
| Placebo | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00027300 |
| Natalizumab | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00027300 |
| Placebo | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00027300 |
| Natalizumab | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00027300 |
| Placebo | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00027300 |
| Natalizumab | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00027300 |
| aducanumab | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT02782975 |
| oral corticosteroids | Other | Phase PHASE2 | Lupus Nephritis | TERMINATED | NCT01499355 |
| mycophenolate mofetil | Other | Phase PHASE2 | Lupus Nephritis | TERMINATED | NCT01499355 |
| Placebo | Other | Phase PHASE2 | Lupus Nephritis | TERMINATED | NCT01499355 |
| BIIB023 | Other | Phase PHASE2 | Lupus Nephritis | TERMINATED | NCT01499355 |
| oral corticosteroids | Other | Phase PHASE2 | Lupus Nephritis | TERMINATED | NCT01499355 |
| mycophenolate mofetil | Other | Phase PHASE2 | Lupus Nephritis | TERMINATED | NCT01499355 |
| Placebo | Other | Phase PHASE2 | Lupus Nephritis | TERMINATED | NCT01499355 |
| BIIB023 | Other | Phase PHASE2 | Lupus Nephritis | TERMINATED | NCT01499355 |
| naproxen | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | COMPLETED | NCT01939002 |
| BIIB017 | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | COMPLETED | NCT01939002 |
| naproxen | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | COMPLETED | NCT01939002 |
| BIIB017 | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | COMPLETED | NCT01939002 |
| tetanus diphtheria toxoid vaccine (Td) | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00536120 |
| keyhole limpet hemocyanin (KLH) | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00536120 |
| BG00002 (natalizumab) | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00536120 |
| tetanus diphtheria toxoid vaccine (Td) | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00536120 |
| keyhole limpet hemocyanin (KLH) | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00536120 |
| BG00002 (natalizumab) | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00536120 |
| tetanus diphtheria toxoid vaccine (Td) | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00536120 |
| keyhole limpet hemocyanin (KLH) | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00536120 |
| BG00002 (natalizumab) | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00536120 |
| BIIB074 Treatment D | Drug | Phase PHASE1 | Trigeminal Neuralgia (TN) | COMPLETED | NCT02951221 |
| BIIB074 Treatment C | Drug | Phase PHASE1 | Trigeminal Neuralgia (TN) | COMPLETED | NCT02951221 |
| BIIB074 Treatment B | Drug | Phase PHASE1 | Trigeminal Neuralgia (TN) | COMPLETED | NCT02951221 |
| BIIB074 Treatment A | Drug | Phase PHASE1 | Trigeminal Neuralgia (TN) | COMPLETED | NCT02951221 |
| BIIB074 Treatment D | Drug | Phase PHASE1 | Trigeminal Neuralgia (TN) | COMPLETED | NCT02951221 |
| BIIB074 Treatment C | Drug | Phase PHASE1 | Trigeminal Neuralgia (TN) | COMPLETED | NCT02951221 |
| BIIB074 Treatment B | Drug | Phase PHASE1 | Trigeminal Neuralgia (TN) | COMPLETED | NCT02951221 |
| BIIB074 Treatment A | Drug | Phase PHASE1 | Trigeminal Neuralgia (TN) | COMPLETED | NCT02951221 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02831517 |
| BIIB074 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02831517 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02831517 |
| BIIB074 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02831517 |
| BIIB019 (Daclizumab) | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01462318 |
| Dextromethorphan | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01462318 |
| Omeprazole | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01462318 |
| Vitamin K | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01462318 |
| S-warfarin | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01462318 |
| Caffeine | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01462318 |
| Midazolam | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01462318 |
| BIIB019 (Daclizumab) | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01462318 |
| Dextromethorphan | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01462318 |
| Omeprazole | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01462318 |
| Vitamin K | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01462318 |
| S-warfarin | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01462318 |
| Caffeine | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01462318 |
| Midazolam | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01462318 |
| Placebo | Other | Phase PHASE1 | Systemic Lupos Erythematosus, SLE | COMPLETED | NCT02829541 |
| BIIB068 | Other | Phase PHASE1 | Systemic Lupos Erythematosus, SLE | COMPLETED | NCT02829541 |
| Placebo | Other | Phase PHASE1 | Systemic Lupos Erythematosus, SLE | COMPLETED | NCT02829541 |
| BIIB068 | Other | Phase PHASE1 | Systemic Lupos Erythematosus, SLE | COMPLETED | NCT02829541 |
| Placebo | Other | Phase PHASE1 | Systemic Lupos Erythematosus, SLE | COMPLETED | NCT02829541 |
| BIIB068 | Other | Phase PHASE1 | Systemic Lupos Erythematosus, SLE | COMPLETED | NCT02829541 |
| BG00012 (DMF) | Other | Phase PHASE4 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT01873417 |
| BG00012 (DMF) | Other | Phase PHASE4 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT01873417 |
| Fampridine | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT01480076 |
| Fampridine | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT01480076 |
| dimethyl fumarate | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01156311 |
| dimethyl fumarate | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01156311 |
| BG00002 (natalizumab) | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis (RRMS) | COMPLETED | NCT00871780 |
| BG00002 (natalizumab) | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis (RRMS) | COMPLETED | NCT00871780 |
| BG00002 (natalizumab) | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00306592 |
| BG00002 (natalizumab) | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00306592 |
| BG00012 (DMF) (Tecfidera®.) | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT02683863 |
| BG00012 (DMF) (Tecfidera®.) | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT02683863 |
| Peanut Butter | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT02217982 |
| Loperamide | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT02217982 |
| Simethicone | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT02217982 |
| Placebo | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT02219932 |
| fampridine | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT02219932 |
| Placebo | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT02219932 |
| fampridine | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT02219932 |
| Purified chick-embryo cell rabies vaccine | Other | Approved | Rabies | COMPLETED | NCT03093545 |
| Equine Rabies Immunoglobulin | Other | Approved | Rabies | COMPLETED | NCT03093545 |
| Purified chick-embryo cell rabies vaccine | Other | Approved | Rabies | COMPLETED | NCT03093545 |
| Equine Rabies Immunoglobulin | Other | Approved | Rabies | COMPLETED | NCT03093545 |
| Placebo | Other | Phase PHASE1 | Healthy | TERMINATED | NCT02555085 |
| BIIB063 | Other | Phase PHASE1 | Healthy | TERMINATED | NCT02555085 |
| Placebo | Other | Phase PHASE1 | Healthy | TERMINATED | NCT02555085 |
| BIIB063 | Other | Phase PHASE1 | Healthy | TERMINATED | NCT02555085 |
| dimethyl fumarate | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02125604 |
| Placebo | Other | Phase PHASE3 | Multiple Sclerosis, Secondary Progressive | TERMINATED | NCT02430532 |
| dimethyl fumarate | Other | Phase PHASE3 | Multiple Sclerosis, Secondary Progressive | TERMINATED | NCT02430532 |
| Placebo | Other | Phase PHASE3 | Multiple Sclerosis, Secondary Progressive | TERMINATED | NCT02430532 |
| dimethyl fumarate | Other | Phase PHASE3 | Multiple Sclerosis, Secondary Progressive | TERMINATED | NCT02430532 |
| dimethyl fumarate | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT02579681 |
| dimethyl fumarate | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT02579681 |
| Avonex | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT01864148 |
| Placebo | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT01864148 |
| BIIB033 | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT01864148 |
| Avonex | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT01864148 |
| Placebo | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT01864148 |
| BIIB033 | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT01864148 |
| dimethyl fumarate | Other | Phase PHASE3 | Multiple Sclerosis | TERMINATED | NCT02428231 |
| dimethyl fumarate | Other | Phase PHASE3 | Multiple Sclerosis | TERMINATED | NCT02428231 |
| dimethyl fumarate | Other | Phase PHASE3 | Multiple Sclerosis | TERMINATED | NCT02428231 |
| non-pegylated interferon | Other | Phase PHASE2 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT02097849 |
| meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent) | Other | Phase PHASE2 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT02097849 |
| 23-valent pneumococcal polysaccharide vaccine | Other | Phase PHASE2 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT02097849 |
| tetanus diphtheria toxoids vaccine | Other | Phase PHASE2 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT02097849 |
| dimethyl fumarate | Other | Phase PHASE2 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT02097849 |
| non-pegylated interferon | Other | Phase PHASE2 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT02097849 |
| meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent) | Other | Phase PHASE2 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT02097849 |
| 23-valent pneumococcal polysaccharide vaccine | Other | Phase PHASE2 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT02097849 |
| tetanus diphtheria toxoids vaccine | Other | Phase PHASE2 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT02097849 |
| dimethyl fumarate | Other | Phase PHASE2 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT02097849 |
| natalizumab | Other | Phase PHASE4 | Relapsing Multiple Sclerosis | TERMINATED | NCT02241785 |
| natalizumab | Other | Phase PHASE4 | Relapsing Multiple Sclerosis | TERMINATED | NCT02241785 |
| fingolimod | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | TERMINATED | NCT02342704 |
| natalizumab | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | TERMINATED | NCT02342704 |
| fingolimod | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | TERMINATED | NCT02342704 |
| natalizumab | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | TERMINATED | NCT02342704 |
| dimethyl fumarate | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT02969304 |
| Cyclophosphamide | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | COMPLETED | NCT00090051 |
| Fludarabine Phosphate | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | COMPLETED | NCT00090051 |
| Rituximab | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | COMPLETED | NCT00090051 |
| Cyclophosphamide | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | COMPLETED | NCT00090051 |
| Fludarabine Phosphate | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | COMPLETED | NCT00090051 |
| Rituximab | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | COMPLETED | NCT00090051 |
| interferon beta 1a 30 ug IM once weekly | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00179478 |
| interferon beta 1a 30 ug IM once weekly | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00179478 |
| Placebo | Other | Phase PHASE3 | Secondary Progressive Multiple Sclerosis | TERMINATED | NCT01416181 |
| natalizumab | Other | Phase PHASE3 | Secondary Progressive Multiple Sclerosis | TERMINATED | NCT01416181 |
| Placebo | Other | Phase PHASE3 | Secondary Progressive Multiple Sclerosis | TERMINATED | NCT01416181 |
| natalizumab | Other | Phase PHASE3 | Secondary Progressive Multiple Sclerosis | TERMINATED | NCT01416181 |
| Placebo | Other | Phase PHASE3 | Secondary Progressive Multiple Sclerosis | TERMINATED | NCT01416181 |
| natalizumab | Other | Phase PHASE3 | Secondary Progressive Multiple Sclerosis | TERMINATED | NCT01416181 |
| Placebo | Other | Phase PHASE1 | Trigeminal Neuralgia | COMPLETED | NCT02359344 |
| CNV1014802 | Other | Phase PHASE1 | Trigeminal Neuralgia | COMPLETED | NCT02359344 |
| Placebo | Other | Phase PHASE1 | Trigeminal Neuralgia | COMPLETED | NCT02359344 |
| CNV1014802 | Other | Phase PHASE1 | Trigeminal Neuralgia | COMPLETED | NCT02359344 |
| Placebo | Other | Phase PHASE2 | Lumbosacral Radiculopathy | COMPLETED | NCT01561027 |
| CNV1014802 | Other | Phase PHASE2 | Lumbosacral Radiculopathy | COMPLETED | NCT01561027 |
| Placebo | Other | Phase PHASE2 | Lumbosacral Radiculopathy | COMPLETED | NCT01561027 |
| CNV1014802 | Other | Phase PHASE2 | Lumbosacral Radiculopathy | COMPLETED | NCT01561027 |
| CNV1014802 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02551497 |
| CNV1014802 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02551497 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT00955396 |
| GSK1014802 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT00955396 |
| dimethyl fumarate | Other | Phase PHASE2 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT02410200 |
| dimethyl fumarate | Other | Phase PHASE2 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT02410200 |
| Tysabri | Other | Approved | Multiple Sclerosis | COMPLETED | NCT01071512 |
| Placebo | Other | Phase PHASE1 | Pain, Neuropathic | TERMINATED | NCT00964288 |
| GSK1014802 high dose | Other | Phase PHASE1 | Pain, Neuropathic | TERMINATED | NCT00964288 |
| Lidocaine | Other | Phase PHASE1 | Pain, Neuropathic | TERMINATED | NCT00964288 |
| GSK1014802 low dose | Other | Phase PHASE1 | Pain, Neuropathic | TERMINATED | NCT00964288 |
| Placebo | Other | Phase PHASE1 | Pain, Neuropathic | TERMINATED | NCT00964288 |
| GSK1014802 high dose | Other | Phase PHASE1 | Pain, Neuropathic | TERMINATED | NCT00964288 |
| Lidocaine | Other | Phase PHASE1 | Pain, Neuropathic | TERMINATED | NCT00964288 |
| GSK1014802 low dose | Other | Phase PHASE1 | Pain, Neuropathic | TERMINATED | NCT00964288 |
| Lamictal | Other | Phase PHASE1 | Bipolar Disorder | COMPLETED | NCT00488566 |
| Placebo | Other | Phase PHASE1 | Bipolar Disorder | COMPLETED | NCT00488566 |
| GSK drug | Drug | Phase PHASE1 | Bipolar Disorder | COMPLETED | NCT00488566 |
| GSK1014802 | Other | Phase PHASE1 | Bipolar Depression | COMPLETED | NCT00908154 |
| Placebo | Other | Phase PHASE1 | Bipolar Depression | COMPLETED | NCT00908154 |
| BMS-986168 Placebo | Other | Phase PHASE1 | Tauopathies | COMPLETED | NCT02294851 |
| BMS-986168 | Other | Phase PHASE1 | Tauopathies | COMPLETED | NCT02294851 |
| Avonex | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01119677 |
| Avonex | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01119677 |
| Avonex | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01119677 |
| Biopsy | Other | Preclinical | Healthy | COMPLETED | NCT02422407 |
| Biopsy | Other | Preclinical | Healthy | COMPLETED | NCT02422407 |
| CT-guidance | Other | Approved | Healthy | COMPLETED | NCT03218111 |
| MR Imaging | Other | Approved | Healthy | COMPLETED | NCT03218111 |
| CT-guidance | Other | Approved | Healthy | COMPLETED | NCT03218111 |
| MR Imaging | Other | Approved | Healthy | COMPLETED | NCT03218111 |
| BG00012 | Other | Phase PHASE1 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT00837785 |
| BG00012 | Other | Phase PHASE1 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT00837785 |
| BG00012 | Other | Phase PHASE1 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT00837785 |
| dimethyl fumarate | Other | Phase PHASE4 | Multiple Sclerosis | UNKNOWN | NCT03092544 |
| dimethyl fumarate | Other | Phase PHASE4 | Multiple Sclerosis | UNKNOWN | NCT03092544 |
| Placebo Cream | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT03091569 |
| Vitamin K Cream | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT03091569 |
| Placebo Cream | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT03091569 |
| Vitamin K Cream | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT03091569 |
| methotrexate | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00037102 |
| interferon beta 1a | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00037102 |
| Valproic Acid | Other | Phase PHASE1 | Drug Interaction | COMPLETED | NCT03385525 |
| BIIB074 | Other | Phase PHASE1 | Drug Interaction | COMPLETED | NCT03385525 |
| Valproic Acid | Other | Phase PHASE1 | Drug Interaction | COMPLETED | NCT03385525 |
| BIIB074 | Other | Phase PHASE1 | Drug Interaction | COMPLETED | NCT03385525 |
| natalizumab | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01943526 |
| natalizumab | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01943526 |
| Placebo | Other | Phase PHASE2 | Lumbosacral Radiculopathy | COMPLETED | NCT02935608 |
| BIIB074 | Other | Phase PHASE2 | Lumbosacral Radiculopathy | COMPLETED | NCT02935608 |
| Placebo | Other | Phase PHASE2 | Lumbosacral Radiculopathy | COMPLETED | NCT02935608 |
| BIIB074 | Other | Phase PHASE2 | Lumbosacral Radiculopathy | COMPLETED | NCT02935608 |
| Placebo | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT02143167 |
| SR-fampridine | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT02143167 |
| Placebo | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT02143167 |
| SR-fampridine | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT02143167 |
| Fampridine-SR | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT01656148 |
| Fampridine-SR | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT01656148 |
| Dimethyl fumarate | Other | Preclinical | Multiple Sclerosis | TERMINATED | NCT02644083 |
| Placebo | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT03224793 |
| BIIB059 | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT03224793 |
| natalizumab | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT02386566 |
| natalizumab | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT02386566 |
| natalizumab | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT02386566 |
| OC (ethinyl estradiol and levonorgestrel) | Other | Phase PHASE1 | Drug Interactions | COMPLETED | NCT03324685 |
| BIIB074 | Other | Phase PHASE1 | Drug Interactions | COMPLETED | NCT03324685 |
| OC (ethinyl estradiol and levonorgestrel) | Other | Phase PHASE1 | Drug Interactions | COMPLETED | NCT03324685 |
| BIIB074 | Other | Phase PHASE1 | Drug Interactions | COMPLETED | NCT03324685 |
| Dimethyl fumarate | Other | Phase PHASE4 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT02461069 |
| Benepali | Other | Preclinical | Rheumatoid Arthritis | COMPLETED | NCT03327454 |
| Benepali | Other | Preclinical | Rheumatoid Arthritis | COMPLETED | NCT03327454 |
| Benepali | Other | Preclinical | Rheumatoid Arthritis | COMPLETED | NCT03327454 |
| Natalizumab | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00884481 |
| Natalizumab | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00884481 |
| trivalent seasonal influenza vaccine | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01051349 |
| BIIB019 (Daclizumab) | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01051349 |
| trivalent seasonal influenza vaccine | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01051349 |
| BIIB019 (Daclizumab) | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01051349 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01838668 |
| Placebo | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01838668 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01838668 |
| Placebo | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01838668 |
| natalizumab | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02677077 |
| natalizumab | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02677077 |
| Higher Dose of Rituximab | Other | Phase PHASE2 | Immune Thrombocytopenic Purpura | COMPLETED | NCT00774202 |
| Rituxan, Cyclophosphamide, Vincristine, Prednisone | Other | Phase PHASE2 | Immune Thrombocytopenic Purpura | COMPLETED | NCT00774202 |
| Higher Dose of Rituximab | Other | Phase PHASE2 | Immune Thrombocytopenic Purpura | COMPLETED | NCT00774202 |
| Rituxan, Cyclophosphamide, Vincristine, Prednisone | Other | Phase PHASE2 | Immune Thrombocytopenic Purpura | COMPLETED | NCT00774202 |
| Placebo | Other | Phase PHASE2 | Trigeminal Neuralgia | COMPLETED | NCT01540630 |
| CNV1014802 | Other | Phase PHASE2 | Trigeminal Neuralgia | COMPLETED | NCT01540630 |
| Placebo | Other | Phase PHASE2 | Trigeminal Neuralgia | COMPLETED | NCT01540630 |
| CNV1014802 | Other | Phase PHASE2 | Trigeminal Neuralgia | COMPLETED | NCT01540630 |
| Placebo | Other | Phase PHASE2 | Primary Sjögren's Syndrome | TERMINATED | NCT01552681 |
| Baminercept | Other | Phase PHASE2 | Primary Sjögren's Syndrome | TERMINATED | NCT01552681 |
| Placebo | Other | Phase PHASE2 | Primary Sjögren's Syndrome | TERMINATED | NCT01552681 |
| Baminercept | Other | Phase PHASE2 | Primary Sjögren's Syndrome | TERMINATED | NCT01552681 |
| natalizumab | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01485003 |
| BIIB074 | Other | Phase PHASE2 | Neuropathic Pain From Lumbosacral Radiculopathy | TERMINATED | NCT02957617 |
| BIIB074 | Other | Phase PHASE2 | Neuropathic Pain From Lumbosacral Radiculopathy | TERMINATED | NCT02957617 |
| Placebo | Other | Phase PHASE4 | Allergic Rhinitis | COMPLETED | NCT02543346 |
| Cetirizine | Other | Phase PHASE4 | Allergic Rhinitis | COMPLETED | NCT02543346 |
| Placebo | Other | Phase PHASE4 | Allergic Rhinitis | COMPLETED | NCT02543346 |
| Cetirizine | Other | Phase PHASE4 | Allergic Rhinitis | COMPLETED | NCT02543346 |
| Outpatient Muscle Biopsy | Other | Preclinical | Sarcopenia | COMPLETED | NCT02839460 |
| Outpatient Muscle Biopsy | Other | Preclinical | Sarcopenia | COMPLETED | NCT02839460 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT03454126 |
| BIIB095 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT03454126 |
| dimethyl fumarate | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT02525874 |
| dimethyl fumarate | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT02525874 |
| Placebo | Other | Phase PHASE1 | Parkinson's Disease | COMPLETED | NCT02459886 |
| BIIB054 | Other | Phase PHASE1 | Parkinson's Disease | COMPLETED | NCT02459886 |
| Bodyweight training | Other | Approved | Multiple Sclerosis | UNKNOWN | NCT04002492 |
| Bodyweight training | Other | Approved | Multiple Sclerosis | UNKNOWN | NCT04002492 |
| Tylenol Pill | Other | Phase PHASE4 | Multiple Sclerosis | UNKNOWN | NCT03424733 |
| Prednisone | Other | Phase PHASE4 | Multiple Sclerosis | UNKNOWN | NCT03424733 |
| Plegridy | Other | Phase PHASE4 | Multiple Sclerosis | UNKNOWN | NCT03424733 |
| Tylenol Pill | Other | Phase PHASE4 | Multiple Sclerosis | UNKNOWN | NCT03424733 |
| Prednisone | Other | Phase PHASE4 | Multiple Sclerosis | UNKNOWN | NCT03424733 |
| Plegridy | Other | Phase PHASE4 | Multiple Sclerosis | UNKNOWN | NCT03424733 |
| BIIB033 100mg/Kg | Other | Phase PHASE2 | Acute Optic Neuritis | COMPLETED | NCT02657915 |
| Placebo | Other | Phase PHASE2 | Acute Optic Neuritis | COMPLETED | NCT02657915 |
| SC interferon beta-1b | Other | Preclinical | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT03347370 |
| SC interferon beta-1a | Other | Preclinical | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT03347370 |
| SC Peginterferon beta-1a | Other | Preclinical | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT03347370 |
| SC interferon beta-1b | Other | Preclinical | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT03347370 |
| SC interferon beta-1a | Other | Preclinical | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT03347370 |
| SC Peginterferon beta-1a | Other | Preclinical | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT03347370 |
| Daclizumab | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis (RRMS) | TERMINATED | NCT02881567 |
| Daclizumab | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis (RRMS) | TERMINATED | NCT02881567 |
| Daclizumab | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis (RRMS) | TERMINATED | NCT02881567 |
| Ipilimumab | Other | Preclinical | Glioblastoma | NO_LONGER_AVAILABLE | NCT03460782 |
| Ipilimumab | Other | Preclinical | Glioblastoma | NO_LONGER_AVAILABLE | NCT03460782 |
| Ipilimumab | Other | Preclinical | Glioblastoma | NO_LONGER_AVAILABLE | NCT03460782 |
| Ipilimumab | Other | Preclinical | Glioblastoma | NO_LONGER_AVAILABLE | NCT03460782 |
| Placebo | Other | Phase PHASE1 | Hearing Loss, Sensorineural | COMPLETED | NCT01518920 |
| PF-04958242 | Other | Phase PHASE1 | Hearing Loss, Sensorineural | COMPLETED | NCT01518920 |
| Placebo | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01518894 |
| PF-04958242 | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01518894 |
| Placebo | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01518894 |
| PF-04958242 | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01518894 |
| Placebo | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01511510 |
| PF-04958242 | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01511510 |
| Placebo | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01511510 |
| PF-04958242 | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01511510 |
| dimethyl fumarate | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT02555215 |
| Placebo | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT02201849 |
| Active Control | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT02201849 |
| Study Drug | Drug | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT02201849 |
| BIIB019 (Daclizumab) | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | TERMINATED | NCT01797965 |
| BIIB019 (Daclizumab) | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | TERMINATED | NCT01797965 |
| BIIB019 (Daclizumab) | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | TERMINATED | NCT01797965 |
| PF-04958242 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT01365338 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT01365338 |
| PF-04958242 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT01365338 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT01365338 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT01238679 |
| PF-04958242 | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT01238679 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT01238679 |
| PF-04958242 | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT01238679 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT01159483 |
| PF-04958242 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT01159483 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT01159483 |
| PF-04958242 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT01159483 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02228395 |
| PF-04958242 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02228395 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02228395 |
| PF-04958242 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02228395 |
| Itraconazole | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02341482 |
| PF-04958242 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02341482 |
| Itraconazole | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02341482 |
| PF-04958242 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02341482 |
| Placebo | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis (IPF) | COMPLETED | NCT01371305 |
| BG00011 | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis (IPF) | COMPLETED | NCT01371305 |
| Placebo | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis (IPF) | COMPLETED | NCT01371305 |
| BG00011 | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis (IPF) | COMPLETED | NCT01371305 |
| SCH 721015 | Other | Phase PHASE1 | Pleural Mesothelioma | COMPLETED | NCT00299962 |
| Adenoviral-mediated Interferon-beta | Other | Phase PHASE1 | Pleural Mesothelioma | COMPLETED | NCT00299962 |
| dimethyl fumarate | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01930708 |
| dimethyl fumarate | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01930708 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT03056729 |
| BIIB076 | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT03056729 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT03056729 |
| BIIB076 | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT03056729 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT03056729 |
| BIIB076 | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT03056729 |
| Methylprednisolone | Other | Phase PHASE2 | Graft Versus Host Disease | COMPLETED | NCT02176031 |
| Natalizumab | Other | Phase PHASE2 | Graft Versus Host Disease | COMPLETED | NCT02176031 |
| Methylprednisolone | Other | Phase PHASE2 | Graft Versus Host Disease | COMPLETED | NCT02176031 |
| Natalizumab | Other | Phase PHASE2 | Graft Versus Host Disease | COMPLETED | NCT02176031 |
| BIIB092 | Other | Phase PHASE1 | Supranuclear Palsy, Progressive | TERMINATED | NCT02658916 |
| BIIB092 | Other | Phase PHASE1 | Supranuclear Palsy, Progressive | TERMINATED | NCT02658916 |
| Assessments | Other | Preclinical | Frontotemporal Dementia | COMPLETED | NCT03088956 |
| Assessments | Other | Preclinical | Frontotemporal Dementia | COMPLETED | NCT03088956 |
| Assessments | Other | Preclinical | Frontotemporal Dementia | COMPLETED | NCT03088956 |
| Dimethyl Fumarate | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT03093324 |
| ALKS 8700 | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT03093324 |
| Dimethyl Fumarate | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT03093324 |
| ALKS 8700 | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT03093324 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | TERMINATED | NCT01677572 |
| Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb) | Other | Phase PHASE1 | Alzheimer's Disease | TERMINATED | NCT01677572 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | TERMINATED | NCT01677572 |
| Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb) | Other | Phase PHASE1 | Alzheimer's Disease | TERMINATED | NCT01677572 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT02434718 |
| Aducanumab | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT02434718 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT02434718 |
| Aducanumab | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT02434718 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT02434718 |
| Aducanumab | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT02434718 |
| Interferon-beta | Other | Phase PHASE1 | Glioblastoma Multiforme | COMPLETED | NCT00031083 |
| Interferon-beta | Other | Phase PHASE1 | Glioblastoma Multiforme | COMPLETED | NCT00031083 |
| interferon beta-1b | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT03177083 |
| interferon beta-1a | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT03177083 |
| peginterferon beta-1a | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT03177083 |
| interferon beta-1b | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT03177083 |
| interferon beta-1a | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT03177083 |
| peginterferon beta-1a | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT03177083 |
| Placebo | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | TERMINATED | NCT03573505 |
| BG00011 | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | TERMINATED | NCT03573505 |
| Placebo | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | TERMINATED | NCT03573505 |
| BG00011 | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | TERMINATED | NCT03573505 |
| Placebo | Other | Phase PHASE2 | Supranuclear Palsy, Progressive | TERMINATED | NCT03068468 |
| BIIB092 | Other | Phase PHASE2 | Supranuclear Palsy, Progressive | TERMINATED | NCT03068468 |
| Placebo | Other | Phase PHASE2 | Supranuclear Palsy, Progressive | TERMINATED | NCT03068468 |
| BIIB092 | Other | Phase PHASE2 | Supranuclear Palsy, Progressive | TERMINATED | NCT03068468 |
| Placebo | Other | Phase PHASE2 | Primary Progressive Multiple Sclerosis | COMPLETED | NCT02959658 |
| Dimethyl fumarate | Other | Phase PHASE2 | Primary Progressive Multiple Sclerosis | COMPLETED | NCT02959658 |
| Placebo | Other | Phase PHASE2 | Primary Progressive Multiple Sclerosis | COMPLETED | NCT02959658 |
| Dimethyl fumarate | Other | Phase PHASE2 | Primary Progressive Multiple Sclerosis | COMPLETED | NCT02959658 |
| Avonex® monotherapy (6.0 MIU administered i.m. each week) | Drug | Preclinical | Multiple Sclerosis | COMPLETED | NCT00463710 |
| Placebo | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00835770 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00835770 |
| Placebo | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00835770 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00835770 |
| Enbrel | Other | Preclinical | Rheumatoid Arthritis | COMPLETED | NCT03100734 |
| Benepali | Other | Preclinical | Rheumatoid Arthritis | COMPLETED | NCT03100734 |
| Enbrel | Other | Preclinical | Rheumatoid Arthritis | COMPLETED | NCT03100734 |
| Benepali | Other | Preclinical | Rheumatoid Arthritis | COMPLETED | NCT03100734 |
| nusinersen | Other | Phase PHASE1 | Spinal Muscular Atrophy | COMPLETED | NCT02052791 |
| nusinersen | Other | Phase PHASE1 | Spinal Muscular Atrophy | COMPLETED | NCT02052791 |
| nusinersen | Other | Phase PHASE1 | Spinal Muscular Atrophy | COMPLETED | NCT02052791 |
| nusinersen | Other | Phase PHASE1 | Spinal Muscular Atrophy | COMPLETED | NCT01780246 |
| nusinersen | Other | Phase PHASE1 | Spinal Muscular Atrophy | COMPLETED | NCT01780246 |
| Melatonin | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT02691702 |
| BIIB118 | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT02691702 |
| Melatonin | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT02691702 |
| BIIB118 | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT02691702 |
| Sham Procedure | Procedure | Phase PHASE2 | Spinal Muscular Atrophy | TERMINATED | NCT02462759 |
| Nusinersen | Other | Phase PHASE2 | Spinal Muscular Atrophy | TERMINATED | NCT02462759 |
| Sham Procedure | Procedure | Phase PHASE2 | Spinal Muscular Atrophy | TERMINATED | NCT02462759 |
| Nusinersen | Other | Phase PHASE2 | Spinal Muscular Atrophy | TERMINATED | NCT02462759 |
| BIIB118 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02443740 |
| BIIB118 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02443740 |
| Sham procedure | Procedure | Phase PHASE3 | Spinal Muscular Atrophy | COMPLETED | NCT02292537 |
| Nusinersen | Other | Phase PHASE3 | Spinal Muscular Atrophy | COMPLETED | NCT02292537 |
| Sham procedure | Procedure | Phase PHASE3 | Spinal Muscular Atrophy | COMPLETED | NCT02292537 |
| Nusinersen | Other | Phase PHASE3 | Spinal Muscular Atrophy | COMPLETED | NCT02292537 |
| Sham procedure | Procedure | Phase PHASE3 | Spinal Muscular Atrophy | TERMINATED | NCT02193074 |
| nusinersen | Other | Phase PHASE3 | Spinal Muscular Atrophy | TERMINATED | NCT02193074 |
| Sham procedure | Procedure | Phase PHASE3 | Spinal Muscular Atrophy | TERMINATED | NCT02193074 |
| nusinersen | Other | Phase PHASE3 | Spinal Muscular Atrophy | TERMINATED | NCT02193074 |
| nusinersen | Other | Phase PHASE2 | Spinal Muscular Atrophy | COMPLETED | NCT01839656 |
| nusinersen | Other | Phase PHASE2 | Spinal Muscular Atrophy | COMPLETED | NCT01839656 |
| nusinersen | Other | Phase PHASE1 | Spinal Muscular Atrophy | COMPLETED | NCT01494701 |
| nusinersen | Other | Phase PHASE1 | Spinal Muscular Atrophy | COMPLETED | NCT01494701 |
| test for SMN1 exon 7 deletion | Other | Preclinical | Spinal Muscular Atrophy | COMPLETED | NCT03554343 |
| test for SMN1 exon 7 deletion | Other | Preclinical | Spinal Muscular Atrophy | COMPLETED | NCT03554343 |
| test for SMN1 exon 7 deletion | Other | Preclinical | Spinal Muscular Atrophy | COMPLETED | NCT03554343 |
| Lidocaine | Other | Phase PHASE1 | Healthy Volunteers | WITHDRAWN | NCT04106050 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | WITHDRAWN | NCT04106050 |
| BIIB074 | Other | Phase PHASE1 | Healthy Volunteers | WITHDRAWN | NCT04106050 |
| BIIB095 | Other | Phase PHASE1 | Healthy Volunteers | WITHDRAWN | NCT04106050 |
| Lidocaine | Other | Phase PHASE1 | Healthy Volunteers | WITHDRAWN | NCT04106050 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | WITHDRAWN | NCT04106050 |
| BIIB074 | Other | Phase PHASE1 | Healthy Volunteers | WITHDRAWN | NCT04106050 |
| BIIB095 | Other | Phase PHASE1 | Healthy Volunteers | WITHDRAWN | NCT04106050 |
| BIIB104 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04068532 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04068532 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT03943056 |
| BIIB091 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT03943056 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT03943056 |
| BIIB091 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT03943056 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04079101 |
| BIIB104 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04079101 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04079101 |
| BIIB104 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04079101 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04079101 |
| BIIB104 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04079101 |
| Natalizumab | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05925049 |
| SAGE-217 low dose | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03284931 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03284931 |
| SAGE-217 high dose | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03284931 |
| SAGE-217 low dose | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03284931 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03284931 |
| SAGE-217 high dose | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03284931 |
| Nusinersen Sodium Injection | Other | Preclinical | Muscular Atrophy, Spinal | COMPLETED | NCT04419233 |
| Nusinersen Sodium Injection | Other | Preclinical | Muscular Atrophy, Spinal | COMPLETED | NCT04419233 |
| Placebo | Other | Phase PHASE2 | Ischemic Stroke | WITHDRAWN | NCT05764122 |
| BIIB131 | Other | Phase PHASE2 | Ischemic Stroke | WITHDRAWN | NCT05764122 |
| Nusinersen | Other | Preclinical | Infantile-onset Spinal Muscular Atrophy | NO_LONGER_AVAILABLE | NCT02865109 |
| Nusinersen | Other | Preclinical | Infantile-onset Spinal Muscular Atrophy | NO_LONGER_AVAILABLE | NCT02865109 |
| Nusinersen | Other | Phase PHASE1 | Spinal Muscular Atrophy | COMPLETED | NCT01703988 |
| Nusinersen | Other | Phase PHASE1 | Spinal Muscular Atrophy | COMPLETED | NCT01703988 |
| Placebo | Other | Phase PHASE2 | Small Fiber Neuropathy | TERMINATED | NCT03339336 |
| BIIB074 | Other | Phase PHASE2 | Small Fiber Neuropathy | TERMINATED | NCT03339336 |
| Placebo | Other | Phase PHASE1 | Parkinson's Disease | TERMINATED | NCT03716570 |
| BIIB054 | Other | Phase PHASE1 | Parkinson's Disease | TERMINATED | NCT03716570 |
| Placebo | Other | Phase PHASE1 | Traumatic Brain Injury | COMPLETED | NCT01132703 |
| Glyburide for Injection | Other | Phase PHASE1 | Traumatic Brain Injury | COMPLETED | NCT01132703 |
| Placebo | Other | Phase PHASE1 | Traumatic Brain Injury | COMPLETED | NCT01132703 |
| Glyburide for Injection | Other | Phase PHASE1 | Traumatic Brain Injury | COMPLETED | NCT01132703 |
| Multiple Dose | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01424163 |
| Single dose standard | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01424163 |
| Single dose reduced | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01424163 |
| Multiple Dose | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01424163 |
| Single dose standard | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01424163 |
| Single dose reduced | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01424163 |
| Brain Imaging | Other | Approved | Stroke, Ischemic | COMPLETED | NCT03662750 |
| Brain Imaging | Other | Approved | Stroke, Ischemic | COMPLETED | NCT03662750 |
| Dosing Interruption of Natalizumab | Other | Phase PHASE4 | Multiple Sclerosis | UNKNOWN | NCT04048577 |
| Dosing Interruption of Natalizumab | Other | Phase PHASE4 | Multiple Sclerosis | UNKNOWN | NCT04048577 |
| [18F]Florbetapir PET imaging | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT01767493 |
| [18F]Florbetapir PET imaging | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT01767493 |
| Placebo | Other | Phase PHASE3 | Alzheimer's Disease | TERMINATED | NCT02484547 |
| Aducanumab (BIIB037) | Other | Phase PHASE3 | Alzheimer's Disease | TERMINATED | NCT02484547 |
| Placebo | Other | Phase PHASE3 | Alzheimer's Disease | TERMINATED | NCT02484547 |
| Aducanumab (BIIB037) | Other | Phase PHASE3 | Alzheimer's Disease | TERMINATED | NCT02484547 |
| Placebo | Other | Phase PHASE3 | Alzheimer's Disease | TERMINATED | NCT02477800 |
| Aducanumab (BIIB037) | Other | Phase PHASE3 | Alzheimer's Disease | TERMINATED | NCT02477800 |
| Placebo | Other | Phase PHASE3 | Alzheimer's Disease | TERMINATED | NCT02477800 |
| Aducanumab (BIIB037) | Other | Phase PHASE3 | Alzheimer's Disease | TERMINATED | NCT02477800 |
| injectable MS DMT | Other | Phase PHASE4 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT02471560 |
| dimethyl fumarate | Other | Phase PHASE4 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT02471560 |
| injectable MS DMT | Other | Phase PHASE4 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT02471560 |
| dimethyl fumarate | Other | Phase PHASE4 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT02471560 |
| No Intervention | Other | Preclinical | Choroideremia | COMPLETED | NCT04795206 |
| No Intervention | Other | Preclinical | Choroideremia | COMPLETED | NCT04795206 |
| No Intervention | Other | Preclinical | Choroideremia | COMPLETED | NCT04795206 |
| Placebo | Other | Phase PHASE2 | Cognitive Dysfunction | TERMINATED | NCT03639987 |
| Aducanumab | Other | Phase PHASE2 | Cognitive Dysfunction | TERMINATED | NCT03639987 |
| Placebo | Other | Phase PHASE2 | Cognitive Dysfunction | TERMINATED | NCT03639987 |
| Aducanumab | Other | Phase PHASE2 | Cognitive Dysfunction | TERMINATED | NCT03639987 |
| nusinersen | Other | Preclinical | Spinal Muscular Atrophy | COMPLETED | NCT04591678 |
| Placebo | Other | Approved | Sarcopenia | UNKNOWN | NCT04702087 |
| OLEP | Other | Approved | Sarcopenia | UNKNOWN | NCT04702087 |
| Placebo | Other | Approved | Sarcopenia | UNKNOWN | NCT04702087 |
| OLEP | Other | Approved | Sarcopenia | UNKNOWN | NCT04702087 |
| No Intervention | Other | Preclinical | Choroideremia | COMPLETED | NCT04750785 |
| No Intervention | Other | Preclinical | Choroideremia | COMPLETED | NCT04750785 |
| Placebo | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT02332798 |
| PF-04958242 | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT02332798 |
| CD4 Antigens | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00000721 |
| CD4 Antigens | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00000721 |
| CD4 Antigens | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00000721 |
| Axitinib | Other | Phase PHASE1 | Endometriosis | WITHDRAWN | NCT03481842 |
| BIBW2992 | Other | Phase PHASE1 | Endometriosis | WITHDRAWN | NCT03481842 |
| Linifanib | Other | Phase PHASE1 | Endometriosis | WITHDRAWN | NCT03481842 |
| Axitinib | Other | Phase PHASE1 | Endometriosis | WITHDRAWN | NCT03481842 |
| BIBW2992 | Other | Phase PHASE1 | Endometriosis | WITHDRAWN | NCT03481842 |
| Linifanib | Other | Phase PHASE1 | Endometriosis | WITHDRAWN | NCT03481842 |
| Placebo | Other | Phase PHASE2 | Epilepsy, Focal Seizures, Partial Seizures | COMPLETED | NCT03283371 |
| Natalizumab | Other | Phase PHASE2 | Epilepsy, Focal Seizures, Partial Seizures | COMPLETED | NCT03283371 |
| Placebo | Other | Phase PHASE2 | Epilepsy, Focal Seizures, Partial Seizures | COMPLETED | NCT03283371 |
| Natalizumab | Other | Phase PHASE2 | Epilepsy, Focal Seizures, Partial Seizures | COMPLETED | NCT03283371 |
| Placebo | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT03626012 |
| BIIB078 | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT03626012 |
| Placebo | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT03626012 |
| BIIB078 | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT03626012 |
| Blood Collection | Other | Phase EARLY_PHASE1 | Angelman Syndrome | COMPLETED | NCT04103333 |
| Lumbar Puncture | Other | Phase EARLY_PHASE1 | Angelman Syndrome | COMPLETED | NCT04103333 |
| Blood Collection | Other | Phase EARLY_PHASE1 | Angelman Syndrome | COMPLETED | NCT04103333 |
| Lumbar Puncture | Other | Phase EARLY_PHASE1 | Angelman Syndrome | COMPLETED | NCT04103333 |
| Blood Collection | Other | Phase EARLY_PHASE1 | Angelman Syndrome | COMPLETED | NCT04103333 |
| Lumbar Puncture | Other | Phase EARLY_PHASE1 | Angelman Syndrome | COMPLETED | NCT04103333 |
| BIIB054 | Other | Phase PHASE2 | Parkinson's Disease | TERMINATED | NCT03318523 |
| Placebo | Other | Phase PHASE2 | Parkinson's Disease | TERMINATED | NCT03318523 |
| BIIB054 | Other | Phase PHASE2 | Parkinson's Disease | TERMINATED | NCT03318523 |
| Placebo | Other | Phase PHASE2 | Parkinson's Disease | TERMINATED | NCT03318523 |
| Natalizumab Injection [Tysabri] | Other | Preclinical | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT04580381 |
| Natalizumab Injection [Tysabri] | Other | Preclinical | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT04580381 |
| Natalizumab Injection [Tysabri] | Other | Preclinical | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT04580381 |
| Placebo Oral Tablet | Other | Phase PHASE1 | Systemic Sclerosis | TERMINATED | NCT02981082 |
| Dimethyl Fumarate (DMF) | Other | Phase PHASE1 | Systemic Sclerosis | TERMINATED | NCT02981082 |
| Placebo Oral Tablet | Other | Phase PHASE1 | Systemic Sclerosis | TERMINATED | NCT02981082 |
| Dimethyl Fumarate (DMF) | Other | Phase PHASE1 | Systemic Sclerosis | TERMINATED | NCT02981082 |
| [11C]-PBR28 | Other | Phase PHASE1 | ALS | TERMINATED | NCT04490096 |
| Placebo | Other | Phase PHASE2 | Multiple Sclerosis | TERMINATED | NCT03222973 |
| BIIB033 (opicinumab) | Other | Phase PHASE2 | Multiple Sclerosis | TERMINATED | NCT03222973 |
| Placebo | Other | Phase PHASE2 | Multiple Sclerosis | TERMINATED | NCT03222973 |
| BIIB033 (opicinumab) | Other | Phase PHASE2 | Multiple Sclerosis | TERMINATED | NCT03222973 |
| Dexpramipexole | Other | Phase PHASE3 | Amyotrophic Lateral Sclerosis | TERMINATED | NCT01622088 |
| Dexpramipexole | Other | Phase PHASE3 | Amyotrophic Lateral Sclerosis | TERMINATED | NCT01622088 |
| Placebo | Other | Phase PHASE4 | Multiple Sclerosis (MS) | COMPLETED | NCT02739542 |
| Tecfidera | Other | Phase PHASE4 | Multiple Sclerosis (MS) | COMPLETED | NCT02739542 |
| Peginterferon beta-1a | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT01911767 |
| Dimethyl fumarate | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT01911767 |
| Diroximel fumarate | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05127564 |
| Diroximel fumarate | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05127564 |
| Diroximel fumarate | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05127564 |
| Clinical assessment | Other | Preclinical | Relapsing Remitting Multiple Sclerosis | UNKNOWN | NCT05446285 |
| ALKS 8700 | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT02634307 |
| Rituximab | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00493467 |
| Ibritumomab Tiuxetan (Zevalin) | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00493467 |
| peginterferon beta-1a | Other | Preclinical | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT02230969 |
| peginterferon beta-1a | Other | Preclinical | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT02230969 |
| Adalimumab | Other | Preclinical | Arthritis, Rheumatoid | COMPLETED | NCT03662919 |
| Infliximab | Other | Preclinical | Arthritis, Rheumatoid | COMPLETED | NCT03662919 |
| steroids | Other | Phase PHASE2 | Acute Graft Versus Host Disease | COMPLETED | NCT02133924 |
| natalizumab | Other | Phase PHASE2 | Acute Graft Versus Host Disease | COMPLETED | NCT02133924 |
| Placebo | Other | Phase PHASE2 | Alzheimer's Disease | TERMINATED | NCT03352557 |
| BIIB092 | Other | Phase PHASE2 | Alzheimer's Disease | TERMINATED | NCT03352557 |
| Placebo | Other | Phase PHASE2 | Alzheimer's Disease | TERMINATED | NCT03352557 |
| BIIB092 | Other | Phase PHASE2 | Alzheimer's Disease | TERMINATED | NCT03352557 |
| Interferon beta 1a, oral doxycycline | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00246324 |
| Interferon beta 1a, oral doxycycline | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00246324 |
| Multiple Sclerosis Performance Test (MSPT) | Other | Preclinical | Multiple Sclerosis | TERMINATED | NCT03926637 |
| Multiple Sclerosis Performance Test (MSPT) | Other | Preclinical | Multiple Sclerosis | TERMINATED | NCT03926637 |
| Multiple Sclerosis Performance Test (MSPT) | Other | Preclinical | Multiple Sclerosis | TERMINATED | NCT03926637 |
| Placebo | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT02106897 |
| BIIB059 (litifilimab) | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT02106897 |
| Placebo | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT02106897 |
| BIIB059 (litifilimab) | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT02106897 |
| Other: Assessments | Other | Preclinical | X-Linked Retinitis Pigmentosa | COMPLETED | NCT04926129 |
| Other: Assessments | Other | Preclinical | X-Linked Retinitis Pigmentosa | COMPLETED | NCT04926129 |
| MSPT | Other | Preclinical | Multiple Sclerosis | TERMINATED | NCT04599023 |
| MSPT | Other | Preclinical | Multiple Sclerosis | TERMINATED | NCT04599023 |
| Oral capsules Talazoparib | Other | Phase PHASE1 | Advanced or Recurrent Solid Tumors | WITHDRAWN | NCT03426254 |
| Injections Subcutaneously Talazoparib | Other | Phase PHASE1 | Advanced or Recurrent Solid Tumors | WITHDRAWN | NCT03426254 |
| Oral capsules Talazoparib | Other | Phase PHASE1 | Advanced or Recurrent Solid Tumors | WITHDRAWN | NCT03426254 |
| Injections Subcutaneously Talazoparib | Other | Phase PHASE1 | Advanced or Recurrent Solid Tumors | WITHDRAWN | NCT03426254 |
| BIIB122 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05229562 |
| Aducanumab | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05216887 |
| Aducanumab | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05216887 |
| BIIB104 Test Formulation | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05152485 |
| BIIB104 Reference Formulation | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05152485 |
| BIIB104 Test Formulation | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05152485 |
| BIIB104 Reference Formulation | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05152485 |
| BIIB104 Test Formulation | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05152485 |
| BIIB104 Reference Formulation | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05152485 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05148481 |
| BIIB104 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05148481 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05148481 |
| BIIB104 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05148481 |
| Konectom Application | Other | Approved | Multiple Sclerosis | COMPLETED | NCT04756700 |
| DigiCog (BCCAMS app) | Other | Approved | Multiple Sclerosis | COMPLETED | NCT04756700 |
| Interferon Beta Therapy | Drug | Preclinical | Multiple Sclerosis | COMPLETED | NCT04655222 |
| Interferon Beta Therapy | Drug | Preclinical | Multiple Sclerosis | COMPLETED | NCT04655222 |
| Interferon Beta Therapy | Drug | Preclinical | Multiple Sclerosis | COMPLETED | NCT04655222 |
| Interferon Beta Therapy | Drug | Preclinical | Multiple Sclerosis | COMPLETED | NCT04655222 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04571424 |
| BIIB133 (Dapirolizumab pegol) | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04571424 |
| Itraconazole | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04564612 |
| Rabeprazole | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04564612 |
| BIIB091 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04564612 |
| Itraconazole | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04564612 |
| Rabeprazole | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04564612 |
| BIIB091 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04564612 |
| BIIB078 | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | TERMINATED | NCT04288856 |
| BIIB078 | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | TERMINATED | NCT04288856 |
| Adalimumab | Other | Preclinical | Arthritis, Rheumatoid (RA) | COMPLETED | NCT04089514 |
| Adalimumab | Other | Preclinical | Arthritis, Rheumatoid (RA) | COMPLETED | NCT04089514 |
| Placebo | Other | Phase PHASE1 | Parkinson's Disease | COMPLETED | NCT04056689 |
| DNL151 | Other | Phase PHASE1 | Parkinson's Disease | COMPLETED | NCT04056689 |
| Placebo | Other | Phase PHASE1 | Parkinson's Disease | COMPLETED | NCT04056689 |
| DNL151 | Other | Phase PHASE1 | Parkinson's Disease | COMPLETED | NCT04056689 |
| Placebo | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT03945279 |
| BIIB100 | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT03945279 |
| Placebo | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT03945279 |
| BIIB100 | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT03945279 |
| Placebo | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT03945279 |
| BIIB100 | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT03945279 |
| Placebo | Other | Phase PHASE2 | Cognitive Impairment Associated With Schizophrenia | COMPLETED | NCT03745820 |
| BIIB104 | Other | Phase PHASE2 | Cognitive Impairment Associated With Schizophrenia | COMPLETED | NCT03745820 |
| Placebo | Other | Phase PHASE2 | Cognitive Impairment Associated With Schizophrenia | COMPLETED | NCT03745820 |
| BIIB104 | Other | Phase PHASE2 | Cognitive Impairment Associated With Schizophrenia | COMPLETED | NCT03745820 |
| Placebo | Other | Phase PHASE3 | Trigeminal Neuralgia | WITHDRAWN | NCT03637387 |
| BIIB074 | Other | Phase PHASE3 | Trigeminal Neuralgia | WITHDRAWN | NCT03637387 |
| Placebo | Other | Phase PHASE3 | Trigeminal Neuralgia | WITHDRAWN | NCT03637387 |
| BIIB074 | Other | Phase PHASE3 | Trigeminal Neuralgia | WITHDRAWN | NCT03637387 |
| Placebo | Other | Phase PHASE3 | Trigeminal Neuralgia | WITHDRAWN | NCT03070132 |
| BIIB074 | Other | Phase PHASE3 | Trigeminal Neuralgia | WITHDRAWN | NCT03070132 |
| Placebo | Other | Phase PHASE3 | Trigeminal Neuralgia | WITHDRAWN | NCT03070132 |
| BIIB074 | Other | Phase PHASE3 | Trigeminal Neuralgia | WITHDRAWN | NCT03070132 |
| Diroximel Fumarate | Other | Preclinical | Relapsing Forms of MS | TERMINATED | NCT04948606 |
| Diroximel Fumarate | Other | Preclinical | Relapsing Forms of MS | TERMINATED | NCT04948606 |
| dimethyl fumarate | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT02047097 |
| dimethyl fumarate | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT02047097 |
| dimethyl fumarate | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT02047097 |
| Diroximel Fumarate | Other | Preclinical | Relapsing Forms of MS | TERMINATED | NCT04746976 |
| Diroximel Fumarate | Other | Preclinical | Relapsing Forms of MS | TERMINATED | NCT04746976 |
| Glatiramer acetate | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | WITHDRAWN | NCT04079088 |
| Interferon-beta1 | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | WITHDRAWN | NCT04079088 |
| BIIB061 | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | WITHDRAWN | NCT04079088 |
| Placebo | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | WITHDRAWN | NCT04079088 |
| Glatiramer acetate | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | WITHDRAWN | NCT04079088 |
| Interferon-beta1 | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | WITHDRAWN | NCT04079088 |
| BIIB061 | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | WITHDRAWN | NCT04079088 |
| Placebo | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | WITHDRAWN | NCT04079088 |
| Voice analysis | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT05561621 |
| Voice analysis | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT05561621 |
| Placebo | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | TERMINATED | NCT03870763 |
| Peginterferon Beta-1a | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | TERMINATED | NCT03870763 |
| Dimethyl Fumarate | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | TERMINATED | NCT03870763 |
| Placebo | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | TERMINATED | NCT03870763 |
| Peginterferon Beta-1a | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | TERMINATED | NCT03870763 |
| Dimethyl Fumarate | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | TERMINATED | NCT03870763 |
| 99mTc-MAG3-BIIB067 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03764488 |
| Tofersen | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03764488 |
| PSP | Other | Preclinical | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT04221191 |
| Dimethyl Fumarate | Other | Preclinical | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT04221191 |
| BIIB132-Matching Placebo | Other | Phase PHASE1 | Spinocerebellar Ataxia Type 3 | TERMINATED | NCT05160558 |
| BIIB132 | Other | Phase PHASE1 | Spinocerebellar Ataxia Type 3 | TERMINATED | NCT05160558 |
| ASA matching placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01281111 |
| BG00012 matching placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01281111 |
| Aspirin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01281111 |
| Dimethyl Fumarate (BG00012) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01281111 |
| ASA matching placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01281111 |
| BG00012 matching placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01281111 |
| Aspirin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01281111 |
| Dimethyl Fumarate (BG00012) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01281111 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01017666 |
| BIIB014 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01017666 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01017666 |
| BIIB014 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01017666 |
| placebo | Other | Phase PHASE2 | Parkinson's Disease | WITHDRAWN | NCT00451815 |
| active drug (BIIB014) at 10, 30, 100, or 300 mg once daily. | Drug | Phase PHASE2 | Parkinson's Disease | WITHDRAWN | NCT00451815 |
| placebo | Other | Phase PHASE2 | Parkinson's Disease | WITHDRAWN | NCT00451815 |
| active drug (BIIB014) at 10, 30, 100, or 300 mg once daily. | Drug | Phase PHASE2 | Parkinson's Disease | WITHDRAWN | NCT00451815 |
| Alefacept | Other | Phase PHASE3 | Chronic Plaque Psoriasis | COMPLETED | NCT00233662 |
| Alefacept | Other | Phase PHASE3 | Chronic Plaque Psoriasis | COMPLETED | NCT00233662 |
| Alefacept | Other | Phase PHASE3 | Chronic Plaque Psoriasis | COMPLETED | NCT00233662 |
| ibritumomab tiuxetan (Zevalin®) | Other | Phase PHASE4 | Lymphoma, Non-Hodgkin | COMPLETED | NCT00168727 |
| BG00012 | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT00168701 |
| BG00012 | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT00168701 |
| peginterferon beta-1a | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis (RRMS) | COMPLETED | NCT02587065 |
| 6 months weight resistance and balance program | Other | Approved | Multiple Sclerosis | COMPLETED | NCT01816100 |
| specifically design 6 month resistance training program | Other | Approved | Multiple Sclerosis | COMPLETED | NCT01816100 |
| 6 months weight resistance and balance program | Other | Approved | Multiple Sclerosis | COMPLETED | NCT01816100 |
| specifically design 6 month resistance training program | Other | Approved | Multiple Sclerosis | COMPLETED | NCT01816100 |
| Placebo | Other | Phase PHASE2 | Renal Insufficiency | TERMINATED | NCT00745316 |
| Tonapofylline | Other | Phase PHASE2 | Renal Insufficiency | TERMINATED | NCT00745316 |
| Placebo | Other | Phase PHASE2 | Renal Insufficiency | TERMINATED | NCT00745316 |
| Tonapofylline | Other | Phase PHASE2 | Renal Insufficiency | TERMINATED | NCT00745316 |
| Placebo | Other | Phase PHASE3 | Renal Insufficiency | COMPLETED | NCT00709865 |
| tonapofylline | Other | Phase PHASE3 | Renal Insufficiency | COMPLETED | NCT00709865 |
| Placebo | Other | Phase PHASE3 | Renal Insufficiency | COMPLETED | NCT00709865 |
| tonapofylline | Other | Phase PHASE3 | Renal Insufficiency | COMPLETED | NCT00709865 |
| Dimethyl fumarate | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT04756687 |
| Rituximab | Other | Phase PHASE1 | Kidney Insufficiency | WITHDRAWN | NCT00476515 |
| Rituximab | Other | Phase PHASE1 | Kidney Insufficiency | WITHDRAWN | NCT00476515 |
| Rituximab | Other | Phase PHASE1 | Kidney Insufficiency | WITHDRAWN | NCT00476515 |
| Placebo | Other | Phase PHASE1 | Chronic Kidney Disease | TERMINATED | NCT01500798 |
| 20 mg bardoxolone methyl | Other | Phase PHASE1 | Chronic Kidney Disease | TERMINATED | NCT01500798 |
| Placebo | Other | Phase PHASE1 | Chronic Kidney Disease | TERMINATED | NCT01500798 |
| 20 mg bardoxolone methyl | Other | Phase PHASE1 | Chronic Kidney Disease | TERMINATED | NCT01500798 |
| Placebo | Other | Phase PHASE2 | Systemic Lupus Erythematosus | COMPLETED | NCT02847598 |
| BIIB059 (litifilimab) | Other | Phase PHASE2 | Systemic Lupus Erythematosus | COMPLETED | NCT02847598 |
| Placebo | Other | Phase PHASE2 | Systemic Lupus Erythematosus | COMPLETED | NCT02847598 |
| BIIB059 (litifilimab) | Other | Phase PHASE2 | Systemic Lupus Erythematosus | COMPLETED | NCT02847598 |
| Placebo | Other | Phase PHASE2 | Major Depression | COMPLETED | NCT03000530 |
| SAGE-217 | Other | Phase PHASE2 | Major Depression | COMPLETED | NCT03000530 |
| Placebo | Other | Phase PHASE2 | Essential Tremor | COMPLETED | NCT02978781 |
| SAGE-217 | Other | Phase PHASE2 | Essential Tremor | COMPLETED | NCT02978781 |
| Placebo | Other | Phase PHASE2 | Essential Tremor | COMPLETED | NCT02978781 |
| SAGE-217 | Other | Phase PHASE2 | Essential Tremor | COMPLETED | NCT02978781 |
| Placebo | Other | Phase PHASE3 | Major Depressive Disorder | TERMINATED | NCT04007367 |
| SAGE-217 | Other | Phase PHASE3 | Major Depressive Disorder | TERMINATED | NCT04007367 |
| Placebo | Other | Phase PHASE3 | Major Depressive Disorder | TERMINATED | NCT04007367 |
| SAGE-217 | Other | Phase PHASE3 | Major Depressive Disorder | TERMINATED | NCT04007367 |
| Placebo | Other | Phase PHASE3 | Major Depressive Disorder | TERMINATED | NCT03771664 |
| SAGE-217 | Other | Phase PHASE3 | Major Depressive Disorder | TERMINATED | NCT03771664 |
| Placebo | Other | Phase PHASE3 | Major Depressive Disorder | TERMINATED | NCT03771664 |
| SAGE-217 | Other | Phase PHASE3 | Major Depressive Disorder | TERMINATED | NCT03771664 |
| Placebo | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT03672175 |
| SAGE-217 | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT03672175 |
| Placebo | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT03672175 |
| SAGE-217 | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT03672175 |
| Antiparkinsonian Agent(s) | Other | Phase PHASE2 | Parkinson Disease | COMPLETED | NCT03000569 |
| Levodopa | Other | Phase PHASE2 | Parkinson Disease | COMPLETED | NCT03000569 |
| SAGE-217 | Other | Phase PHASE2 | Parkinson Disease | COMPLETED | NCT03000569 |
| Blood | Other | Preclinical | Amyotrophic Lateral Sclerosis | COMPLETED | NCT04819555 |
| Placebo | Other | Phase PHASE3 | Depression, Postpartum | COMPLETED | NCT04442503 |
| SAGE-217 | Other | Phase PHASE3 | Depression, Postpartum | COMPLETED | NCT04442503 |
| Placebo | Other | Phase PHASE3 | Depression, Postpartum | COMPLETED | NCT04442503 |
| SAGE-217 | Other | Phase PHASE3 | Depression, Postpartum | COMPLETED | NCT04442503 |
| BIIB111 | Other | Phase PHASE3 | Choroideremia | COMPLETED | NCT03496012 |
| Placebo | Other | Phase PHASE2 | Bipolar Disorder I | COMPLETED | NCT03692910 |
| SAGE-217 | Other | Phase PHASE2 | Bipolar Disorder I | COMPLETED | NCT03692910 |
| Placebo | Other | Phase PHASE2 | Bipolar Disorder I | COMPLETED | NCT03692910 |
| SAGE-217 | Other | Phase PHASE2 | Bipolar Disorder I | COMPLETED | NCT03692910 |
| SAGE 217 30 mg Capsules | Other | Phase PHASE3 | Postpartum Depression | COMPLETED | NCT02978326 |
| Placebo | Other | Phase PHASE3 | Postpartum Depression | COMPLETED | NCT02978326 |
| SAGE-217 15/20 mg Oral Solution | Other | Phase PHASE3 | Postpartum Depression | COMPLETED | NCT02978326 |
| SAGE 217 30 mg Capsules | Other | Phase PHASE3 | Postpartum Depression | COMPLETED | NCT02978326 |
| Placebo | Other | Phase PHASE3 | Postpartum Depression | COMPLETED | NCT02978326 |
| SAGE-217 15/20 mg Oral Solution | Other | Phase PHASE3 | Postpartum Depression | COMPLETED | NCT02978326 |
| Desvenlafaxine | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT04476030 |
| Duloxetine | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT04476030 |
| Citalopram | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT04476030 |
| Escitalopram | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT04476030 |
| Sertraline | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT04476030 |
| Matching Placebo | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT04476030 |
| SAGE-217 | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT04476030 |
| Desvenlafaxine | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT04476030 |
| Duloxetine | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT04476030 |
| Citalopram | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT04476030 |
| Escitalopram | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT04476030 |
| Sertraline | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT04476030 |
| Matching Placebo | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT04476030 |
| SAGE-217 | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT04476030 |
| Placebo | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT04442490 |
| SAGE-217 | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT04442490 |
| yttrium Y 90 ibritumomab tiuxetan | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00031642 |
| rituximab | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00031642 |
| yttrium Y 90 ibritumomab tiuxetan | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00031642 |
| rituximab | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00031642 |
| Questionnaire | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT05209815 |
| Questionnaire | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT05209815 |
| Questionnaire | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT05209815 |
| BIIB112 | Other | Phase PHASE1 | X-Linked Retinitis Pigmentosa | COMPLETED | NCT03116113 |
| 11^C]BIO-1819578 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05195008 |
| BIIB113-Matching Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05195008 |
| BIIB113 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05195008 |
| 11^C]BIO-1819578 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05195008 |
| BIIB113-Matching Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05195008 |
| BIIB113 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05195008 |
| Natalizumab | Other | Preclinical | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT04832399 |
| Konectom NMD Application | Other | Approved | Spinal Muscular Atrophy | COMPLETED | NCT05109637 |
| Placebo | Other | Phase PHASE2 | Ischemic Stroke | WITHDRAWN | NCT05764122 |
| BIIB131 | Other | Phase PHASE2 | Ischemic Stroke | WITHDRAWN | NCT05764122 |
| BIIB111 | Other | Phase PHASE2 | Choroideremia | COMPLETED | NCT03507686 |
| BIIB111 | Other | Phase PHASE2 | Choroideremia | COMPLETED | NCT03507686 |
| No Intervention | Other | Preclinical | KCNT1-Related Epilepsy | COMPLETED | NCT04924153 |
| No Intervention | Other | Preclinical | KCNT1-Related Epilepsy | COMPLETED | NCT04924153 |
| No Intervention | Other | Preclinical | KCNT1-Related Epilepsy | COMPLETED | NCT04924153 |
| Tysabri | Other | Preclinical | Progressive Multifocal Leukoencephalopathy | COMPLETED | NCT03399981 |
| Tysabri | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00493298 |
| Tysabri | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00493298 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04593121 |
| BIIB107 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04593121 |
| Natalizumab 300 MG in 15 ML Injection | Other | Phase PHASE4 | Multiple Sclerosis | TERMINATED | NCT05177718 |
| Natalizumab 300 MG in 15 ML Injection | Other | Phase PHASE4 | Multiple Sclerosis | TERMINATED | NCT05177718 |
| Placebo | Other | Phase PHASE2 | Antibody-mediated Rejection | COMPLETED | NCT05021484 |
| Felzartamab | Other | Phase PHASE2 | Antibody-mediated Rejection | COMPLETED | NCT05021484 |
| Placebo | Other | Phase PHASE2 | Antibody-mediated Rejection | COMPLETED | NCT05021484 |
| Felzartamab | Other | Phase PHASE2 | Antibody-mediated Rejection | COMPLETED | NCT05021484 |
| Natalizumab | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis (RRMS) | COMPLETED | NCT05304520 |
| Natalizumab | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis (RRMS) | COMPLETED | NCT05304520 |
| Konectom platform | Other | Preclinical | Multiple Sclerosis (MS) | COMPLETED | NCT05106465 |
| Konectom platform | Other | Preclinical | Multiple Sclerosis (MS) | COMPLETED | NCT05106465 |
| [14C]-BIIB091 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06311786 |
| [14C]-BIIB091 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06311786 |
| Placebo group 2: Placebo powder corresponding to Wasabi leaf powder | Other | Approved | PreDiabetes | RECRUITING | NCT06437938 |
| Placebo group 1: Placebo capsules corresponding to DiaPhyt® Formula 3.0/Berberin Phytoactive Gold | Other | Approved | PreDiabetes | RECRUITING | NCT06437938 |
| Dietary supplement C: DiaPhyt® Formula 3.0 (product of BIOGENA GmbH & Co KG) | Other | Approved | PreDiabetes | RECRUITING | NCT06437938 |
| Dietary supplement B: Berberin Phytoactive Gold (product of BIOGENA GmbH & Co KG) | Other | Approved | PreDiabetes | RECRUITING | NCT06437938 |
| Dietary supplement A: Wasabi leaf powder (product of BIOGENA GmbH & Co KG) | Other | Approved | PreDiabetes | RECRUITING | NCT06437938 |
| Placebo group 2: Placebo powder corresponding to Wasabi leaf powder | Other | Approved | PreDiabetes | RECRUITING | NCT06437938 |
| Placebo group 1: Placebo capsules corresponding to DiaPhyt® Formula 3.0/Berberin Phytoactive Gold | Other | Approved | PreDiabetes | RECRUITING | NCT06437938 |
| Dietary supplement C: DiaPhyt® Formula 3.0 (product of BIOGENA GmbH & Co KG) | Other | Approved | PreDiabetes | RECRUITING | NCT06437938 |
| Dietary supplement B: Berberin Phytoactive Gold (product of BIOGENA GmbH & Co KG) | Other | Approved | PreDiabetes | RECRUITING | NCT06437938 |
| Dietary supplement A: Wasabi leaf powder (product of BIOGENA GmbH & Co KG) | Other | Approved | PreDiabetes | RECRUITING | NCT06437938 |
| natalizumab | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | TERMINATED | NCT02142192 |
| TYSABRI and AVONEX | Other | Phase PHASE4 | Relapsing-remitting Multiple Sclerosis | WITHDRAWN | NCT00771043 |
| TYSABRI and AVONEX | Other | Phase PHASE4 | Relapsing-remitting Multiple Sclerosis | WITHDRAWN | NCT00771043 |
| TYSABRI and AVONEX | Other | Phase PHASE4 | Relapsing-remitting Multiple Sclerosis | WITHDRAWN | NCT00771043 |
| natalizumab | Other | Preclinical | Crohn's Disease | TERMINATED | NCT00707512 |
| natalizumab | Other | Preclinical | Crohn's Disease | TERMINATED | NCT00707512 |
| natalizumab | Other | Preclinical | Crohn's Disease | TERMINATED | NCT00707512 |
| Tofersen | Other | Preclinical | Superoxide Dismutase 1-Amyotropic Lateral Sclerosis | APPROVED_FOR_MARKETING | NCT04972487 |
| Tofersen | Other | Preclinical | Superoxide Dismutase 1-Amyotropic Lateral Sclerosis | APPROVED_FOR_MARKETING | NCT04972487 |
| Natalizumab | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT03689972 |
| Natalizumab | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT03689972 |
| Natalizumab | Other | Phase PHASE4 | Multiple Sclerosis, Relapsing-Remitting | TERMINATED | NCT05532163 |
| Rabeprazole | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06264440 |
| BIIB122 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06264440 |
| Patient Registry | Other | Preclinical | Spinal Muscular Atrophy | RECRUITING | NCT04292574 |
| Patient Registry | Other | Preclinical | Spinal Muscular Atrophy | RECRUITING | NCT04292574 |
| Moxifloxacin Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01689116 |
| Moxifloxacin 400mg | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01689116 |
| Bardoxolone Methyl Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01689116 |
| Bardoxolone Methyl 80mg | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01689116 |
| Bardoxolone Methyl 20mg | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01689116 |
| Moxifloxacin Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01689116 |
| Moxifloxacin 400mg | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01689116 |
| Bardoxolone Methyl Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01689116 |
| Bardoxolone Methyl 80mg | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01689116 |
| Bardoxolone Methyl 20mg | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01689116 |
| Placebo | Other | Phase PHASE2 | Renal Insufficiency, Chronic | WITHDRAWN | NCT01655186 |
| Bardoxolone Methyl | Other | Phase PHASE2 | Renal Insufficiency, Chronic | WITHDRAWN | NCT01655186 |
| Placebo | Other | Phase PHASE2 | Renal Insufficiency, Chronic | WITHDRAWN | NCT01655186 |
| Bardoxolone Methyl | Other | Phase PHASE2 | Renal Insufficiency, Chronic | WITHDRAWN | NCT01655186 |
| Rosuvastatin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01598363 |
| Digoxin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01598363 |
| Rosuvastatin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01598363 |
| Digoxin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01598363 |
| Placebo | Other | Phase PHASE2 | End-Stage Renal Disease | WITHDRAWN | NCT01576887 |
| Bardoxolone Methyl 20 mg | Other | Phase PHASE2 | End-Stage Renal Disease | WITHDRAWN | NCT01576887 |
| Placebo | Other | Phase PHASE2 | End-Stage Renal Disease | WITHDRAWN | NCT01576887 |
| Bardoxolone Methyl 20 mg | Other | Phase PHASE2 | End-Stage Renal Disease | WITHDRAWN | NCT01576887 |
| Bardoxolone Methyl | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT01563562 |
| Bardoxolone Methyl | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT01563562 |
| Bardoxolone Methyl | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT01563562 |
| Bardoxolone Methyl | Other | Phase PHASE1 | Renal Insufficiency, Chronic | WITHDRAWN | NCT01551446 |
| Bardoxolone Methyl | Other | Phase PHASE1 | Renal Insufficiency, Chronic | TERMINATED | NCT01549769 |
| Bardoxolone Methyl | Other | Phase PHASE1 | Renal Insufficiency, Chronic | TERMINATED | NCT01549769 |
| bardoxolone methyl | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01503866 |
| Placebo | Other | Phase PHASE2 | Mild Cognitive Impairment (MCI) | RECRUITING | NCT07027072 |
| KDS2010 | Other | Phase PHASE2 | Mild Cognitive Impairment (MCI) | RECRUITING | NCT07027072 |
| Placebo | Other | Phase PHASE2 | Mild Cognitive Impairment (MCI) | RECRUITING | NCT07027072 |
| KDS2010 | Other | Phase PHASE2 | Mild Cognitive Impairment (MCI) | RECRUITING | NCT07027072 |
| • Biological: GYNORYLAQ-TM Personalized Neoantigenic Peptide Vaccine | Other | Phase EARLY_PHASE1 | Endometrial Carcinoma | ENROLLING_BY_INVITATION | NCT07316361 |
| • Biological: GYNORYLAQ-TM Personalized Neoantigenic Peptide Vaccine | Other | Phase EARLY_PHASE1 | Endometrial Carcinoma | ENROLLING_BY_INVITATION | NCT07316361 |
| No Intervention | Other | Preclinical | Muscular Atrophy, Spinal | RECRUITING | NCT05789758 |
| Placebo | Other | Phase PHASE3 | Antibody-mediated Rejection | RECRUITING | NCT06685757 |
| Felzartamab | Other | Phase PHASE3 | Antibody-mediated Rejection | RECRUITING | NCT06685757 |
| Placebo | Other | Phase PHASE3 | Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation | ACTIVE_NOT_RECRUITING | NCT04856982 |
| Tofersen | Other | Phase PHASE3 | Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation | ACTIVE_NOT_RECRUITING | NCT04856982 |
| Placebo | Other | Phase PHASE3 | Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation | ACTIVE_NOT_RECRUITING | NCT04856982 |
| Tofersen | Other | Phase PHASE3 | Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation | ACTIVE_NOT_RECRUITING | NCT04856982 |
| SAGE-217 | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT03864614 |
| SAGE-217 | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT03864614 |
| Natalizumab | Other | Preclinical | Multiple Sclerosis | TERMINATED | NCT05701423 |
| nusinersen | Other | Phase PHASE3 | Spinal Muscular Atrophy | COMPLETED | NCT02594124 |
| nusinersen | Other | Phase PHASE3 | Spinal Muscular Atrophy | COMPLETED | NCT02594124 |
| nusinersen | Other | Phase PHASE3 | Spinal Muscular Atrophy | COMPLETED | NCT02594124 |
| Placebo | Other | Phase PHASE1 | Immune System Diseases | COMPLETED | NCT05928585 |
| HIB210 | Other | Phase PHASE1 | Immune System Diseases | COMPLETED | NCT05928585 |
| Placebo | Other | Phase PHASE1 | Immune System Diseases | COMPLETED | NCT05928585 |
| HIB210 | Other | Phase PHASE1 | Immune System Diseases | COMPLETED | NCT05928585 |
| Placebo | Other | Phase PHASE2 | Immunoglobulin A (IgA) Nephropathy | COMPLETED | NCT05065970 |
| Felzartamab | Other | Phase PHASE2 | Immunoglobulin A (IgA) Nephropathy | COMPLETED | NCT05065970 |
| MOR202 | Other | Phase PHASE2 | Glomerulonephritis | COMPLETED | NCT04733040 |
| MOR202 | Other | Phase PHASE2 | Glomerulonephritis | COMPLETED | NCT04733040 |
| BIIB091 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06640933 |
| Aducanumab | Other | Phase PHASE3 | Alzheimer's Disease | TERMINATED | NCT04241068 |
| Aducanumab | Other | Phase PHASE3 | Alzheimer's Disease | TERMINATED | NCT04241068 |
| MOR202 | Other | Phase PHASE1 | Glomerulonephritis, Membranous | COMPLETED | NCT04145440 |
| MOR202 | Other | Phase PHASE1 | Glomerulonephritis, Membranous | COMPLETED | NCT04145440 |
| Zuranolone | Other | Phase PHASE1 | Major Depressive Disorder | COMPLETED | NCT05655507 |
| Zuranolone | Other | Phase PHASE1 | Major Depressive Disorder | COMPLETED | NCT05655507 |
| Moxifloxacin-matched Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06574828 |
| BIIB091-matched Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06574828 |
| Moxifloxacin | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06574828 |
| BIIB091 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06574828 |
| Moxifloxacin-matched Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06574828 |
| BIIB091-matched Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06574828 |
| Moxifloxacin | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06574828 |
| BIIB091 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06574828 |
| Standard of Care | Other | Approved | Spinal Muscular Atrophy (SMA) | COMPLETED | NCT05354414 |
| Virtual reality | Other | Approved | Spinal Muscular Atrophy (SMA) | COMPLETED | NCT05354414 |
| Standard of Care | Other | Approved | Spinal Muscular Atrophy (SMA) | COMPLETED | NCT05354414 |
| Virtual reality | Other | Approved | Spinal Muscular Atrophy (SMA) | COMPLETED | NCT05354414 |
| Adaptive Optics Ophthalmoscopy (AOO) | Other | Approved | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT04289909 |
| Omaveloxolone | Other | Preclinical | Friedreich Ataxia | RECRUITING | NCT06623890 |
| Omaveloxolone | Other | Preclinical | Friedreich Ataxia | RECRUITING | NCT06623890 |
| Omaveloxolone | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06612879 |
| Omaveloxolone | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06612879 |
| Omaveloxolone | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06612879 |
| Placebo | Other | Phase PHASE3 | Alzheimer's Disease | TERMINATED | NCT05310071 |
| Aducanumab | Other | Phase PHASE3 | Alzheimer's Disease | TERMINATED | NCT05310071 |
| Nusinersen | Other | Phase PHASE3 | Spinal Muscular Atrophy | ACTIVE_NOT_RECRUITING | NCT05067790 |
| Nusinersen | Other | Phase PHASE3 | Spinal Muscular Atrophy | ACTIVE_NOT_RECRUITING | NCT05067790 |
| Natalizumab | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT05236777 |
| Natalizumab | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT05236777 |
| Dimethyl fumarate | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT05658484 |
| Dimethyl fumarate | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT05658484 |
| Nusinersen Injectable Product | Other | Preclinical | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT06978985 |
| Risdiplam | Other | Preclinical | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT06978985 |
| Nusinersen Injectable Product | Other | Preclinical | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT06978985 |
| Risdiplam | Other | Preclinical | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT06978985 |
| BIIB080-matching placebo | Other | Phase PHASE2 | Mild Cognitive Impairment Due to Alzheimer's Disease | ACTIVE_NOT_RECRUITING | NCT05399888 |
| BIIB080 | Other | Phase PHASE2 | Mild Cognitive Impairment Due to Alzheimer's Disease | ACTIVE_NOT_RECRUITING | NCT05399888 |
| BIIB080-matching placebo | Other | Phase PHASE2 | Mild Cognitive Impairment Due to Alzheimer's Disease | ACTIVE_NOT_RECRUITING | NCT05399888 |
| BIIB080 | Other | Phase PHASE2 | Mild Cognitive Impairment Due to Alzheimer's Disease | ACTIVE_NOT_RECRUITING | NCT05399888 |
| Lotion vehicle/placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02029716 |
| RTA 408 Lotion 0.5%, 1%, 3% | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02029716 |
| Bardoxolone methyl | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT00529438 |
| Bardoxolone methyl | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT00529438 |
| RTA 744 injection | Other | Phase PHASE1 | Glioma | COMPLETED | NCT00526812 |
| RTA 744 | Other | Phase PHASE1 | Glioma | COMPLETED | NCT00526812 |
| RTA 744 injection | Other | Phase PHASE1 | Glioma | COMPLETED | NCT00526812 |
| RTA 744 | Other | Phase PHASE1 | Glioma | COMPLETED | NCT00526812 |
| RTA 1701 capsules | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03579030 |
| Placebo oral capsule | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03579030 |
| RTA 1701 capsules | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03579030 |
| Placebo oral capsule | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03579030 |
| Itraconazole capsules 100 mg | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03264079 |
| Bardoxolone methyl capsules 10 mg | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03264079 |
| Itraconazole capsules 100 mg | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03264079 |
| Bardoxolone methyl capsules 10 mg | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03264079 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02666963 |
| RTA 901 Capsules, 10 or 40 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02666963 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02666963 |
| RTA 901 Capsules, 10 or 40 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02666963 |
| omaveloxolone | Other | Phase PHASE1 | Metastatic or Incurable Non-small Cell Lung Cancer | COMPLETED | NCT02029729 |
| omaveloxolone | Other | Phase PHASE1 | Metastatic or Incurable Non-small Cell Lung Cancer | COMPLETED | NCT02029729 |
| bardoxolone methyl | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01461161 |
| Bardoxolone Methyl: 20 mg | Other | Phase PHASE3 | Renal Insufficiency, Chronic | TERMINATED | NCT01351675 |
| Placebo | Other | Phase PHASE3 | Renal Insufficiency, Chronic | TERMINATED | NCT01351675 |
| Bardoxolone Methyl: 20 mg | Other | Phase PHASE3 | Renal Insufficiency, Chronic | TERMINATED | NCT01351675 |
| Placebo | Other | Phase PHASE3 | Renal Insufficiency, Chronic | TERMINATED | NCT01351675 |
| Bardoxolone methyl (amorphous dispersion) | Other | Phase PHASE2 | Renal Insufficiency, Chronic | COMPLETED | NCT01053936 |
| Bardoxolone methyl (amorphous dispersion) | Other | Phase PHASE2 | Renal Insufficiency, Chronic | COMPLETED | NCT01053936 |
| Bardoxolone methyl (amorphous dispersion) | Other | Phase PHASE2 | Renal Insufficiency, Chronic | COMPLETED | NCT01053936 |
| Bardoxolone Methyl (RTA 402) | Other | Phase PHASE2 | Chronic Kidney Disease | COMPLETED | NCT00811889 |
| Placebo | Other | Phase PHASE2 | Chronic Kidney Disease | COMPLETED | NCT00811889 |
| Bardoxolone Methyl (RTA 402) | Other | Phase PHASE2 | Chronic Kidney Disease | COMPLETED | NCT00811889 |
| Placebo | Other | Phase PHASE2 | Chronic Kidney Disease | COMPLETED | NCT00811889 |
| RTA 402 (Bardoxolone Methyl) | Other | Phase PHASE2 | Diabetic Nephropathy | COMPLETED | NCT00664027 |
| RTA 402 (Bardoxolone Methyl) | Other | Phase PHASE2 | Diabetic Nephropathy | COMPLETED | NCT00664027 |
| berubicin hydrochloride (RTA 744) | Other | Phase PHASE2 | Brain Metastases | TERMINATED | NCT00538343 |
| berubicin hydrochloride (RTA 744) | Other | Phase PHASE2 | Brain Metastases | TERMINATED | NCT00538343 |
| Placebo | Other | Phase PHASE1 | Pancreatic Neoplasms | TERMINATED | NCT00529113 |
| Gemcitabine | Other | Phase PHASE1 | Pancreatic Neoplasms | TERMINATED | NCT00529113 |
| Bardoxolone methyl | Other | Phase PHASE1 | Pancreatic Neoplasms | TERMINATED | NCT00529113 |
| Placebo | Other | Phase PHASE1 | Pancreatic Neoplasms | TERMINATED | NCT00529113 |
| Gemcitabine | Other | Phase PHASE1 | Pancreatic Neoplasms | TERMINATED | NCT00529113 |
| Bardoxolone methyl | Other | Phase PHASE1 | Pancreatic Neoplasms | TERMINATED | NCT00529113 |
| Placebo | Other | Phase PHASE1 | Pancreatic Neoplasms | TERMINATED | NCT00529113 |
| Gemcitabine | Other | Phase PHASE1 | Pancreatic Neoplasms | TERMINATED | NCT00529113 |
| Bardoxolone methyl | Other | Phase PHASE1 | Pancreatic Neoplasms | TERMINATED | NCT00529113 |
| Moxifloxacin | Other | Phase PHASE1 | Health Adult Subjects | COMPLETED | NCT05927649 |
| Omaveloxolone | Other | Phase PHASE1 | Health Adult Subjects | COMPLETED | NCT05927649 |
| Moxifloxacin | Other | Phase PHASE1 | Health Adult Subjects | COMPLETED | NCT05927649 |
| Omaveloxolone | Other | Phase PHASE1 | Health Adult Subjects | COMPLETED | NCT05927649 |
| Moxifloxacin | Other | Phase PHASE1 | Health Adult Subjects | COMPLETED | NCT05927649 |
| Omaveloxolone | Other | Phase PHASE1 | Health Adult Subjects | COMPLETED | NCT05927649 |
| Efavirenz | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT05909644 |
| Omaveloxolone | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT05909644 |
| RTA 901-Matching Placebo | Other | Phase PHASE2 | Diabetic Peripheral Neuropathic Pain | TERMINATED | NCT05895552 |
| RTA 901 | Other | Phase PHASE2 | Diabetic Peripheral Neuropathic Pain | TERMINATED | NCT05895552 |
| Verapamil Pill | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Itraconazole capsule | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Gemfibrozil Tablets | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Digoxin tablet | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Rosuvastatin | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| MetFORMIN 500 Mg Oral Tablet | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Repaglinide 1 MG | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Midazolam oral solution | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Omaveloxolone | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Verapamil Pill | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Itraconazole capsule | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Gemfibrozil Tablets | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Digoxin tablet | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Rosuvastatin | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| MetFORMIN 500 Mg Oral Tablet | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Repaglinide 1 MG | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Midazolam oral solution | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Omaveloxolone | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Verapamil Pill | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Itraconazole capsule | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Gemfibrozil Tablets | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Digoxin tablet | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Rosuvastatin | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| MetFORMIN 500 Mg Oral Tablet | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Repaglinide 1 MG | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Midazolam oral solution | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Omaveloxolone | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| [14C]-Omaveloxolone | Other | Phase PHASE1 | Healthy Male Subjects | COMPLETED | NCT03931590 |
| [14C]-Omaveloxolone | Other | Phase PHASE1 | Healthy Male Subjects | COMPLETED | NCT03931590 |
| Omaveloxolone 50 mg capsules | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT03902002 |
| Omaveloxolone 50 mg capsules | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT03902002 |
| Omaveloxolone 50 mg capsules | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT03902002 |
| omaveloxolone | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03664453 |
| omaveloxolone | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03664453 |
| omaveloxolone | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03664453 |
| RTA 402 | Other | Phase PHASE1 | Liver Disease | TERMINATED | NCT00550849 |
| RTA 744 | Other | Phase PHASE1 | Leptomeningeal Carcinomatosis | TERMINATED | NCT00527410 |
| RTA 744 | Other | Phase PHASE1 | Leptomeningeal Carcinomatosis | TERMINATED | NCT00527410 |
| RTA 744 | Other | Phase PHASE1 | Leptomeningeal Carcinomatosis | TERMINATED | NCT00527410 |
| omaveloxolone | Other | Preclinical | Melanoma | NO_LONGER_AVAILABLE | NCT03593499 |
| RTA 402 Dose2 | Other | Phase PHASE2 | Malignant Melanoma | WITHDRAWN | NCT00535314 |
| RTA 402 Dose1 | Other | Phase PHASE2 | Malignant Melanoma | WITHDRAWN | NCT00535314 |
| Placebo oral capsule | Other | Phase PHASE2 | Chronic Kidney Diseases | COMPLETED | NCT04702997 |
| Bardoxolone methyl oral capsule | Other | Phase PHASE2 | Chronic Kidney Diseases | COMPLETED | NCT04702997 |
| Placebo oral capsule | Other | Phase PHASE3 | Autosomal Dominant Polycystic Kidney | TERMINATED | NCT03918447 |
| Bardoxolone methyl oral capsule | Other | Phase PHASE3 | Autosomal Dominant Polycystic Kidney | TERMINATED | NCT03918447 |
| Placebo oral capsule | Other | Phase PHASE3 | Autosomal Dominant Polycystic Kidney | TERMINATED | NCT03918447 |
| Bardoxolone methyl oral capsule | Other | Phase PHASE3 | Autosomal Dominant Polycystic Kidney | TERMINATED | NCT03918447 |
| Bardoxolone methyl | Other | Phase PHASE3 | Chronic Kidney Diseases | TERMINATED | NCT03749447 |
| Bardoxolone methyl | Other | Phase PHASE3 | Chronic Kidney Diseases | TERMINATED | NCT03749447 |
| Bardoxolone methyl | Other | Phase PHASE3 | Chronic Kidney Diseases | TERMINATED | NCT03749447 |
| Bardoxolone methyl capsules | Other | Phase PHASE2 | IgA Nephropathy | COMPLETED | NCT03366337 |
| Bardoxolone methyl capsules | Other | Phase PHASE2 | IgA Nephropathy | COMPLETED | NCT03366337 |
| Bardoxolone methyl capsules | Other | Phase PHASE2 | IgA Nephropathy | COMPLETED | NCT03366337 |
| 3D conformal radiation therapy | Drug | Phase PHASE2 | Breast Cancer | COMPLETED | NCT02142959 |
| Vehicle Lotion | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT02142959 |
| Omaveloxolone Lotion 3% | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT02142959 |
| Omaveloxolone Lotion 0.5% | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT02142959 |
| 3D conformal radiation therapy | Drug | Phase PHASE2 | Breast Cancer | COMPLETED | NCT02142959 |
| Vehicle Lotion | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT02142959 |
| Omaveloxolone Lotion 3% | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT02142959 |
| Omaveloxolone Lotion 0.5% | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT02142959 |
| Omaveloxolone Ophthalmic Suspension 1% | Other | Phase PHASE2 | Corneal Endothelial Cell Loss | COMPLETED | NCT02128113 |
| Omaveloxolone Ophthalmic Suspension 0.5% | Other | Phase PHASE2 | Corneal Endothelial Cell Loss | COMPLETED | NCT02128113 |
| Vehicle Ophthalmic Solution | Other | Phase PHASE2 | Corneal Endothelial Cell Loss | COMPLETED | NCT02128113 |
| Omaveloxolone Ophthalmic Suspension 1% | Other | Phase PHASE2 | Corneal Endothelial Cell Loss | COMPLETED | NCT02128113 |
| Omaveloxolone Ophthalmic Suspension 0.5% | Other | Phase PHASE2 | Corneal Endothelial Cell Loss | COMPLETED | NCT02128113 |
| Vehicle Ophthalmic Solution | Other | Phase PHASE2 | Corneal Endothelial Cell Loss | COMPLETED | NCT02128113 |
| Placebo | Other | Phase PHASE2 | Inflammation and Pain Following Ocular Surgery | COMPLETED | NCT02065375 |
| Omaveloxolone Opthalmic Suspension 0.5% | Other | Phase PHASE2 | Inflammation and Pain Following Ocular Surgery | COMPLETED | NCT02065375 |
| Omaveloxolone Ophthalmic Suspension 1.0% | Other | Phase PHASE2 | Inflammation and Pain Following Ocular Surgery | COMPLETED | NCT02065375 |
| Placebo | Other | Phase PHASE2 | Inflammation and Pain Following Ocular Surgery | COMPLETED | NCT02065375 |
| Omaveloxolone Opthalmic Suspension 0.5% | Other | Phase PHASE2 | Inflammation and Pain Following Ocular Surgery | COMPLETED | NCT02065375 |
| Omaveloxolone Ophthalmic Suspension 1.0% | Other | Phase PHASE2 | Inflammation and Pain Following Ocular Surgery | COMPLETED | NCT02065375 |
| Bardoxolone methyl capsules | Other | Phase PHASE3 | Connective Tissue Disease-Associated Pulmonary Arterial Hypertension | TERMINATED | NCT02657356 |
| Placebo capsules | Other | Phase PHASE3 | Connective Tissue Disease-Associated Pulmonary Arterial Hypertension | TERMINATED | NCT02657356 |
| Bardoxolone methyl capsules | Other | Phase PHASE3 | Connective Tissue Disease-Associated Pulmonary Arterial Hypertension | TERMINATED | NCT02657356 |
| Placebo capsules | Other | Phase PHASE3 | Connective Tissue Disease-Associated Pulmonary Arterial Hypertension | TERMINATED | NCT02657356 |
| Omaveloxolone Capsules (50 mg/capsule) | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT02259231 |
| Omaveloxolone Capsules (10 mg/capsule) | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT02259231 |
| Nivolumab (240 mg) | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT02259231 |
| Ipilimumab (3 mg/kg) | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT02259231 |
| Omaveloxolone Capsules (2.5 mg/capsule) | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT02259231 |
| Nusinersen | Other | Phase PHASE3 | Muscular Atrophy, Spinal | COMPLETED | NCT04089566 |
| Nusinersen | Other | Phase PHASE3 | Muscular Atrophy, Spinal | COMPLETED | NCT04089566 |
| omaveloxolone capsules, 160 mg | Other | Phase PHASE2 | MItochondrial Myopathies | COMPLETED | NCT02255422 |
| omaveloxolone capsules, 80 mg | Other | Phase PHASE2 | MItochondrial Myopathies | COMPLETED | NCT02255422 |
| omaveloxolone capsules, 40 mg | Other | Phase PHASE2 | MItochondrial Myopathies | COMPLETED | NCT02255422 |
| omaveloxolone capsules, 20 mg | Other | Phase PHASE2 | MItochondrial Myopathies | COMPLETED | NCT02255422 |
| Placebo capsules | Other | Phase PHASE2 | MItochondrial Myopathies | COMPLETED | NCT02255422 |
| omaveloxolone capsules, 10 mg | Other | Phase PHASE2 | MItochondrial Myopathies | COMPLETED | NCT02255422 |
| omaveloxolone capsules, 5 mg | Other | Phase PHASE2 | MItochondrial Myopathies | COMPLETED | NCT02255422 |
| Omaveloxolone capsules, 2.5 mg | Other | Phase PHASE2 | MItochondrial Myopathies | COMPLETED | NCT02255422 |
| omaveloxolone capsules, 160 mg | Other | Phase PHASE2 | MItochondrial Myopathies | COMPLETED | NCT02255422 |
| omaveloxolone capsules, 80 mg | Other | Phase PHASE2 | MItochondrial Myopathies | COMPLETED | NCT02255422 |
| omaveloxolone capsules, 40 mg | Other | Phase PHASE2 | MItochondrial Myopathies | COMPLETED | NCT02255422 |
| omaveloxolone capsules, 20 mg | Other | Phase PHASE2 | MItochondrial Myopathies | COMPLETED | NCT02255422 |
| Placebo capsules | Other | Phase PHASE2 | MItochondrial Myopathies | COMPLETED | NCT02255422 |
| omaveloxolone capsules, 10 mg | Other | Phase PHASE2 | MItochondrial Myopathies | COMPLETED | NCT02255422 |
| omaveloxolone capsules, 5 mg | Other | Phase PHASE2 | MItochondrial Myopathies | COMPLETED | NCT02255422 |
| Omaveloxolone capsules, 2.5 mg | Other | Phase PHASE2 | MItochondrial Myopathies | COMPLETED | NCT02255422 |
| Placebo | Other | Phase PHASE2 | Pulmonary Arterial Hypertension | COMPLETED | NCT02036970 |
| Bardoxolone methyl | Other | Phase PHASE2 | Pulmonary Arterial Hypertension | COMPLETED | NCT02036970 |
| Bardoxolone methyl | Other | Phase PHASE3 | Pulmonary Hypertension | TERMINATED | NCT03068130 |
| Bardoxolone Methyl | Other | Phase PHASE2 | Alport Syndrome | COMPLETED | NCT03019185 |
| Placebo Oral Capsule | Other | Phase PHASE2 | Alport Syndrome | COMPLETED | NCT03019185 |
| BIIB112 | Other | Phase PHASE3 | Choroideremia | ENROLLING_BY_INVITATION | NCT03584165 |
| BIIB111 | Other | Phase PHASE3 | Choroideremia | ENROLLING_BY_INVITATION | NCT03584165 |
| BIIB112 | Other | Phase PHASE3 | Choroideremia | ENROLLING_BY_INVITATION | NCT03584165 |
| BIIB111 | Other | Phase PHASE3 | Choroideremia | ENROLLING_BY_INVITATION | NCT03584165 |
| Omaveloxolone | Other | Preclinical | Friedreich Ataxia | RECRUITING | NCT06628687 |
| Omaveloxolone | Other | Preclinical | Friedreich Ataxia | RECRUITING | NCT06628687 |
| Omaveloxolone | Other | Preclinical | Friedreich Ataxia | RECRUITING | NCT06628687 |
| BIIB115-Matching Placebo | Other | Phase PHASE1 | Healthy Volunteer | ACTIVE_NOT_RECRUITING | NCT05575011 |
| BIIB115 | Other | Phase PHASE1 | Healthy Volunteer | ACTIVE_NOT_RECRUITING | NCT05575011 |
| BIIB115-Matching Placebo | Other | Phase PHASE1 | Healthy Volunteer | ACTIVE_NOT_RECRUITING | NCT05575011 |
| BIIB115 | Other | Phase PHASE1 | Healthy Volunteer | ACTIVE_NOT_RECRUITING | NCT05575011 |
| Nusinersen Sodium Injection | Other | Preclinical | Muscular Atrophy, Spinal | ACTIVE_NOT_RECRUITING | NCT04317794 |
| Nusinersen Sodium Injection | Other | Preclinical | Muscular Atrophy, Spinal | ACTIVE_NOT_RECRUITING | NCT04317794 |
| Interferon β-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| Interferon β-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| Interferon β-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| Dimethyl Fumarate | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05658497 |
| Tysabri | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05658497 |
| Avonex | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05658497 |
| Diroximel Fumarate | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05658497 |
| Dimethyl Fumarate | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05658497 |
| Tysabri | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05658497 |
| Avonex | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05658497 |
| Diroximel Fumarate | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05658497 |
| Zuranolone | Other | Preclinical | Depression, Postpartum | RECRUITING | NCT07047820 |
| Zuranolone | Other | Preclinical | Depression, Postpartum | RECRUITING | NCT07047820 |
| Leukapheresis | Other | Phase PHASE1 | Sickle Cell Disease | COMPLETED | NCT05618301 |
| Natalizumab | Other | Phase PHASE1 | Sickle Cell Disease | COMPLETED | NCT05618301 |
| Motixafortide | Other | Phase PHASE1 | Sickle Cell Disease | COMPLETED | NCT05618301 |
| Leukapheresis | Other | Phase PHASE1 | Sickle Cell Disease | COMPLETED | NCT05618301 |
| Natalizumab | Other | Phase PHASE1 | Sickle Cell Disease | COMPLETED | NCT05618301 |
| Motixafortide | Other | Phase PHASE1 | Sickle Cell Disease | COMPLETED | NCT05618301 |
| BIIB142-Matching Placebo | Other | Phase PHASE1 | Healthy Volunteer | RECRUITING | NCT07133828 |
| BIIB142 | Other | Phase PHASE1 | Healthy Volunteer | RECRUITING | NCT07133828 |
| BIIB142-Matching Placebo | Other | Phase PHASE1 | Healthy Volunteer | RECRUITING | NCT07133828 |
| BIIB142 | Other | Phase PHASE1 | Healthy Volunteer | RECRUITING | NCT07133828 |
| Interferon beta type 1a | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | ACTIVE_NOT_RECRUITING | NCT03958877 |
| BIIB017 (peginterferon beta-1a) | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | ACTIVE_NOT_RECRUITING | NCT03958877 |
| Cold pressor test | Other | Approved | Nitrate | COMPLETED | NCT06602921 |
| Caffeine | Other | Approved | Nitrate | COMPLETED | NCT06602921 |
| TruBeet inorganic beetroot juice | Other | Approved | Nitrate | COMPLETED | NCT06602921 |
| Cold pressor test | Other | Approved | Nitrate | COMPLETED | NCT06602921 |
| Caffeine | Other | Approved | Nitrate | COMPLETED | NCT06602921 |
| TruBeet inorganic beetroot juice | Other | Approved | Nitrate | COMPLETED | NCT06602921 |
| Omaveloxolone | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT07019064 |
| Actemra | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06262477 |
| BIIB800 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06262477 |
| Actemra | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06262477 |
| BIIB800 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06262477 |
| Placebo | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | TERMINATED | NCT04494256 |
| BIIB105 | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | TERMINATED | NCT04494256 |
| Nusinersen | Other | Phase PHASE4 | Muscular Atrophy, Spinal | COMPLETED | NCT04488133 |
| Nusinersen | Other | Phase PHASE4 | Muscular Atrophy, Spinal | COMPLETED | NCT04488133 |
| Disease-Modifying Therapies (DMTs) | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05767736 |
| Dimethyl Fumarate | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05767736 |
| Diroximel Fumarate | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05767736 |
| Disease-Modifying Therapies (DMTs) | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05767736 |
| Dimethyl Fumarate | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05767736 |
| Diroximel Fumarate | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05767736 |
| Disease-Modifying Therapies (DMTs) | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05767736 |
| Dimethyl Fumarate | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05767736 |
| Diroximel Fumarate | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05767736 |
| Siponimod | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05688436 |
| Ponesimod | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05688436 |
| Peginterferon beta-1a | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05688436 |
| Ozanimod | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05688436 |
| Ofatumumab | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05688436 |
| Ocrelizumab | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05688436 |
| Natalizumab | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05688436 |
| Interferon beta | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05688436 |
| Glatiramer acetate | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05688436 |
| Fingolimod | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05688436 |
| Alemtuzumab | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05688436 |
| Diroximel Fumarate | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05688436 |
| Nusinersen | Other | Phase PHASE2 | Spinal Muscular Atrophy | COMPLETED | NCT02386553 |
| Nusinersen | Other | Phase PHASE2 | Spinal Muscular Atrophy | COMPLETED | NCT02386553 |
| Omeprazole | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT07149415 |
| Omaveloxolone | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT07149415 |
| Diroximel fumarate | Other | Phase PHASE3 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT05083923 |
| Diroximel fumarate | Other | Phase PHASE3 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT05083923 |
| Diroximel fumarate | Other | Phase PHASE3 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT05083923 |
| Natalizumab | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | TERMINATED | NCT05265728 |
| Natalizumab | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | TERMINATED | NCT05265728 |
| Natalizumab | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | TERMINATED | NCT05265728 |
| Biological: personalized vaccine Based on genetic and transcriptional sequencing information, personalized peptide vaccines would be designed and produced; | Other | Phase EARLY_PHASE1 | Glioma | RECRUITING | NCT07077616 |
| Biological: personalized vaccine Based on genetic and transcriptional sequencing information, personalized peptide vaccines would be designed and produced; | Other | Phase EARLY_PHASE1 | Glioma | RECRUITING | NCT07077616 |
| Biological: personalized vaccine Based on genetic and transcriptional sequencing information, personalized peptide vaccines would be designed and produced; | Other | Phase EARLY_PHASE1 | Glioma | RECRUITING | NCT07077616 |
| RTA 901-Matching Placebo | Other | Phase PHASE2 | Diabetic Peripheral Neuropathic Pain | TERMINATED | NCT05895552 |
| RTA 901 | Other | Phase PHASE2 | Diabetic Peripheral Neuropathic Pain | TERMINATED | NCT05895552 |
| RTA 901-Matching Placebo | Other | Phase PHASE2 | Diabetic Peripheral Neuropathic Pain | TERMINATED | NCT05895552 |
| RTA 901 | Other | Phase PHASE2 | Diabetic Peripheral Neuropathic Pain | TERMINATED | NCT05895552 |
| Microlyvaq™ (Personalized Multi-Epitope Immunotherapeutic) | Other | Phase EARLY_PHASE1 | NSCLC (Non-small Cell Lung Cancer) | ENROLLING_BY_INVITATION | NCT07285434 |
| Microlyvaq™ (Personalized Multi-Epitope Immunotherapeutic) | Other | Phase EARLY_PHASE1 | NSCLC (Non-small Cell Lung Cancer) | ENROLLING_BY_INVITATION | NCT07285434 |
| Microlyvaq™ (Personalized Multi-Epitope Immunotherapeutic) | Other | Phase EARLY_PHASE1 | NSCLC (Non-small Cell Lung Cancer) | ENROLLING_BY_INVITATION | NCT07285434 |
| Felzartamab | Other | Phase PHASE1 | Lupus Nephritis | ACTIVE_NOT_RECRUITING | NCT06064929 |
| Felzartamab | Other | Phase PHASE1 | Lupus Nephritis | ACTIVE_NOT_RECRUITING | NCT06064929 |
| • Biological: GYNORYLAQ-TM Personalized Neoantigenic Peptide Vaccine | Other | Phase EARLY_PHASE1 | Endometrial Carcinoma | ENROLLING_BY_INVITATION | NCT07316361 |
| Omaveloxolone | Other | Phase PHASE1 | Friedreich Ataxia | RECRUITING | NCT06054893 |
| Omaveloxolone | Other | Phase PHASE1 | Friedreich Ataxia | RECRUITING | NCT06054893 |
| Placebo | Other | Phase PHASE2 | Multiple Sclerosis | RECRUITING | NCT05418010 |
| Tyruko Injectable Product | Other | Phase PHASE2 | Multiple Sclerosis | RECRUITING | NCT05418010 |
| Placebo | Other | Phase PHASE2 | Multiple Sclerosis | RECRUITING | NCT05418010 |
| Tyruko Injectable Product | Other | Phase PHASE2 | Multiple Sclerosis | RECRUITING | NCT05418010 |
| Experimental: COLONYVAQ-CRC + mFOLFOX6 or CAPOX + Nivolumab | Other | Phase EARLY_PHASE1 | Colorectal Cancer Metastatic | RECRUITING | NCT07328087 |
| Experimental: COLONYVAQ-CRC + mFOLFOX6 or CAPOX + Nivolumab | Other | Phase EARLY_PHASE1 | Colorectal Cancer Metastatic | RECRUITING | NCT07328087 |
| Experimental: COLONYVAQ-CRC + mFOLFOX6 or CAPOX + Nivolumab | Other | Phase EARLY_PHASE1 | Colorectal Cancer Metastatic | RECRUITING | NCT07328087 |
| Salanersen | Other | Phase PHASE3 | Muscular Atrophy, Spinal | RECRUITING | NCT07221669 |
| Salanersen | Other | Phase PHASE3 | Muscular Atrophy, Spinal | RECRUITING | NCT07221669 |
| Tofersen | Other | Phase PHASE4 | Amyotrophic Lateral Sclerosis | RECRUITING | NCT07223723 |
| Tofersen | Other | Phase PHASE4 | Amyotrophic Lateral Sclerosis | RECRUITING | NCT07223723 |
| Omaveloxolone Capsules, 150 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 300 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 160 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 80 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 40 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 20 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Placebo | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 10 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 5 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 2.5 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 150 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 300 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 160 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 80 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 40 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 20 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Placebo | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 10 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 5 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 2.5 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Placebo | Other | Phase PHASE3 | Lupus Erythematosus, Systemic | ACTIVE_NOT_RECRUITING | NCT04961567 |
| Litifilimab | Other | Phase PHASE3 | Lupus Erythematosus, Systemic | ACTIVE_NOT_RECRUITING | NCT04961567 |
| Placebo | Other | Phase PHASE3 | Lupus Erythematosus, Systemic | ACTIVE_NOT_RECRUITING | NCT04961567 |
| Litifilimab | Other | Phase PHASE3 | Lupus Erythematosus, Systemic | ACTIVE_NOT_RECRUITING | NCT04961567 |
| Communication with the clinic | Other | Approved | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT02454907 |
| Observational | Other | Preclinical | Spinal Muscular Atrophy | RECRUITING | NCT06955897 |
| Observational | Other | Preclinical | Spinal Muscular Atrophy | RECRUITING | NCT06955897 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | RECRUITING | NCT07225517 |
| BIIB145 | Other | Phase PHASE1 | Healthy Volunteer | RECRUITING | NCT07225517 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | RECRUITING | NCT07225517 |
| BIIB145 | Other | Phase PHASE1 | Healthy Volunteer | RECRUITING | NCT07225517 |
| Tofersen | Other | Phase PHASE2 | ALS (Amyotrophic Lateral Sclerosis) | RECRUITING | NCT07294144 |
| Tofersen | Other | Phase PHASE2 | ALS (Amyotrophic Lateral Sclerosis) | RECRUITING | NCT07294144 |
| Tofersen | Other | Phase PHASE2 | ALS (Amyotrophic Lateral Sclerosis) | RECRUITING | NCT07294144 |
| Zuranolone | Other | Preclinical | Postpartum Depression | RECRUITING | NCT07398469 |
| Placebo | Other | Phase PHASE3 | Lupus Erythematosus, Systemic | ACTIVE_NOT_RECRUITING | NCT04895241 |
| Litifilimab | Other | Phase PHASE3 | Lupus Erythematosus, Systemic | ACTIVE_NOT_RECRUITING | NCT04895241 |
| Placebo | Other | Phase PHASE3 | Lupus Erythematosus, Systemic | ACTIVE_NOT_RECRUITING | NCT04895241 |
| Litifilimab | Other | Phase PHASE3 | Lupus Erythematosus, Systemic | ACTIVE_NOT_RECRUITING | NCT04895241 |
| Omaveloxolone | Other | Phase PHASE1 | Healthy Volunteer | RECRUITING | NCT07297199 |
| Omaveloxolone | Other | Phase PHASE1 | Healthy Volunteer | RECRUITING | NCT07297199 |
| Nusinersen | Other | Phase PHASE3 | Muscular Atrophy, Spinal | ACTIVE_NOT_RECRUITING | NCT04729907 |
| Nusinersen | Other | Phase PHASE3 | Muscular Atrophy, Spinal | ACTIVE_NOT_RECRUITING | NCT04729907 |
| Placebo | Other | Phase PHASE2 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT05798520 |
| DRF | Other | Phase PHASE2 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT05798520 |
| BIIB091 | Other | Phase PHASE2 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT05798520 |
| Placebo | Other | Phase PHASE2 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT05798520 |
| DRF | Other | Phase PHASE2 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT05798520 |
| BIIB091 | Other | Phase PHASE2 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT05798520 |
| Omeveloxolone | Other | Approved | Friedreich's Ataxia | NOT_YET_RECRUITING | NCT07444333 |
| Aerobic Exercise | Other | Approved | Friedreich's Ataxia | NOT_YET_RECRUITING | NCT07444333 |
| Tofersen | Other | Preclinical | Amyotrophic Lateral Sclerosis | NOT_YET_RECRUITING | NCT07259980 |
| Salanersen | Other | Phase PHASE3 | Spinal Muscular Atrophy | NOT_YET_RECRUITING | NCT07444476 |
| Sham Procedure | Procedure | Phase PHASE3 | Muscular Atrophy, Spinal | NOT_YET_RECRUITING | NCT07444450 |
| Salanersen | Other | Phase PHASE3 | Muscular Atrophy, Spinal | NOT_YET_RECRUITING | NCT07444450 |
| Sham Procedure | Procedure | Phase PHASE3 | Muscular Atrophy, Spinal | NOT_YET_RECRUITING | NCT07444450 |
| Salanersen | Other | Phase PHASE3 | Muscular Atrophy, Spinal | NOT_YET_RECRUITING | NCT07444450 |
| Placebo | Other | Phase PHASE3 | Prediabetes | NOT_YET_RECRUITING | NCT07448974 |
| Vitamin D (Cholecalciferol ) | Other | Phase PHASE3 | Prediabetes | NOT_YET_RECRUITING | NCT07448974 |
| Placebo | Other | Phase PHASE3 | Prediabetes | NOT_YET_RECRUITING | NCT07448974 |
| Vitamin D (Cholecalciferol ) | Other | Phase PHASE3 | Prediabetes | NOT_YET_RECRUITING | NCT07448974 |
| No Intervention | Other | Preclinical | Muscular Atrophy, Spinal | RECRUITING | NCT05789758 |
| No Intervention | Other | Preclinical | Muscular Atrophy, Spinal | RECRUITING | NCT05789758 |
| Placebo | Other | Phase PHASE3 | Friedreich Ataxia | RECRUITING | NCT06953583 |
| Omaveloxolone | Other | Phase PHASE3 | Friedreich Ataxia | RECRUITING | NCT06953583 |
| Placebo matching fingolimod | Other | Phase PHASE3 | Relapsing Forms of Multiple Sclerosis | NOT_YET_RECRUITING | NCT07483632 |
| Placebo matching DMF | Other | Phase PHASE3 | Relapsing Forms of Multiple Sclerosis | NOT_YET_RECRUITING | NCT07483632 |
| Placebo matching DRF | Other | Phase PHASE3 | Relapsing Forms of Multiple Sclerosis | NOT_YET_RECRUITING | NCT07483632 |
| Fingolimod | Other | Phase PHASE3 | Relapsing Forms of Multiple Sclerosis | NOT_YET_RECRUITING | NCT07483632 |
| Dimethyl Fumarate | Other | Phase PHASE3 | Relapsing Forms of Multiple Sclerosis | NOT_YET_RECRUITING | NCT07483632 |
| Diroximel Fumarate | Other | Phase PHASE3 | Relapsing Forms of Multiple Sclerosis | NOT_YET_RECRUITING | NCT07483632 |
| BIIB080 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06454721 |
| [89Zr]Zr-DFO-BIIB080 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06454721 |
| BIIB080 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06454721 |
| [89Zr]Zr-DFO-BIIB080 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06454721 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| PFS | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| OBI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| Litifilimab | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| PFS | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| OBI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| Litifilimab | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | RECRUITING | NCT05531565 |
| Litifilimab | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | RECRUITING | NCT05531565 |
| Felzartamab | Other | Phase PHASE3 | Antibody-mediated Rejection | NOT_YET_RECRUITING | NCT07444489 |
| Felzartamab | Other | Phase PHASE3 | Antibody-mediated Rejection | NOT_YET_RECRUITING | NCT07444489 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| BIIB059 (litifilimab) | Other | Phase PHASE3 | Subacute Cutaneous Lupus Erythematosus | ENROLLING_BY_INVITATION | NCT06044337 |
| Natalizumab | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05925049 |
| Natalizumab | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05925049 |
| Tofersen | Other | Preclinical | Amyotrophic Lateral Sclerosis | RECRUITING | NCT07259980 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| BIIB059 (litifilimab) | Other | Phase PHASE3 | Subacute Cutaneous Lupus Erythematosus | ENROLLING_BY_INVITATION | NCT06044337 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | RECRUITING | NCT05531565 |
| Litifilimab | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | RECRUITING | NCT05531565 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Placebo | Other | Phase PHASE2 | Immunoglobulin A (IgA) Nephropathy | COMPLETED | NCT05065970 |
| Felzartamab | Other | Phase PHASE2 | Immunoglobulin A (IgA) Nephropathy | COMPLETED | NCT05065970 |
Total products: 2456